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Background   Ultrasmall superparamagnetic particles of iron oxide (USPIO)-
enhanced magnetic resonance imaging (MRI) can detect tissue-resident 
inflammatory macrophages and identify cellular inflammation. Clinical studies using 
this non-invasive technique are now emerging. 
 
Objectives   The aims of this thesis were (i) to determine whether USPIO-enhanced 
MRI can detect and serially monitor myocardial inflammation after myocardial 
infarction (MI) using single and repeated USPIO administration, (ii) to report a range 
of normal R2* (1/T2*) values at 1.5 tesla (T) and 3 T in healthy myocardium and 
other tissues before and after USPIO administration, (iii) to determine whether 
USPIO-enhanced MRI can detect myocardial inflammation in acute myocarditis, and 
(iv) to determine whether USPIO-enhanced MRI can detect myocardial inflammation 
in patients with a prior cardiac transplant. 
 
Methods   Thirty-one patients were recruited following acute MI and followed up for 
3 months with repeated T2 and USPIO-enhanced T2* mapping 3 T MRI. Twenty 
healthy volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2 and USPIO-
enhanced T2* mapping MRI was conducted. Fourteen patients with suspected acute 
myocarditis underwent T2 and USPIO-enhanced T2* mapping 3 T MRI, with further 
imaging at 3 months. Eleven patients with prior cardiac transplant underwent T2 and 
USPIO-enhanced T2* mapping 1.5 T MRI with further imaging at 3 months. 
Regions of interest within the myocardium, along with other tissues, were selected 
for analysis. Pre-contrast T2 values, and the change in R2* due to USPIO from 
baseline to 24 hours after USPIO were compared for each region of interest.  
 
Results   In patients with MI, USPIO uptake in the infarct zone peaked at days 2-3, 
and greater USPIO uptake was detected in the infarct zone compared to remote 
myocardium in the first 2 weeks after myocardial infarction. In contrast, T2-defined 
myocardial oedema peaked at days 3-9 and remained increased in the infarct zone 
throughout the 3-month follow up period. Histology confirmed colocalisation of iron 
and macrophages within the infarcted, but not the non-infarcted, myocardium. 
 
In healthy volunteers, we reported a range of normal myocardial and tissue R2* 
values at baseline, and following USPIO. Tissues showing greatest USPIO 
enhancement were organs of the reticuloendothelial system: the liver, spleen and 
bone marrow. 
  
Myocarditis was confirmed in 9 of the 14 suspected cases of myocarditis. There was 
greater myocardial oedema, but no demonstrable difference in USPIO enhancement, 
in inflamed myocardial regions in patients with myocarditis when compared to 
healthy myocardium. We recorded an improvement in cardiac function and reduced 




Ten patients with cardiac transplant were retained for analysis. Measures of 
myocardial oedema were greater in patients with cardiac transplant than healthy 
volunteers. There was no difference in the change in R2* due to USPIO between 
patients with transplantation and healthy volunteers. Imaging recordings did not 
change when repeated at 3 months. 
 
Conclusions   Myocardial macrophage activity can be detected using USPIO-
enhanced MRI in the first 2 weeks following acute MI. This observed pattern of 
cellular inflammation is distinct, and provides complementary information to, the 
more prolonged myocardial oedema detectable using T2 mapping.  
 
In patients with acute myocarditis, USPIO-enhanced MRI does not provide 
additional clinically relevant information to standard clinical MRI sequences. This 
suggests that tissue-resident macrophages do not provide a substantial contribution to 
the myocardial inflammation in this condition. 
 
Stable patients with cardiac transplantation have increased myocardial T2 values, 
consistent with resting myocardial oedema or fibrosis. In contrast, USPIO-enhanced 
MRI is normal and stable over time suggesting the absence of chronic macrophage-
driven cellular inflammation.  
 
In conclusion, this imaging technique holds promise as a non-invasive method of 
assessing and monitoring macrophage-driven myocardial inflammation after 
myocardial infarction with potential application to diagnosis, risk stratification and 
assessment of novel anti-inflammatory therapeutic interventions. It remains to be 
determined whether USPIO-enhanced MRI may be able to identify myocardial 
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B0	 	 	 External	magnetic	field		
BMI	 	 	 Body	mass	index	
BSA	 	 	 Body	surface	area		
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FDG-PET	 	 18F-Fluorodeoxyglucose	positron	emission	tomography		
GE	 	 	 Gradient	echo	
KO	mice			 	 Kockout	mice	
LAD	 	 	 Left	anterior	descending	
LGE	 	 	 Late	gadolinium	enhancement	
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LV	 	 	 Left	ventricular		
MHRA		 	 Medicines	and	Healthcare	products	Regulatory	Agency		
MI	 	 	 Myocardial	infarction	
MNPs	 	 	 Magneto-fluorescent	nanoparticles		
MPIO			 	 Micron-sized	particles	of	iron	oxide	
MRCA		 	 Magnetic	resonance	coronary	angiography	
MSCs		 	 	 Mesenchymal	stem	cells		
MRI	 	 	 Magnetic	resonance	imaging	
NMV	 	 	 Net	magnetisation	vector		
PCI	 	 	 Percutaneous	coronary	intervention	
PEG		 	 	 Polyethylene	glycol		
PET	 	 	 Positron	emission	tomography		
r2	 	 	 Coefficient	of	determination	
R2*	 	 	 R2-star	
RES		 	 	 Reticuloendothelium	system		
RF	 	 	 radiofrequency	
RITC		 	 	 Rhodamine	B	isothiocyanate		
ROI	 	 	 Region	of	interest	
RV	 	 	 Right	ventricular	
SE	 	 	 Spin	echo	
SI	 	 	 Signal	intensity	
SPIO	 	 	 Small	superparmagnetic	particles	of	iron	oxide	
SPIO-MAb	 	 SPIO-monoclonal	antibody	




T	 	 	 Tesla		
T1W	 	 	 T1-weighted	
T2*	 	 	 T2-star	
T2*W	 	 	 T2*-weighted	
T2P	 	 	 T2	prepared	
T2W	 	 	 T2-weighted	
TE	 	 	 Echo	time	
TI		 	 	 Inversion	time	
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Beyond the anatomical and morphological information afforded by standard clinical 
cardiovascular imaging techniques, it is increasingly recognised that additional 
information examining underlying biological processes would be valuable in a range 
of cardiovascular diseases to aid understanding of disease pathogenesis, provide 
diagnostic information, predict disease progression, and to monitor response to 
treatment. Novel molecular and cellular imaging techniques can identify metabolic 
and biological processes that are critical to disease pathogenesis, and therefore have 
the potential to predict clinical events and guide therapeutic intervention. It would 
therefore be a major clinical advance if a reliable non-invasive imaging technique 
capable of detecting tissue inflammation could be developed. 
 
A range of potential imaging modalities exists (Table 1.1). Ultrasound is readily 
available, has good temporal and spatial resolution, is non-invasive, avoids ionising 
radiation and is relatively cheap. However it suffers from poor penetration and relies 
heavily on an experienced operator and patient factors such as body habitus and good 
acoustic windows for optimal imaging. Single-photon emission computerised 
tomography (SPECT) and positron emission tomography (PET) both suffer from 
relatively poor spatial and temporal resolution and involve radiation so are not ideal 
for serial cardiac imaging. Poor penetration of fluorescence imaging limits it’s 
application for inflammatory cardiac imaging in vivo, in man. 
Magnetic resonance imaging (MRI) has a number of advantages including excellent 
discrimination of soft tissue components, good spatial resolution and in particular, 
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absence of ionising radiation, an important consideration if serial imaging is 
envisaged. Here, I will discuss the basic principles of CMR image acquisition, 
comment upon the use of T2* MRI in the assessment of iron accumulation, and 














Sensitivity Penetration Radiation Cost 
MRI 10-100 micron High Low Good No High 
US 50 micron High Medium cm No Medium 
SPECT 1-2 mm Low Medium Good Yes Medium 
PET 1-2 mm Low High Good Yes High 
Fluorescence 2-3 mm High High <1cm Y/N Low 
 
MRI - magnetic resonance imaging; US - ultrasound; SPECT - single-photon emission computed tomography; 





1.2 BASIC PRINCIPLES OF CARDIAC MAGNETIC RESONANCE 
IMAGING 
The origin of the magnetic resonance imaging signal is based on nuclear magnetic 
resonance, which is the response of the hydrogen nuclei to radiofrequency (RF) 
waves. Each hydrogen nucleus consists of one proton nucleus orbited by one electron. 
It is the lack of a neutron within the nucleon that allows the hydrogen atom to be 
magnetically active, giving it a property called ‘spin’, allowing the proton a small 
magnetic moment. Although there are other atoms that possess similar magnetic 
activity, hydrogen is most commonly used for MRI due to its abundance in the 
human body and large magnetic moment. MRI techniques are essentially based on 
receiving and processing RF signals from protons.  
 
Protons usually have a randomly orientated magnetic axis. In the presence of a 
magnetic field however, protons align in the direction, or against the direction of the 
external magnetic field (B0) (Figure 1.1). They are unable to align exactly with B0 
but rather spin around this axis. Generally, there is a net magnetisation in the 
direction of B0, called longitudinal magnetisation, although protons possessing more 
intrinsic energy may align in the opposite direction. In magnets with higher field 
strength, the native energy possessed by protons is unable to overcome the field 
strength of the magnet, and greater numbers of protons align in the direction of B0, 









Figure 1.1.   In the resting state within an MRI scanner, protons align either in the direction, or in 
opposition to the external magnetic field, B0. They do not align exactly with B0 but rather spin around 
an axis that is aligned with B0. An excess of protons align with B0 and the net magnetisation vector 
(NMV) is in the direction of B0. In the resting state there is no phase coherence as illustrated by the 





The spin of protons is termed precession, and the rate at which they spin is termed 
the precession frequency, which changes linearly as the field strength of the magnet 
increases. When protons precess in synchrony they are in-phase, and when they are 
out of synchrony, this is termed out-of-phase.  
 
1.2.1   RESONANCE AND THE RADIOFREQUENCY PULSE 
Resonance occurs when particles are excited by energy at the same frequency as 
their own oscillation (the Larmor frequency). For protons precessing at a frequency 
within a clinical MRI scanner, the frequency of energy required for resonance to 
occur is within the RF range of the electromagnetic spectrum. The equilibrium of the 
magnetic field within an MRI scanner can be disrupted by a further magnetic field 
applied at the Larmor frequency perpendicular to the existing magnetic field. This is 
termed the radiofrequency field, and the excitation pulse called the RF pulse, 
transmitted by the RF coil. During excitation, a proportion of protons will gain 
sufficient energy to flip their axis and spin in the opposite direction from B0. As a 
consequence of this, the NMV is altered away from its resting state and the angle at 
which it is altered is termed the flip angle. The flip angle is directly proportional to 
the amplitude and duration of the RF pulse. In addition, the RF pulse causes all 
protons, previously precessing out-of-phase, to precess in-phase. This                







1.2.2   DETECTION AND PROCESSING OF THE MAGNETIC RESONANCE SIGNAL 
Fluctuating magnetic fields generated by a radiofrequency pulse in an MRI scanner 
induce a voltage in the conductive RF coil placed nearby. The RF coil acts as both a 
signal detector and transmitter, and allows the signal received to be conveyed to 
specialised computer processors that generate images through a process known as the 
Fourier transformation. This image formation process is complicated and will not be 
discussed in depth. Somewhat simplified, by applying a phase encoded magnetic 
field gradient during the RF pulse, the resonant frequencies of the spins that are 
subsequently generated vary spatially. As the position of a spinning proton is 
proportional to its frequency, the Fourier transformation is able to calculate the 
anatomical position of a signal by determining its spatial frequency.  
 
Following the radiofrequency pulse, protons gradually lose energy, lose 
phase coherence, and return to their previous state to align with, or opposite to B0. In 
doing so they recover longitudinal magnetisation (T1 recovery) and lose transverse 
magnetisation (T2 relaxation) simultaneously.   
 
1.2.3   RELAXOMETRY AND T2* 
T1 recovery (Figure 1.2) and T2 relaxation (Figure 1.3) are independent exponential 
processes that are tissue and environment specific. T2 decay is caused by loss of 










Figure 1.2.   T1 recovery occurs during realignment of net longitudinal magnetisation following the 




















Figure 1.3.   T2 decay occurs as a result of spin-spin interaction and dephasing of protons. The T2 
value is time taken for transverse magnetisation to decay to 37% of its original value. T2* decay is the 















RF pulse. This loss of phase coherence occurs prior to realignment of net 
magnetisation (T1 recovery), so transverse relaxation always decays faster than 
longitudinal recovery. Therefore T2 is always shorter than T1. Values can be 
attributed to T1 and T2; the T1 value is the time taken for 63% of longitudinal 
recovery, and T2 value is the time taken for T2 to decay to 37% of the original value.  
 
T2* decay is the combination of T2 decay in addition to loss of phase coherence due 
to small magnetic field inhomogeneities. Due to this additional decay process, T2* is 
always less than T2. These inhomogeneities may be the result of intrinsic defects in 
the magnet itself, or from susceptibility-induced field distortions produced by tissues 
or other materials, particularly iron and calcium, placed within the field. Therefore 
T2* imaging is ideally placed to detect exogenous iron-based contrast agents. 
 
1.2.4   BASIC PARAMETERS 
Following the radiofrequency pulse, a period of time is allowed to elapse before data 
sampling takes place. This is called the echo time (TE) and determines the amount of 
T2 decay that occurs between RF pulses, so a long TE increases the T2 weighting of 
the sequence. Data sampling at multiple echo times can be made after a single 
RF pulse to improve accuracy of T2 decay curve fitting. Similarly, the time between 
RF pulses is called the repetition time (TR) and this determines the amount of 
T1 recovery between pulses. Therefore by manipulating TE and TR, the sequence 
can be optimised for T1, T2 or T2* depending on the tissue under examination. For 
example, fat has a short T1 and T2, whereas water has a long T1 and T2. 
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1.3 COMMONLY USED SEQUENCES IN CARDIAC MAGNETIC  
RESONANCE IMAGING 
 
There are two types of sequence fundamental to cardiac MRI; gradient echo (GE) 
and spin echo (SE). In GE imaging, the composite field strength varies along the axis 
of B0, being equal to B0 at the centre of the magnet, steadily increasing in strength to 
one side of B0, and steadily decreasing in strength to the opposite side. As the 
precession frequency of protons is directly proportional to the magnetic field strength, 
protons along this magnetic gradient spin at different frequencies. They do not 
exhibit phase coherence. If a second magnetic gradient in the opposite direction is 
then applied, phase coherence occurs and the signal sampled at this moment is called 
the gradient echo. In GE sequences, both blood and fat appear white, so this 
technique is known as ‘white-blood’ imaging. Generally gradient echo imaging 
provides some advantages over spin echo in that flip angles are usually smaller, so 
recovery of longitudinal magnetisation is faster, allowing shorter repetition times. 
Rephasing with gradient echo is also faster than the 180° RF pulse used in spin echo, 
and this allows for shorter echo times. As a consequence of shorter TE and TR, scan 
times are shorter. The disadvantages of GE are poor signal-to-noise ratio and 
susceptibility to magnetic field inhomogeneities, although this can be advantageous 
when trying to detect iron. Gradient echo imaging clinically forms the basis of 
functional imaging and also inversion recovery techniques used in late gadolinium 





Spin echo imaging uses a different principle, that after the initial RF pulse, a further 
180° pulse is applied to reverse the NMV in the opposite direction, further rephasing 
protons to achieve phase coherence before data sampling takes place. This additional 
pulse that rephases protons is required because after the initial RF pulse, spinning 
protons begin to rapidly dephase and precess at different frequencies, particularly in 
regions of inhomogeneites. If this did not take place, the signal would be lost before 
T1 and T2 weighting can be achieved. In spin echo sequences, blood is usually black, 
fat is white, so is often referred to as ‘black-blood’ imaging, commonly used for 
anatomical imaging.    
 
1.4 T2* IMAGING IN THE ASSESSMENT OF IRON ACCUMULATION 
 
Gradient echo T2* sequences are highly sensitive to magnetic field inhomogeneities 
such as susceptibility artefacts due to the presence of iron. In order to maximise 
T2*weighting, long echo and repetition times are used. Data can be collected at 
multiple consecutive echo times (echos) following a single RF pulse, speeding up 
data acquisition, reducing the need for co-registration image that would be required 
if individual echos were acquired from separate RF pulses.  
 
The intensity of T2* signal exponentially decreases with time and the curve can be 
plotted using data collected from each echo time. The T2* decay value is the initial 
decay constant that is calculated using the equation S(t)=S(0)exp-(t/T2*) where S(t) 
is the signal intensity at time t, and S(0) is the signal intensity at time 0. Thus an 
increasing rate of decay, as is seen with iron accumulation, results in a reduction in 
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T2* value. However iron accumulation is often described and quantified as R2*, the 
reciprocal of T2*, which has a linear relationship to tissue iron concentration       
[Wang et al 2005; Wood 2005]. 
 
The presence of both endogenous and exogenous iron, including iron-based contrast 
agents, results in local magnetic field inhomogeneities, rapid dephasing of protons 
and faster decay of transverse magnetisation. T2* imaging for assessing iron 
accumulation has successfully been used clinically for over a decade in diagnosing 
and grading the severity of iron accumulation in transfusion-dependent thalassaemia 
major, helping guide therapy that improves prognosis, and provides serial disease 
monitoring [Anderson et al 2001; Anderson et al 2004]. T2* MRI has improved 
sensitivity in detecting myocardial iron accumulation compared to serum iron 
sampling [Anderson et al 2001]. This technique is easily quantifiable, well validated, 
highly reproducible, clinically robust, and is achievable in a single breath-hold 
[Westwood et al 2003a; Westwood et al 2003b; Tanner et al 2006; Carpenter et al 
2009; Kirk et al 2010; Carpenter et al 2011]. Using identical methodology to that 
described throughout this thesis, Alam et al found excellent repeatability for the 
assessment of R2* with a mean bias of −0.208 s−1, coefficient of repeatability of 
26.96 s−1, and intraclass coefficient of 0.989 [Alam et al 2012]. 
 
T2 also varies inversely with myocardial iron concentration [Wood 2005] although 
its reciprocal R2 (1/T2) has a curvilinear relationship with tissue iron, in contrast to 
the more linear relationship of tissue iron and R2* [Anderson et al 2001;                   
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St Pierre et al 2005], and for this reason, T2* (or R2*) imaging has generally been 
preferred.   
 
1.5 IRON OXIDE CONTRAST AGENTS 
 
Iron oxide particles are a group of magnetic resonance imaging contrast agents that 
were initially used for gastrointestinal, reticuloendothelial system and lymph node 
imaging [Saini et al 1987; Hahn et al 1990; Rogers et al 1994], and subsequently as 
a blood pool contrast agent for the evaluation of cerebral, myocardial and renal 
perfusion [Canet et al 1993; Trillaud et al 1995; Zimmer et al 1995]. 
  
1.5.1   CLASSIFICATION OF IRON OXIDE PARTICLES 
Iron oxide particles can be categorised according to their size: nano-sized very small 
(VSPIO, <20nm in diameter), ultrasmall (USPIO, 20-50nm in diameter) and small 
(SPIO, 60-250nm in diameter) superparamagnetic particles of iron oxide, and 
micron-sized (MPIO, 1-8µm in diameter) particles of iron oxide. VSPIO and SPIO 
are often classified together (as USPIO) due to similar size. Paramagnetism occurs 
when the size of the iron oxide crystal is smaller than that of ferromagnetic domains 
(approx. 30nm). Under the influence of a strong external magnetic field, such as 
exists within an MRI scanner, iron oxide nanoparticles have a large magnetic 
moment, but unlike larger ferromagnetic particles, this magnetic moment is lost 
when the field is removed. Table 1.2 lists the different applications for USPIO 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.5.2   CONSTRUCTION AND DISTRIBUTION OF IRON NANOPARTICLES 
Ultrasmall superparmagnetic particles of iron oxide generally consist of an iron 
oxide core surrounded by a coating, usually of carbohydrate or polymer construction, 
with a total particle diameter of less than 50 nm. The purpose of the coating is to 
prevent aggregation, to retain particles within a colloidal suspension and to provide a 
surface for conjugation of drug molecules and targeting ligands. A range of particles 
exists varying in size and coating; these two properties are the key determinants of 
biodistribution, magnetic behaviour and thus the potential applications of the particle 
[Mandeville et al 1997; Allkemper et al 2002]. The biodistribution of USPIO is 
individual to each particle but in general a blood pool half-life of several hours is 
expected with distribution predominantly in the spleen, liver, bone marrow and 
lymph nodes, before being cleared within a matter of days. Cytotoxicity data for iron 
nanoparticles is limited but is not found until exposure to high levels of iron and is 
also dependent on factors such as surface coating or it’s breakdown products, 
composition of the cell medium, and protein-iron nanoparticle interaction          
[Berry et al 2003; Berry et al 2004; Mahmoudi et al 2009; Mahmoudi et al 2010]. 
 
1.5.3   CELLULAR DETECTION OF IRON NANOPARTICLES 
The majority of proposed imaging applications for iron oxide nanoparticles utilise 
particles within the ultrasmall and small size ranges. Following administration, cells 
of the reticuloendothelial system, particularly tissue macrophages, identify and 
internalise iron oxide nanoparticles (Figure 1.4).  Ingestion of ultrasmall 
superparamagnetic particles of iron oxide appear to be  predominantly by phagocytes 




granulocytes such as neutrophils does occur albeit less readily [Moore et al 1997; 
Gellissen et al 1999; Kaim et al 2002; Weinstein et al 2010; Han et al 2015]. 










Figure 1.4.   Perl’s iron stain reveals aggregates of SPIO within the cytoplasm of human mononuclear 







Due to their larger size, small superparamagnetic particles of iron oxide are more 
easily identified and rapidly engulfed, principally by resident macrophages in the 
lymphoreticular organs of the liver, spleen and lymph nodes. In contrast, USPIO are 
much smaller and escape immediate phagocytosis, resulting in a much longer 
blood pool half-life compared to larger particles (up to 36 hours for USPIO 
[McLachlan et al 1994] versus as low as 2 hours for larger SPIO in humans [Clément 
et al 1998]). 
 
Whilst circulating within the blood pool, USPIO are small enough to migrate 
passively across the endothelium [Wang et al 2001] especially in regions of inflamed 
vasculature where there is loss of endothelial integrity. Once present within tissues, 
nanoparticles are concentrated and engulfed by resident macrophages through 
phagocytosis and pinocytosis resulting in their accumulation within inflamed tissues. 
Concentration and compartmentalisation within macrophages results in magnetic 
cooperativity and enhances their superparamagnetic effects. This in turn generates 
markedly shorter T2 and T2* relaxation times than would be achieved at similar iron 
concentrations within the interstitium [Brisset et al 2010]. In the presence of iron, 
local signal deficits are created on T2- and T2*-weighted images, and thus USPIO 
can be employed as a ‘tracer’, highlighting areas of tissue inflammation on MRI 
















Figure 1.5.   Patient imaged 5 days after an anterior myocardial infarct with T2*-weighted magnetic 
resonance imaging. Images show T2* maps of baseline pre iron scan (left), and 24 hours following 
ferumoxytol (USPIO) administration (middle), and late gadolinium enhancement in the region of 
infarction (right). Iron uptake is seen in the dark myocardial regions in the region of the anterior 
infarct (arrow), and also the liver and ventricular cavity blood pool.  USPIO - ultrasmall 






1.5.4   COMMERCIAL AVAILABILITY AND SAFETY OF IRON NANOPARTICLE AGENTS 
The development of iron nanoparticle-enhanced MRI has been greatly affected by 
the discontinuation of several agents in recent years. The safety profile of the USPIO, 
ferumoxtran-10 (Sinerem®), was felt to be acceptable (<1/200 Serious Adverse 
Event risk) and importantly not toxic to macrophages, but production was 
discontinued due to a high false-positive rate of detecting lymph node metastasis in 
patients with prostate cancer [Bourrinet et al 2006; Muller et al 2007; Bernd et al 
2009; Heesakkers et al 2009]. NC100500 (Clariscan™) was discontinued over 
concerns regarding long-term liver retention [Ho and Reddy 2010], and the larger 
SPIO ferumoxides (Feridex® in USA, Endorem™ in Europe), and ferucarbotran 
(Resovist®) have also been discontinued; the latter two agents were the only two 
clinically approved SPIO agents for MRI. At present there is only one USPIO 
preparation available for clinical use, and this is in the USA only: ferumoxytol 
(Feraheme™, AMAG Pharmaceuticals), a 17-30 nm USPIO. Feraheme™ is 
marketed for the intravenous treatment of iron deficiency anaemia in adult patients 
with chronic kidney disease (CKD), but is currently not licensed for MR imaging. 
The manufacturer recently terminated its EU marketing license (branded Rienso® in 
the EU), due to economical and not safety reasons. Serious hypersensitivity reactions 
with ferumoxytol are rare (0.2%) and anaphylaxis has been recorded, but no such 
episodes have been observed in several hundred intravenous injections at our centre 







1.5.5   ANALYSIS TECHNIQUES AND TECHNICAL CONSIDERATIONS 
Earlier studies using iron nanoparticles employed semi-quantitative methods to 
calculate reduction in signal intensity consistent with iron accumulation. Such 
methods involve the comparison of relative signal intensities of a study tissue to a 
control tissue (such as healthy skeletal muscle). However these methods are liable to 
variations in signal across the image relative to proximity to surface coils between 
visits, and also assumes that signal intensity in the control tissue is consistent across 
scans. Calculation of changes in T2 and T2* relaxivity values has now been adopted 
for a more sensitive and objective quantitative approach. The T2* relaxivity value is 
the initial decay constants for the exponential decay of signal intensity with 
increasing echo time. Calculation and comparison of decay constants for each region 
of interest allows a more objective and quantitative approach and accounts for the 
problems mentioned by older techniques. In the presence of iron, the signal decays 
more rapidly and the T2 and T2* relaxivity values are reduced. On the resulting 
images, particularly on T2* imaging that is more sensitive than T2 imaging for iron 
accumulation, a profound reduction in signal intensity is evident as a region of signal 
void (hypointense region) where USPIO have accumulated (see Figure 1.5). 
 
In the following sections, I will review the use of iron oxide nanoparticles in cardiac 
MRI. I will discuss their previously studied applications as a blood pool contrast 
agent, and more recently, a tracer highlighting inflammatory tissue macrophages 






1.6 BLOOD POOL CONTRAST IMAGING 
 
1.6.1   VENTRICULAR CONTRAST 
Ultrasmall superparamagnetic particles of iron oxide have been used successfully as 
coronary and ventricular MRI blood pool contrast agents for around two decades. 
USPIO have a longer blood pool circulating time compared to standard MRI 
angiographic agents such as gadolinium. In 1997, Stillman et al                                                   
demonstrated ferumoxtran-10 administration improved myocardial to blood pool 
border definition on T1-weighted cine images. Image intensity gradients at the 
myocardial to blood pool interface increased significantly in both long and short axis 
views. At the time it was thought that ferumoxtran-10 would improve and facilitate 
automated ventricular cavity edge detection allowing for easier and less time-
consuming functional analysis.   
 
These findings were largely replicated by Taylor et al [1999] who used an alternative 
USPIO agent, NC100150 (Clariscan™) with a blood pool half-life of over 2 hours, to 
again improve ventricular cavity edge detection using MRI. They administered 
NC100150 to 18 healthy male volunteers and examined cine imaging sequences. At 
higher doses (3 and 4 mg Fe/kg) an increase in signal intensity was seen in the 
blood pool once again enabling better detection of ventricular blood pool to 
myocardial interface, improving functional assessment of the left ventricle. These 
early studies have since been replicated in other human studies (Figure 1.6) [Amano 




















Figure 1.6.   A 28-year-old volunteer. A) Pre contrast 3D cardiac cine MR image at end-systole. B) Pre contrast 
3D cine image at end-diastole. C) Post contrast 3D cine image at end-systole. D) Post contrast 3D cine image at 
end-diastole. Pre contrast 3D cardiac cine MR images do not show the contrast between myocardium and 
ventricular cavity clearly (A and B), whereas post contrast 3D cardiac cine MR images exhibit high imaging 
contrast between them after administration of USPIO (NC100150) at 3 mg Fe/kg body weight (C and D).             




1.6.2   CORONARY CONTRAST 
Following use as a ventricular blood pool contrast agent, the next logical step worth 
exploring was the potential for iron nanoparticles to improve coronary artery 
imaging. This would have an immediate advantage over standard coronary 
catheterisation, being non-invasive and without radiation. It therefore comes as no 
surprise that NC100150 has been used extensively as a coronary contrast agent for 
magnetic resonance coronary angiography (MRCA), but with mixed results. 
Johansson et al compared invasive x-ray angiography with T1-weighted MRCA 
using NC100150 in pigs with coronary artery stenosis [Johansson et al 1999]. Initial 
results were encouraging. Although the sample size was small (n=6), the location and 
severity grading of stenoses on NC100150-enhanced MRCA correlated well with     
x-ray angiography. Within a few years, Sandstede et al [2001] carried out a 
feasibility study using the same contrast agent, this time in human patients with 
coronary artery disease. They found that proximal segments of coronary arteries 
were well visualised, however distal segment visualisation was poor. Increasing 
doses of USPIO were used in a failed attempt to improve image quality, and only     
6 of 8 important proximal coronary stenoses seen on conventional angiography were 
detected using NC100150 contrast-enhanced MRI. 
 
Klein et al [2003] conducted more coronary imaging comparing NC100150-
enhanced MRI with unenhanced MRI again yielding disappointing results. Although 
the visible length of mid and distal portions of the coronary artery improved with 
USPIO-enhanced imaging, there was no improvement when assessing the proximal 




stenoses (>50% luminal narrowing on conventional angiography) were detected on 
USPIO-enhanced MRI compared to 6 of 11 on the non-contrast scan. 
 
1.6.3   MYOCARDIAL VIABILITY 
Soon after the trialling of USPIO as a blood pool contrast agent for ventricular cavity 
and coronary imaging, attempts were made to illustrate myocardial viability after 
myocardial infarction (MI). Studies examined the theory that USPIO would 
illuminate vasculature in viable, but not non-viable, myocardium. Kroft et al [1998] 
administered ferumoxtran-10 (AMI-227, Sinerem®) in a pig model of myocardial 
infarction. Contrary to expectations, MRI using ferumoxtran-10 failed to illuminate 
viable myocardium. This was likely due to low dose iron (30 µmol Fe/kg), fast 
elimination time of the contrast agent and a low field strength MR scanner           
(1.5 tesla (T)). Increasing the magnetic field strength provides improved signal-to-
noise ratio, greater spatial resolution and improves sensitivity for detecting lower 
concentrations of iron, which is advantageous in the detection of USPIO. 
 
Using a similar model, Bjerner et al [2000] had more success using increased iron 
dosing. Using T1-, T2- and T2*-weighted imaging, they found that T1-weighted 
MRI at USPIO doses of 4 and 8 mg Fe/kg provided the best evaluation of perfused 
myocardium when compared with fluorescein stain on ex vivo histology.  
 
The use of USPIO as a myocardial tissue contrast agent was extended to a model of 
ischaemia-reperfusion in rats to evaluate microvascular injury in reperfused 




waited 3 hours following ligation release to mimic ischaemia-reperfusion, before 
administering NC100150 to help define regions of microvascular injury and 
obstruction after myocardial infarction. USPIO distributes by diffusion and is 
retained in the extravascular space of injured myocardium with damaged, leaky 
vasculature. They found that USPIO-enhanced imaging provided some indication of 
transmural and non-transmural microvascular injury. This imaging approach tended 
to overestimate the area of true infarction when compared to triphenyltetrazolium 
chloride histological staining, and underestimate the area of myocardium deemed     
‘at risk’ of infarction determined by redo coronary ligation and intravenous 
phthalocyanine blue dye injection.  
 
1.7  INFLAMMATION IMAGING 
 
Endomyocardial biopsy is the ‘gold standard’ diagnostic investigation for 
inflammatory diseases of the myocardium, however this carries the risk of                     
life-threatening complications [Cooper et al 2007]. Furthermore, sampling error is 
common due to the focal nature and spatial heterogeneity of underlying 
inflammatory processes. Today this procedure is rarely performed outside specialist 
tertiary referral centres. The following sections discuss applications of iron 
nanoparticle-enhanced CMR to highlight tissue inflammation as cells of the 
reticuloendothelial system, particularly tissue macrophages, identify and internalise 


















Figure 1.7.   Histology from an abdominal aortic aneurysm wall. (i) Haematoxylin and eosin staining 
at x20 (magnification) – inflammatory cell infiltrates seen in the endoluminal region with focal 
calcified atheroma. (ii) Perls stain for iron at x100 and (iii) x600 showing the presence of iron (blue). 
(iv) CD68 staining for macrophages (brown) at x100 and (v) x600 showing colocalisation of 














The development of cross-linked USPIO (CLIO) [Wunderbaldinger et al 2002] 
opened avenues allowing for more targeted inflammatory imaging. Cross-linking and 
amination of the USPIO dextran chains encourages circumferential adherence of the 
dextran coat to the iron nanoparticle providing chemical stability and improved 
conjugation to other molecules including antibodies thus enabling targeted imaging 
of specific antigens [Wunderbaldinger et al 2002]. Preclinical studies discussed in 
the following sections often make use of CLIO for targeted inflammatory imaging. 
 
1.7.1   MYOCARDIAL INFARCTION 
Myocardial infarction caused by sustained interruption to coronary blood flow is 
associated with a potent inflammatory response that is essential for cardiac repair. 
The magnitude of the inflammatory response is greater if ischaemic tissue is 
reperfused, which is the current standard practice for treating patients with MI in the 
developed world. The inflammatory response seen is a prerequisite for scar 
formation and ultimately healing of the injured myocardium.  
 
Acute myocyte death rapidly activates innate immune pathways triggering an 
inflammatory reaction. Injured, necrotic tissue generates and releases endogenous 
signals, known as ‘alarmins’ that promote activation of innate immune cells [Chan et 
al 2012]. Other intracellular constituents released by necrotic cells also activate an 
immune response [Arslan et al 2011]. Innate immune cells identify danger signals 
via engagement of Toll Like Receptors (TLRs) that activate pro-inflammatory 




Activation of the complement system and generation of reactive oxygen species after 
ischaemia are also involved in attracting of inflammatory cells. Upregulation of pro-
inflammatory chemokines and cytokines ultimately lead to attraction of 
inflammatory cells into the heart.  
 
The cellular response is dominated initially by neutrophil influx, and later with 
interleukin and monocyte-derived macrophage invasion [Entman and Smith 1994; 
Frangogiannis et al 1998; Frangogiannis et al 2002]. Macrophages contribute a 
source of cytokines and growth factors necessary to support neovascularisation, 
extracellular matrix metabolism and fibroblast proliferation. However it is not simply 
a case of the more macrophages the better. Recently, it has been shown that 
monocytes and their derived macrophages influence both the extent of myocardial 
salvage and recovery of left ventricular (LV) function, but if early levels of 
macrophages become uncontrolled, this leads to poorer outcomes [Maekawa et al 
2002; Nahrendorf et al 2007; Tsujioka et al 2009; Nahrendorf et al 2010; Panizzi et 
al 2010]. Therefore it appears that an ‘optimum’ degree of macrophage infiltration 
exists after myocardial infarction, and it would be a major advance if a reliable 
imaging technique capable of detecting and quantifying inflammatory tissue 
macrophages after MI could be developed. 
 
Yang et al [2010] successfully imaged inflammatory cell infiltration in a murine left 
anterior descending (LAD) coronary artery ligation model of myocardial infarction. 
Large micron-sized particles of iron oxide were administered and T2* signal 




were (i) administered MPIO and had a ‘sham’ operation, or (ii) subjected to 
myocardial infarction but did not receive MPIO. Unsurprisingly, they noted 
increased signal attenuation in the infarct area, illustrating MPIO accumulation 
secondary to macrophage ingestion, and this was confirmed using histology data. 
Signal attenuation from accumulation of macrophages correlated with a reduction in 
left ventricular ejection fraction suggesting greater levels of inflammation predict 
poorer functional recovery. This adds further evidence to suggest that optimal      
post-MI recovery is determined by the balance between proinflammatory and 
reparative macrophages, with uncontrolled early inflammation leading to adverse 
functional recovery.  
 
The same group subsequently carried out a slightly modified experiment proving that 
monocytes travelled from storage within organs of the reticuloendothelium system to 
the myocardium after MI. They injected mice with MPIO and waited 7 days before 
carrying out iatrogenic myocardial infarction again using LAD ligation. As micron-
sized particles of iron oxide are rapidly phagocytosed and cleared from the blood 
within one minute, this allows adequate time for MPIO to be distributed only within 
organs of the reticuloendothelium system. After LAD ligation 7 days later, mice 
were imaged at various intervals over the following month, and signal attenuation 
was seen within the infarct zone for 2 weeks post-MI. The signal attenuation seen 
must be due to accumulation of MPIO-labelled macrophages originating from the 
reticuloendothelial system. Myocardial haemorrhage was discounted as a 




MI-induced mice that did not receive MPIO showed less signal attenuation  than the 
MPIO groups [Yang et al 2011]. 
  
Sosnovik et al [2007] used multimodality imaging in assessing inflammation       
post-MI. They conjugated CLIO with cyanine 5.5 dye creating a magneto-fluorescent 
particle allowing co-registration of MRI and fluorescence molecular tomography 
data. They administered CLIO-Cy5.5 48 hours after left coronary artery ligation in a 
mouse model of myocardial infarction with dual modality imaging 48 hours later. 
Accumulation of CLIO-Cy5.5 within infarcted regions of myocardium was clearly 
seen on fluorescence and MR images that were not present on control mice (mice 
injected with CLIO-Cy5.5 but had a sham operation). In vivo imaging findings were 
subsequently confirmed with histology: inflammatory cell infiltrate seen on 
haematoxylin and eosin staining colocalised with regions of increased signal 
intensity on fluorescence microscopy, and regions displaying an abundance of 
macrophages on immunohistochemistry staining. This is consistent with uptake of 
CLIO-Cy5.5 by macrophages infiltrating the infarcted myocardium. 
 
Clinical applications of USPIO highlighting tissue inflammation after myocardial 
infarction have since emerged. Alam et al [2012] used USPIO to image myocardial 
tissue inflammation following acute MI. Within 48 hours of acute MI patients 
underwent MRI scanning at baseline (pre USPIO), before receiving an infusion of 
ferumoxytol (USPIO) with subsequent serial MRI scans thereafter. Following 
USPIO administration, there was a significant increase in R2* (R2*=1/T2*) in the 




were observed in the peri-infarct (surrounding areas of delayed enhancement) and 
remote myocardial zones when compared with control tissue (skeletal muscle). The 
authors suggested the R2* increase seen in non-infarcted myocardium was due to 
pan-myocardial inflammation, however no histological data or healthy volunteer 
comparison group was available to confirm this. Importantly, changes in R2* were 
not due to myocardial infarction alone. A control group of MI patients not 
administered USPIO did not show a change in infarct zone R2*. Notably, the R2* 
value was greatest 24 hours following USPIO infusion, and had started to decline by 
48 hours suggesting that 24 hour post infusion was the most sensitive imaging time 
point for detecting infarct-related inflammation  in  this group of patients. 
 
Yilmaz et al [2013] conducted a study of similar design, yielding similar results, 
detecting significant USPIO uptake within the infarct, peri-infarct and remote 
myocardium besides the lymphoreticular system. They imaged the first 3 patients at 
6, 24, 48 and 96 hours after ferumoxytol administration in an attempt to find the 
optimal time window to characterise USPIO uptake within the myocardium. Like 
Alam et al [2012], signal attenuation was maximal at 24 hours, although the authors 
chose imaging at 48 hours as they considered this the best time for combination 
imaging of T2- and T2* imaging. 
 
The finding of T2* signal void in remote myocardium in both these studies is 
interesting and may suggest a pan-myocardial inflammatory response in the context 
of a focal infarct. Clinical histological data are clearly required to address the exact 




within the myocardium after MI, and the relative contribution to changes in T2* of 
extracellular USPIO accumulation in the interstitium, (peri-) capillary bed and 
inflammatory macrophages.  
 
1.7.2   MYOCARDITIS 
Myocarditis is a disease characterised by inflammatory cell infiltration of the 
myocardium with evidence of myocyte necrosis. Acute myocarditis comprises a 
wide clinical spectrum from subclinical disease to severe heart failure. There is a 
variety of different causes for myocarditis that include infections, iatrogenic toxins 
(such as anthracyclines) and immune-mediated, although frequently no cause is 
found [Caforio et al 2013]. 
 
A variety of inflammatory cells infiltrate the myocardium during myocarditis. The 
pathogenesis and recruitment of inflammatory cells into the myocardium are 
determined by the aetiology. In viral myocarditis, the most common cause of 
myocarditis, myocytes can be injured by direct viral entry and toxicity which can 
result in cell death and lysis, cytokine expression and inflammatory cell attraction 
[Esfandiarei m et al 2008]. In viral myocarditis, the infiltrate is predominantly 
lymphocyte rich, but plasma cells, neutrophils, eosinophils, giant cells, and 
macrophages have been found [Aretz et al 1987; Magnani and Dec 2006; Barin et al 
2012; Sagar et al 2012; Jaquenod De Giusti et al 2015]. In man, coxsackie B virus is 





Autoimmune mechanisms have also been implicated in the pathogenesis of 
myocarditis. Again, viral infection may be the initial insult releasing intracellular 
antigens that are then recognised as foreign by the body’s own antibodies. The T cell 
response to these ‘self-antigens’ stimulate other inflammatory B and T cells and 
cytotoxic cytokines. Autoantibodies to several cardiomyocyte components have been 
described {Caforio et al 1997, Schultheiss HP 1989]. Hypersensitivity myocarditis, a 
further cause for autoimmune myocarditis, is usually related to a recently initiated 
medication and is characterised by a predominantly eosinophilic infiltrate [Fenoglio 
et al 1981]. 
 
Although not the most prevalent cell type, macrophages appear to be intimately 
involved in myocarditis. In a rat model of myocarditis, monocytes have been found 
to differentiate into macrophages at sites of inflammation and exhibit a T helper cell 
type 1 (Th1) cytokine/chemokine profile suggesting they play an important role in 
the pathogenesis of myocarditis [Baba et al 2006]. Again macrophages may have 
divergent functions. In a mouse model of viral myocarditis, macrophage knock out 
(KO) mice had higher viral titres but paradoxically lower levels of inflammation seen 
on histology [Jaquenod De Giusti et al 2015]. In another study, mice with depletion 
of macrophages failed to develop myocardial inflammation [Hirasawa et al 1996]. 
These findings may tentatively suggest that similar to myocardial infarction, 
macrophages have both pro and anti-inflammatory effects in myocarditis. 
 
Endomyocardial biopsy is considered the gold standard, and is recommended for 




performed [Caforia et al 2013]. Cardiac MRI plays a key part in diagnosis and shows 
typical appearances on T2-weighted and gadolinium contrast imaging according to 
the Lake Louise Criteria [Friedrich et al 2009], and recent advances in quantitative 
MRI mapping techniques have recently been shown to improve diagnostic accuracy 














Figure 1.8.   Three chamber image of patient with basal posterior wall myocarditis (arrow) displaying  
typical MRI features of LGE (left) and high signal on T2 mapping (right). MRI - magnetic resonance 






Experimental models of myocarditis have been scrutinised by molecular imaging 
employing iron particles. Moon et al [2012] examined a rat model of experimental 
autoimmune myocarditis. They made use of a dual superparamagnetic and 
fluorescent ‘magneto-fluorescent’ nanoparticles (MNPs) consisting of a SPIO core 
with a rhodamine B isothiocyanate (RITC)-incorporated silica coating of 
approximately 20 nm thickness, and polyethylene glycol (PEG) conjugated onto the 
silica coating. They compared MNP-enhanced (10 mg Fe/kg) MRI with unenhanced 
conventional MRI protocols using T2-weighted, T1-weighted and early and late 
gadolinium enhancement sequences. The degree of inflammation was also assessed 
histologically. MNP-enhanced T2*-weighted CMR more accurately detected 
scattered foci of inflammation within the myocardium of rats with autoimmune 
myocarditis and improved visualisation of small and less severe myocardial 
inflammation than conventional CMR imaging. Areas detected by MNP-enhanced 
T2*-weighted CMR correlated well with inflammatory foci on histology as well as 
signal on fluorescence microscopy. However, MNP-enhanced MRI ultimately 
proved unable to detect milder  histological grades of myocardial inflammation, and 











1.7.3   CARDIAC TRANSPLANTATION 
Cardiac transplantation is a life prolonging treatment option for end stage cardiac 
disease. Transplant rejection is a major threat to the allograft, occurring in 20-30% of 
recipients in the first year [Hertz et al 2009], but can occur at any stage after 
transplantation and causes significant morbidity and mortality. Rejection is 
notoriously difficult to diagnose using existing non-invasive imaging methods so 
surveillance myocardial biopsies are routinely taken after transplantation. 
 
Most cases of acute graft rejection after transplantation are due to cellular rejection 
with antibody-mediated rejection less prevalent. Acute cell-mediated rejection is 
primarily a host T-cell response mounted against allograft tissue. Antibody-mediated 
rejection occurs when the allograft is injured resulting from activation of the 
complement system, typically by recipient-generated antibodies directed against the 
allograft tissue.  
 
Following tissue damage by the above mechanisms, bioactive cytokines are released 
by T cells and necrotic tissue. Cytokines such as IL-1α and TNFα are involved in 
stimulating the production of chemokines that in turn attract neutrophil migration to 
the site of inflammation [Eigenbrod et al 2008, Ishii et al 2010]. Other ‘danger’ 
signaling mechanisms are activated following insult to the graft during the 
transplantation process. These mechanisms activate dendritic cells leading to 
antigen-presenting cell maturation and release of proinflammatory cytokines [La 
Rosa et al 2007, Moreau et al 2013]. Donor antigen presenting cells induce 




in secondary lymphoid organs. These effector T cells subsequently activate 
macrophages and granulocytes that have infiltrated the graft in response to 
inflammatory stimuli [Moreau et al 2013].  
 
The severity of rejection is graded according to histological findings, and although 
the cellular infiltrate in acute cellular rejection is predominantly lymphocytic, 
macrophage infiltration is known to have a key role [Stewart et al 2005; Mannon 
2012]. The importance of macrophages in acute cardiac allograft rejection was 
highlighted in a recent study that showed depletion of circulating macrophages 
protected rodent hearts against allograft rejection, thus suggesting potential 
therapeutic targeting of macrophages in this condition [Wu et al 2013]. This study 
used USPIO-enhanced MRI to track macrophages within the heart, but the use of this 
technique in assessing cardiac allograft rejection is not new and has been used for 
over a decade.  
 
Kanno et al [2001] detected cardiac allograft rejection using MRI and dextran coated 
USPIO in rats with evidence of allograft rejection, again exploiting the ability of 
activated macrophages to accumulate iron nanoparticles within their cytoplasm. 
Histopathology confirmed active rejection and iron staining closely correlated with 
staining for macrophages. Treatment response could also be monitored with this 
method; rats that received prolonged immunosuppression, controlling the 





Subsequent studies have again confirmed the value of USPIO-enhanced MRI to 
detect acute cardiac rejection in rats with intensity of USPIO signal detected 
correlating with more severe rejection on histology and also poorer cardiac function 
[Johansson et al 2002; Penno et al 2005; Wu et al 2009; Wu et al 2013], although 
ferumoxtran-10 proved inferior to NC100150 in one study [Penno et al 2005] and 
was unable to detect acute rejection in another [Penno et al 2009]. In this latter study, 
ferumoxtran-10 was given at two doses of 2 mg and 11 mg Fe/kg with T2*-weighted 
MRI conducted using 1.5 T MR imaging at postoperative day 7, 24 hours after 
USPIO administration. Failure to detect USPIO was likely due to the low magnetic 
field strength of the MR scanner. 
 
Besides simply tracking tissue macrophages, iron oxide particles can be conjugated 
to antibodies or peptides allowing targeting of specific pathophysiological processes 
[McAteer et al 2010]. Recent work by Guo et al [2012] targeted T cells that play a 
central role in acute cardiac allograft rejection. They used ligand targeting of cells to 
employ a ‘theranostic’ strategy, combining diagnostic imaging with administration of 
therapy within the one system. They targeted T cells in the endocardium of rejecting 
rat hearts by using a CD3 antibody multifunctional polymeric nanocarrier that 
included SPIO and also a therapy gene (pDNA-DGKalpha). This enabled 
simultaneous imaging by detecting SPIO, at the same time as providing immune 
modulation to the CD3 expressing T cells. 
 
USPIO has also proved useful in detecting renal transplant rejection. Recent work by 




renal allografts compared with isografts and native kidneys. USPIO accumulation 





Iron nanoparticles, in particular USPIO, have been used in functional and molecular 
MR imaging of the heart with variable success over the last 20 years. Initially used as 
a blood pool contrast agent, it is in their ability to detect cardiac inflammation that 
there is major promise for clinical translation. This exciting imaging technique has 
great potential and the results of these research studies, and others in the coming 
years, will help determine its place in the clinic. 
 
1.9 AIMS AND HYPOTHESES 
 
The aim of this thesis is to investigate the role of USPIO-enhanced MR imaging in 
the detection of cardiac inflammation. Specifically, I will assess whether               
USPIO-enhanced MRI is able to detect and serially monitor macrophage-driven 
inflammation after myocardial infarction. Additionally, I wish to assess whether 
USPIO-enhanced MRI is able to detect cardiac inflammation in other conditions with 
macrophage infiltration of the myocardium; myocarditis; and cardiac transplant 
rejection. In order to do this we will also examine a control group of healthy 





The following hypotheses will be addressed: 
 
1. A range of normal T2* values at 1.5 T and 3 T in healthy volunteers before 
and after USPIO administration can be determined  (Chapter 3). 
2. USPIO-enhanced T2* MRI can be used to detect and serially monitor 
myocardial inflammation after MI using single and repeated USPIO 
administration  (Chapter 4). 
3. USPIO-enhanced T2* MRI can be used to detect myocardial inflammation in 
acute myocarditis  (Chapter 5). 
4. USPIO-enhanced T2* MRI can be used to detect myocardial inflammation in 






























2.1.1   ETHICAL AND REGULATORY CONSIDERATIONS 
All studies were approved by the South East Scotland Research Ethics Committee or 
Scotland A Research Ethics Committee. The Medicines and Healthcare products 
Regulatory Agency (MHRA) approved the use of Rienso® (Takeda Italia S.p.A. Via 
Crosa, 86. 28065 Cerano (NO) Italy) to investigate patients with myocarditis, cardiac 
transplant rejection and healthy volunteers as a Clinical Trial of an Investigational 
Medical Product (CTIMP). All studies were conducted in accordance with the 
Declaration of Helsinki. Studies were registered on the public website 
www.clinicaltrials.gov (NCT01995799; NCT02319278). 
 
2.1.2 		SUBJECT RECRUITMENT 
Written informed consent was received by all participants following appropriate 
review of the patient information sheet. A copy of the consent form and participant 
information sheet was filed in the medical case records. Participants’ GPs were 
informed of their inclusion in writing and received a participant information sheet. 
 
2.1.3   MYOCARDIAL INFARCTION 
Participants were aged 18 to 80 years of age and had sustained a recent MI according 
to the Third Universal Definition of Myocardial Infarction [Thygesen et al 2012], 
with 12-hour plasma troponin I concentration ≥5000 ng/L. Exclusion criteria were 
known critical stenosis (>95%) of the left main stem, ongoing symptoms of angina, 
heart failure (Killip class ≥2), renal failure (estimated glomerular filtration rate        
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<30 mL/min/1.73 m2), and contraindication to MR imaging or ferumoxytol infusion. 
 
2.1.4   HEALTHY SUBJECTS 
Healthy subjects were recruited via adverts at the Royal Infirmary of Edinburgh, and 
the Golden Jubilee National Hospital, Clydebank. Healthy subjects were over         
18 years of age and had no past medical history of an inflammatory process. Other 
exclusion criteria were contraindication to MRI or ferumoxytol infusion, pregnancy, 
breastfeeding and women of childbearing potential without reliable contraception. 
 
2.1.5   ACUTE MYOCARDITIS 
Adult (>18 years of age) patients with suspected acute myocarditis were recruited 
into the study. The clinical diagnosis was made by an independent clinical 
cardiologist based on the history, electrocardiogram, serum troponin and other 
available imaging modalities. The diagnosis of myocarditis was verified from 
case note review by an independent cardiologist and retained for analysis if the MRI 
scan (reported and agreed by two independent radiologists) showed typical imaging 
features of myocarditis [Friedrich et al 2009]. Healthy volunteers had no clinically 
significant past medical history. Exclusion criteria were contraindication to MRI or 
ferumoxytol infusion, any other inflammatory comorbidity, renal failure (estimated 
glomerular filtration rate <30 mL/min/1.73 m2), pregnancy, breastfeeding and 






2.1.6   CARDIAC TRANSPLANT 
Participants were over 18 years of age and had undergone cardiac transplantation. 
Exclusion criteria were contraindication to MRI (including pacemaker and ICD) or 
ferumoxytol infusion, recent myocardial infarction (1 month), any other 
inflammatory comorbidity, renal failure (estimated glomerular filtration rate         
<30 mL/min/1.73 m2), pregnancy, breastfeeding and women of childbearing 
potential without reliable contraception. 
 
2.2 MAGNETIC RESONANCE IMAGING 
 
Basic principles of magnetic resonance imaging are discussed in Chapter 1. 
Contraindications to MRI scanning included claustrophobia and metallic implants.  
 
2.2.1   MRI PROTOCOL 
Magnetic resonance imaging was performed using a 3 tesla scanner at the University 
of Edinburgh and a 1.5 tesla scanner at the Golden Jubilee National Hospital, 
Clydebank (Magnetom Verio and Avanto respectively, Siemens AG, Healthcare 
Division GmbH, Erlangen, Germany), all with dedicated cardiac array coils. All 
images were acquired using electrocardiogram-gated breath-holds. 
 
All cardiac MRI scans had the following sequences as standard. Scanning started 
with axial and coronal localisers to ensure the heart is in the isocentre of the 
magnetic field. This was immediately followed by a free breathing, 30 slice series of 
black-blood HASTE imaging, useful to determine anatomy, followed by breath held 
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steady-state free precession (SSFP) vertical and horizontal long, and short axis 
images of the heart, necessary to plan short axis, 2, 3 and 4 chamber views of the 
heart. 
 
Following the above standard sequencing, participants were imaged with some or all 
of three following sequences depending on the specific study protocol. 
 
2.2.2   T2* IMAGING 
Quantitative USPIO imaging by calculation of T2* decay times was performed in a 
short axis stack, 2, 3 and chamber views, and a sagittal view through the spine using 
a prototype T2*-weighted multi-echo gradient-echo acquisition using a volumetric 
shim applied over the entire heart volume (TR 996 ms, TE 2.13, 4.3, 6.4, 8.6, 10.7, 
12.8, 15.0, 17.1 ms, flip angle 18º, matrix 130x256, FoV 400 mm, slice thickness 
6 mm, 4 mm gap). The T2*-weighted acquisitions included views through the liver, 
spleen and spine to allow quantification of USPIO accumulation within organs of the 
reticuloendothelial system. The same T2* protocol was used to quantify USPIO 
accumulation 24 hours after infusion allowing calculation of T2* relaxation rates 
before and after administration of USPIO. The in-plane resolution differed as 
required for larger or smaller objects; generally, a field of view of 400×300 mm was 
used with an in-plane resolution of 2.6×1.6 mm. 
 
2.2.3   T2 MAPPING 
Oedema imaging was conducted using a Siemens T2 mapping (Siemens Healthcare, 
Erlangen, Germany) (based on a prototype T2-prepared (T2P) True fast imaging 
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steady-state precession (FISP) acquisition acquiring identical long and short axis 
slice positions (TR 219.3 ms, TE 1.07 ms, T2P durations 0, 25, 50 ms, flip angle 70º, 
matrix 130x192, FoV 400 mm, slice thickness 6 mm, 4 mm gap). T2P-TrueFisp 
images were acquired at intervals of at least 3 RR intervals to allow for sufficient 
magnetisation recovery in between acquisitions. 
 
2.2.4   WALL MOTION CINE IMAGING 
Routine steady-state free precession sequences were used to acquire long and 
short axis cine images of the heart (TR 85.8 ms, TE 1.45 ms, flip angle 50º, matrix 
173x256, FoV 400 mm, slice thickness 8 mm, 2 mm gap).  
 
 
2.2.5   LATE GADOLINIUM ENHANCEMENT IMAGING 
Immediately after the baseline T2 and T2*-weighted scan, participants received an 
intravenous administration of gadolinium contrast medium (0.1 or 0.15 mmol/kg; 
Gadovist, Bayer Plc, Germany) followed by breath held inversion recovery 
sequences in long axis and short axis planes to acquire late enhancement images. 
Gadolinium-enhanced imaging is the current gold standard for infarct detection using 
MRI. Optimal inversion time (TI) was determined on a slice-by-slice basis using 
standard late enhancement TI-scout protocols (TR 750 ms, TE 2.61 ms, flip angle 
20º, matrix 173x256, FoV 400 mm, slice thickness 9 mm, 1 mm gap). The 
inversion recovery late enhancement short axis slices were acquired using similar 




2.3 STUDY PROTOCOLS (see Figures 2.1a-d) 
 
Protocols were individually designed for each study.  
 
2.3.1   HEALTHY VOLUNTEERS 
One pair of pre and 24 hours post USPIO-enhanced MRI scans was sufficient to 
determine ‘normal’ tissue uptake of USPIO (Chapter 3). 
 
2.3.2   MYOCARDIAL INFARCTION 
A variable study protocol was used that was purposely designed for imaging at 
different time points after acute MI. Over a 3-month period following MI, patients 
received up to 7 MRI scans and up to 3 infusions of USPIO. Two principal analyses 
were performed using data from the same participants. 
 
First, to assess the duration of a single dose of ultrasmall superparamagnetic 
particles of iron oxide, R2* values of participants that first received USPIO within 
7 days of myocardial infarction were followed on all subsequent MRI scans prior to 
receiving any further doses of USPIO (Chapter 4). Second, to assess the duration of 
myocardial macrophage activity, USPIO uptake was compared using repeated 
USPIO infusions over the 3-month follow up period. USPIO uptake was calculated 
by subtracting the baseline R2* value from values obtained at 24 hours following 
USPIO infusion (Chapter 4). This allowed repeated assessment of myocardial 
USPIO uptake. Finally, to assess myocardial oedema, T2 values were compared on 




Following clinical guidance for the administration of ferumoxytol, participants were 
allowed a maximum of two doses of USPIO in a 1-month period, and a total of three 
over the 3-month follow up period to prevent iatrogenic iron overload. It was 
therefore not possible to perform repeated USPIO-enhanced imaging at every time 
point in the same patient. 
 
2.3.3   ACUTE MYOCARDITIS AND CARDIAC TRANSPLANTATION 
To assess myocardial macrophage activity in patients with acute myocarditis and 
cardiac transplantation, USPIO uptake was calculated at baseline, and repeated after 






2.4 INFUSION OF ULTRASMALL SUPERPARAMAGNETIC 
PARTICLES OF IRON OXIDE AND BLOOD TESTING 
 
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg) (Figure 2.1) was performed 
immediately following the baseline, and selected subsequent magnetic resonance 
scans (depending on above protocol) over at least 15 minutes using a concentration 
of 2-8 mg/mL, diluted in 0.9% saline or 5% dextrose. Haemodynamic monitoring 
was conducted throughout and patients were observed for at least 30 minutes 
following administration to ensure no hypersensitivity reactions. 
 
Routine blood tests were collected at all visits other than when patients attended for 
the 24 hour post USPIO MRI scan (as they had been collected the previous day). We 
measured full blood count, urea and electrolytes, C-reactive protein (CRP) and high 
sensitivity troponin. 
 
2.5 IMAGE ANALYSIS 
 
Several methods of analysis were attempted, but only those retained for data 
presented in this thesis will be outlined. Using identical methodology to that 
described throughout this thesis,  Alam et al found excellent repeatability for the 
assessment of R2* with a mean bias of −0.208 s−1, coefficient of repeatability of 






Figure 2.1.   Vial of ferumoxytol – 510 mg in 17 mL (note trade name of Feraheme™ in the USA; 
previously licensed as Rienso® in the EU). 
 
 
2.5.1   T2 MAP AND T2* ANALYSIS 
All T2 map and T2*-weighted multi-gradient-echo images for each patient were 
analysed using Circle CVI software (Circle CVI42, Canada). For T2* analysis, an 
experimentally determined threshold used in previous work [Alam et al 2010] for the 
coefficient of determination (r2>0.85) was used to exclude data that did not have an 
acceptable exponential decay when signal intensity was plotted against echo time. 
The relaxation rate, R2*, is the inverse of the mean T2*, and was calculated to assess 
the uptake of USPIO for each region of interest (ROI), where the higher the value, 
the greater the USPIO accumulation.  
 
T2 and T2* values were measured immediately prior to USPIO administration. 
USPIO-enhanced T2* data was also collected 24 hours following ferumoxytol 
administration (see Region of Interest Selection below).  
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2.5.2   FUNCTIONAL ANALYSIS 
Ventricular volume and functional analyses were performed using QMass software 
(Medis Medical Imaging Systems, The Netherlands). Endocardial and epicardial 
contours were manually drawn on short axis slices through the heart in end-diastole 
and end-systole from the base of the heart at the level of the mitral valve annulus to 
the apex (Figure 2.2). Data collected included myocardial mass, end-diastolic and 
end-systolic volumes (indexed to body surface area (BSA)) and finally ejection 
fraction. 
 
2.5.3   LATE GADOLINIUM ENHANCEMENT ANALYSIS AND REGION OF INTEREST 
SELECTION 
Late gadolinium enhancement analysis was performed using Medis Qmass Delayed 
Signal Intensity (DSI) analysis wizard (Medis Medical Imaging Systems, The 
Netherlands). LGE images were aligned with each series of T2 and T2* scans at each 
visit. After drawing LV endocardial and epicardial contours, we then selected and 








Figure 2.2.   Epicardial (green) and endocardial (red) contours for a single short axis slice in end-
diastole (left) and end-systole (right) to calculate myocardial mass, end-diastolic and end-systolic 




DSI threshold and segmentation. To delineate areas of LGE, we used two standard 
deviations above normal remote myocardium, with further adjustments with manual 
correction if required (Figure 2.3). This allowed myocardial ROIs to be selected on 
the LGE images and applied to coaligned T2* maps. Regions of interest were also 
drawn in the heart using standard cardiac segmentation [Cerqueira et al 2002], and 
pan-myocardial values averaged using segments 1-16 (Figures 2.4 and 2.5). 
 
For patients with myocardial infarction, regions were categorised into infarct zone, 
peri-infarct zone, and remote myocardium (defined by late gadolinium enhancement,  
½ segment immediately adjacent to late gadolinium enhancement, and opposite the 
infarct zone on short axis slice and at least 1 full myocardial segment clear of LGE 
respectively, Figure 2.6). Where there was not clear delineation between infarct and 
peri-infarct tissue, the infarct and peri-infarct regions did not meet. This was to 
ensure the infarct region was purely within infarcted tissue, and the peri-infarct 
region outwith infarcted tissue. 
 
To focus on inflamed myocardium in patients with acute myocarditis, regions with 
contiguous LGE >1 cm2 on a single short axis slice were retained and visually         
coaligned with corresponding T2 and T2* images. These corresponding coaligned 
regions were then averaged to form  LGE+ T2 and T2* regions. 
 
Other selected regions included liver, spleen, bone marrow, kidney, blood pool, 








Figure 2.3.   LGE selection using Medis Qmass Delayed Signal Intensity (DSI) wizard. After drawing 
LV endocardial and epicardial contours, we then selected and verified areas of healthy and 
hyperintense (infarct) myocardium (A), and verified the DSI threshold and segmentation (B). To 
delineate areas of LGE, we used two standard deviations above normal remote myocardium, with 
further adjustments with manual correction if required (C, D). In this example of a large anteroseptal 
myocardial infarction, reducing the threshold (from B to C), subsequently excluded areas of 
microvascular obstruction (black core within white infarct area) which then needed to be manually 















Figure 2.4.   Basal short axis slice showing T2 map in greyscale. Segments 1-6 are manually drawn 
with care taken to ensure sampling of the myocardium only. A mean T2 value (ms) for each segment 











Figure 2.5.   Short  axis mid ventricular slice of a single T2* echo. Segments 9 (yellow), 10 (purple), 
11 (orange) and 12 (turquoise) are selected and the T2* decay curve for each region is displayed on 
the graph (right). Here, all segments have an r2 close to 1 indicating excellent curve fitting. Care is 
taken to avoid sampling the epicardium and endocardium and regions of artefact. All 8 individual 
echos for each slice are available for viewing at the bottom of the image to ensure no artefact is 









Figure 2.6.   Region of interest selection in myocardial infarction. Regions of interest including 
infarct (orange), peri-infarct (green) and remote (yellow) are drawn with reference to the LGE image. 
Here all regions on this post USPIO short axis slice display good T2* decay curve fitting (r2 close to 
1). The infarct zone displays the lowest T2* value (highest R2*). As the boundary between infarct and 
peri-infarct tissue was not clear, the infarct region was drawn from purely infarcted tissue, and the 
peri-infarct region outwith the region of infarction. LGE - late gadolinium enhancement;            





2.6 HISTOLOGICAL ANALYSIS 
 
Myocardial tissue samples were obtained from patients undergoing coronary artery 
bypass graft (CABG) surgery for treatment of their coronary disease within 2 weeks 
of their index myocardial infarction. A further biopsy was obtained from a patient 
with cardiac transplant having routine myocardial surveillance biopsies. USPIO was 
administered 24 hours prior to the biopsy, and a trucut myocardial biopsy sample 
was taken from the myocardium (infarct area for MI patients) during the procedure. 
The biopsy sample was fixed in formalin, embedded in paraffin, sectioned, and 
stained to look at the architecture (haematoxylin and eosin), and the accumulation 
and distribution of USPIO (Prussian Blue) and macrophages (CD68). Patients that 
underwent CABG surgery were excluded from further MRI follow up. 
 
2.7  STATISTICAL ANALYSIS 
 
All statistical analysis was performed with GraphPad Prism, version 6 (GraphPad 
Software, San Diego, CA, USA). To assess duration of USPIO enhancement in 
tissues following single administration in the first week after myocardial infarction, 
R2* values from subsequent MRI scans (prior to any further USPIO dosing) were 
compared using one-way analysis of variance (ANOVA) with Tukey’s post hoc test 
for multiple comparisons. To assess variation and duration of myocardial 
inflammation after MI, USPIO uptake (R2* increase from pre to 24 hours post 
USPIO) was compared using one-way ANOVA with Tukey’s post hoc test for 
multiple comparisons (repeated measures where appropriate). As a further method to 
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assess USPIO accumulation within the heart, R2* values 24 hours after 
administration (without baseline R2* subtraction) was compared in the same way. 
Finally, to assess variation and duration of myocardial oedema after MI, T2 values 
were compared again using one-way ANOVA with Tukey’s post hoc test for 
multiple comparisons (repeated measures where appropriate). 
 
To compare USPIO uptake and myocardial oedema between groups (volunteers with 
either patients with acute myocarditis or cardiac transplantation), R2* and T2 values 
were compared using unpaired t-test. To compare results at 3 months with baseline 
within patient groups, a paired t-test was used. Statistical significance was defined as 
two-sided p<0.05 for all statistical tests mentioned above. 
 
2.8  SAMPLE SIZE CALCULATIONS 
Previous work [Alam et al 2012] has shown the change in R2* due to USPIO in 
‘healthy’ myocardium (remote from the site of myocardial infarction) to be 40 +/- 11 
s-1 at 24 hours following USPIO. Assuming the change due to USPIO is similar in 
truly healthy myocardium, a sample size of 10 in each group is needed to detect an 
effect size of 20s-1 due to USPIO, (ie an increase of 50%) with 80% power and 














FERUMOXYTOL-ENHANCED MAGNETIC RESONANCE IMAGING; 
 
METHODOLOGY AND NORMAL VALUES 




3.1 SUMMARY  
 
Background   Ultrasmall superparamagnetic particles of iron oxide-enhanced 
magnetic resonance imaging can detect tissue-resident macrophage activity and 
identify cellular inflammation. Clinical studies using this technique are now 
emerging. I aimed to report a range of normal R2* values at 1.5 tesla and 3 tesla in 
the myocardium and other tissues following ferumoxytol administration, outline the 
methodology used and suggest solutions to commonly encountered analysis 
problems. 
Methods   Twenty volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2* 
and late gadolinium-enhanced MRI was conducted at baseline with further T2* 
imaging conducted approximately 24 hours after USPIO infusion (ferumoxytol, 
4 mg/kg). Regions of interest were selected in the myocardium and compared to 
other tissues. 
Results   Following administration, USPIO were detected by changes in R2* from 
baseline (1/T2*) at 24 hours in myocardium, skeletal muscle, kidney, liver, spleen 
and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and bone at 3 T 
(p<0.05 for all). Myocardial changes in R2* due to USPIO were 26.5±7.3 s-1 at 1.5 T, 
and 37.2±9.6 s-1 at 3 T (p<0.0001 for both). Tissues showing greatest ferumoxytol 
enhancement were in the reticuloendothelial system: the liver, spleen and bone 
marrow (216.3±32.6 s-1, 336.3±60.3 s-1, 69.9±79.9 s-1; p<0.0001, p<0.0001, p=ns 
respectively at 1.5 T, and 275.6±69.9 s-1, 463.9±136.7 s-1, 417.9±370.3 s-1; p<0.0001, 




Conclusion   Ferumoxytol-enhanced MR imaging is feasible at both 1.5 T and 3 T. 
Careful data selection and dose administration, along with refinements to echo time 
acquisition, post processing and analysis techniques are essential to ensure reliable 




Iron oxide nanoparticles are a class of magnetic resonance imaging contrast agents 
that are generating interest as a method of detecting tissue inflammation. Historically, 
these nanoparticles were initially used for gastrointestinal, reticuloendothelial system 
and lymph node imaging [Saini et al 1987; Hahn et al 1990; Rogers et al 1994], and 
subsequently in hepatic and cardiac imaging [Canet et al 1993; Ros et al 1995; Kroft 
et al 1998; Taylor et al 1999]. Recently however, it is in their use as an MRI contrast 
agent for detecting tissue-resident macrophages that clinical applications are now 
emerging [Trivedi et al 2004; Tang et al 2006; Trivedi et al 2006; Tang et al 2009; 
Richards et al 2011; Alam et al 2012; Yilmaz et al 2013; McBride et al 2015].  
 
T2* MR imaging has been successfully used for over a decade in diagnosing and 
grading severity of iron accumulation in transfusion-dependent thalassaemia major, 
and has been instrumental in guiding therapy that improves prognosis, and allows 
serial disease monitoring [Anderson et al 2001; Anderson et al 2004]. T2* MRI in 
the assessment of iron accumulation is easily quantifiable, well validated, highly 




[Westwood et al 2003a; Westwood et al 2003b; Carpenter et al 2009; Kirk et al 
2010; Carpenter et al 2011]. 
 
Ultrasmall superparamagnetic particles of iron oxide consist of an iron oxide core 
surrounded by a carbohydrate or polymer coating. These particles can extravasate 
through damaged capillaries, where they are engulfed and concentrated by tissue-
resident macrophages [Ruehm et al 2001]. Gradient echo T2*-weighted sequences 
are highly sensitive to magnetic field inhomogeneities such as susceptibility artefacts 
due to the presence of iron, including USPIO. Accumulation of USPIO in 
macrophages can be quantified and visualised using T2*W MR imaging [Alam et al 
2012; Yilmaz et al 2013] and calculation of, and observing the reduction in, T2* 
relaxation time due to the presence of iron. Thus USPIO-enhanced MRI can detect 
tissue-resident macrophage activity and identify localised cellular inflammation 
within tissues. 
 
In this present study I  aimed to observe and quantify the distribution of  ferumoxytol 
enhancement following intravenous administration at 1.5 T and 3 T MRI and 
establish a range of normal healthy myocardial and other tissue values. I also aimed 
to develop our methodology and describe commonly encountered problems in T2* 










This was an open label observational multicentre cohort study using human 
volunteers recruited as part of a larger trial, recruiting patients with cardiac 
inflammation. The study was performed in accordance with the Declaration of 
Helsinki, the approval of the Scotland A Research Ethics Committee, and the written 
informed consent of all participants. 
 
3.3.1   SUBJECTS 
Participants were aged over 18 years of age. Exclusion criteria were contraindication 
to MR imaging or ferumoxytol infusion, any systemic inflammatory comorbidity (eg 
rheumatoid arthritis), renal failure (estimated glomerular filtration rate <30 mL/min), 
pregnancy, breastfeeding and women of childbearing age not ensuring reliable 
contraception. 
 
3.3.2   MAGNETIC RESONANCE IMAGING 
MRI was performed using 3	T and 1.5 T scanners (Magnetom Verio and Avanto 
respectively), with dedicated cardiac array coils. All images were acquired using 
electrocardiogram-gated breath-hold imaging. Routine steady state free precession 
sequences were used to acquire long axis and short axis images of the heart. Standard 
cardiac slice widths (6 mm width with 4 mm gap) and 8 echo times (2.1-17.1 ms 
range) with matrix size of 256×115 were acquired in order to generate T2* maps. 
The in-plane resolution differed as required for larger or smaller subjects; generally, 




T2* relaxation maps were generated before and approximately 24 hours after 
administration of USPIO. 
 
Immediately after the baseline T2* and SSFP cine imaging, breath held inversion 
enhancement images were acquired following an intravenous administration of 
gadolinium contrast medium (0.1 and 0.15 mmol/kg at 3 T and 1.5 T respectively). 
Optimal inversion time was determined on a slice-by-slice basis using standard 
late enhancement TI-scout protocols. The inversion recovery late enhancement 
short axis slices were acquired using similar slice positions to the myocardial T2* 
imaging. The T2* acquisitions also included imaging of the liver, spleen and spine to 
allow quantification of USPIO accumulation within organs of the reticuloendothelial 
system.  
 
3.3.3   USPIO 
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg) was performed immediately 
following the baseline magnetic resonance scan over at least 15 minutes using a 
concentration of 2-8 mg/mL, diluted in 0.9% saline or 5% dextrose. Haemodynamic 
monitoring was conducted throughout.  
 
3.3.4   STUDY PROTOCOL 
Volunteers received two MRI scans approximately 24 hours apart (Figure 3.1).  
 
3.3.5   IMAGE ANALYSIS 




Circle CVI software. Regions of interest were drawn in the heart using standard 
cardiac segmentation [Cerqueira et al 2002], and pan-myocardial values averaged 
using segments 1-16. Further regions of interest were drawn in skeletal muscle, 





Figure 3.1.   MRI  Protocol.  
USPIO - ultrasmall superparamagnetic particles of iron oxide; MRI - magnetic resonance imaging; 














An experimentally determined threshold used in previous work [Alam et al 2012] for 
the coefficient of determination (r2>0.85) was used to exclude data that did not have 
an acceptable exponential decay when signal intensity was plotted against    
echo time. The inverse of the mean T2* (R2*) for each ROI was then calculated to 
assess the uptake of USPIO, where the higher the value, the greater the USPIO 
accumulation.  
 
Late gadolinium enhancement, ventricular volume and functional analyses were 
performed using Circle CVI software. T2* data were collected immediately prior to 
USPIO administration. USPIO-enhanced T2* data were collected 24-25 hours 
following ferumoxytol administration.  
 
3.3.6   STATISTICAL ANALYSIS 
All statistical analysis was performed with GraphPad Prism, version 6. To assess 
uptake of USPIO in tissues following single administration, R2* increase from pre to 
24 hours following USPIO were compared using repeated measures one-way 
ANOVA. Univariate and multivariable linear regression models were constructed to 
examine the association of clinically relevant variables with myocardial R2* uptake. 
As myocardial R2* uptake was highly skewed, this was log transformed. Statistical 










Twenty volunteer patients were recruited in total (10 at 1.5 T, 10 at 3 T). Forty MRI 
scans and 20 infusions of ferumoxytol were completed over the course of the study. 
Data from one participant at 1.5 T has been removed due to the presence of LGE, 
(which was included in the MRI protocol so that we could exclude volunteers with 
any detectable cardiac MRI abnormalities according to standard MRI protocols). All 
other volunteers that were included had structurally normal hearts. One participant 
was prescribed antihypertensive medication but had a normal CMR study and was 
normotensive so the data was retained for analysis. Administration of ferumoxytol 
was well tolerated with no adverse reactions reported during or immediately after 
administration  in any of the participants. 
 
Participants were predominantly middle-aged, with greater numbers of women in 
both groups (Table 3.1). There were no differences between 1.5 T and 3 T groups in 
body mass index (BMI) or ejection fraction at baseline.  
 
A summary of results is shown in Table 3.2. At baseline, pan-myocardial R2* values 
were greater at 3 T than 1.5 T (46.9±4.1 versus 33.5±5.4 s-1, Figure 3.2; p<0.01) as 
expected. Baseline R2* values were also greater at 3 T in bone (p<0.0001) but no 
baseline differences were seen between magnetic field strength in all other tissues 
(Figure 3.3; p>0.05 for all). USPIO increased pan-myocardial R2* values at    
24 hours in both 1.5 T and 3 T scanners (p<0.0001 for both). Post USPIO pan-




(84.2±12.4 versus 60.5±7.2 s-1; p<0.0001). Pan-myocardial change in R2* between 
baseline and 24 hours post USPIO at 1.5 T was 26.5±7.3 s-1 and at 3 T was   
37.2±9.6 s-1; (p<0.0001 for both). Detectable increases in R2* were also observed at 
24 hours post USPIO in skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and 
kidney, liver, spleen, blood and bone at 3 T (Figure 3.3; p<0.05 for all).  
 
BMI correlated with the pan-myocardial R2* changes due to USPIO contrast 
(Figure 4.4; r=0.72,  p<0.001). With univariate analysis, age, weight and BMI were 
all associated with R2 value (P<0.05 for all, Table 3.3). However, in a multivariable 
adjusted model, only BMI was independently associated with R2 value (P=0.026, 
Table 3.3).  
 
TABLE 3.1    Participant Characteristics 
 1.5 T 3 T 
Number 9 10 
Male/Female 3:6 4:6 
Age 52 (45.5-61.) 50 (45.25-53) 
BMI (kg/m2) 22.9 (20.1-26.9) 25.9 (22.5-29.4) 
Ejection fraction (%) 63.6±4.9 61.1±4.1 
 
N (%),  mean±SD, or median (interquartile range). 

































































































































































































































































































































































































   
   
   






   



























































Figure 3.2.   Myocardial R2* pre  and post USPIO administration at 1.5 tesla  and 3 tesla. Following 
administration, USPIO was detected by an increase in R2* at 24 hours in the myocardium at both 
1.5 T and 3 T (**** = p<0.0001, ** = p<0.01). USPIO - ultrasmall superparamagnetic particles of 






















































Figure 3.3.   Tissue R2* pre and post USPIO administration at 1.5 tesla and 3 tesla. Following 
administration, USPIO was detected by an increase in R2*, 24 hours after administration in skeletal 
muscle, kidney, liver, spleen and blood at 1.5 T, and kidney, liver, spleen, blood and bone at 3 T 
(**** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05). USPIO - ultrasmall superparamagnetic 


























































































































































































Figure 3.4.   Body mass index versus pan-myocardial R2* change at 1.5 tesla  and 3 tesla. Body mass 
index correlates with pan-myocardial R2* change pre  and post  USPIO. BMI - body mass index; 
USPIO - ultrasmall superparamagnetic particles of iron oxide. 
  


















TABLE 3.3  ASSOCIATION OF VARIABLES WITH PAN-MYOCARDIAL 
R2* UPTAKE  
 
 Univariate Multivariable 
 
 Relative change in 
R2* value  
(95%CI) 
P value  Relative change 
in R2* value 
(95%CI) 
P value 
Age, per 1 year 
increase 
0.98 
(0.97 to 0.99) 
0.001 0.99 
(0.98 to 1.01) 
0.415 
Sex (Female) 0.94 
(0.70 to 1.28) 
0.688 1.08 
(0.76 to 1.55) 
0.634 
Height, per cm 
increase 
1.00 
(0.99 to 1.02) 
0.630 1.08 
(1.00 to 1.17) 
0.050 
Weight, per kg 
increase 
1.01 
(1.00 to 1.02) 
0.020 0.91 
(0.83 to 1.00) 
0.055 
BMI, per unit 
increase 
1.06 
(1.03 to 1.09) 
<0.001 1.36  
(1.04 to 1.76) 
0.026 
 
Univariate and multivariable linear regression analysis to examine association of variables with R2* 
value. R2* values were log-transformed as these were highly skewed. Multivariable linear regression 







For the first time, I report a range of normal T2* values in the healthy human heart 
and other tissues 24 hours after ferumoxytol administration at 1.5 T and 3 T. I will 
also describe problems, solutions and guidance in ferumoxytol-enhanced T2* image 
analysis.  
 
Following administration, USPIO is detectable by T2* imaging in the myocardium 
and other tissues at both 1.5 T and 3 T. Tissues with small increases in R2* (less than 
the blood pool) are likely to represent detection of USPIO within the intravascular 
space and include skeletal muscle (at 1.5 T only), myocardium and kidney. In 
contrast, R2* changes that are greater than the blood pool must be due to 
accumulation of USPIO, either through iron storage, uptake by macrophages or other 
phagocytes, or sequestered within tissue interstitium. In the absence of tissue 
biopsies, I cannot be certain, but as the most pronounced R2* changes were seen in 
the spleen, liver and bone marrow (organs of the reticuloendothelial system), it 
would appear likely that USPIO is incorporated quickly into tissue-resident 
phagocytes and macrophages.  
 
Detection of USPIO enhancement in skeletal muscle at 1.5 T but not 3 T is due to 
generally noisier data seen across all tissues at 3 T. Due to wider data confidence 
intervals, a larger sample size would be required to detected the same mean change 
in R2*. The variation in data at 3 T is partly artefact in the images, but also because 




sampling echo times, there are fewer data points to construct the decay curve at 3 T 
than 1.5 T so our error in estimation also increases.    
 
I chose 24 hours post USPIO to re-image participants as myocardial signal 
attenuation at 24 hours has shown to be optimal in the myocardium compared to later 
time points [Alam et al 2012; Yilmaz et al 2013]. In view of this, scanning 
appointments were generally separated by 25 hours, and in practice, this regime 
worked well for both participants and MRI planning. According to previous work 
[Alam et al 2012], I chose a weight-adjusted USPIO dose of 4 mg Fe/kg body weight. 
However, acknowledging that the distribution of USPIO following administration is 
predominantly in the organs of the reticuloendothelial system and blood pool, this 
may not be the optimum administration strategy as blood volume does not increase 
linearly with weight. I found a correlation between BMI and myocardial R2* change, 
probably due to increased blood pool USPIO concentration in those with a higher 
BMI. I therefore suggest that a fixed dose approach may also be appropriate 
depending on the application.  
 
Artefacts were commonly encountered with USPIO-enhanced T2* imaging and 
made data analysis challenging. Post contrast artefacts at the blood pool to 
myocardial interface were commonly seen and needed careful exclusion when 
selecting myocardial ROI (Figure 3.5). This limited the assessment of USPIO 
accumulation at the endocardium. Similarly, blooming artefacts from nearby organs 
with high iron or blood pool USPIO content, such as lung and liver, commonly 
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Figure 3.5.   Inferior blooming artefact. Example illustrating the challenge in assessing whether the 
inferior myocardial signal attenuation seen arrowed on the T2* colourmap (A, scale 0-60 ms) is true 
or caused by artefact. Drawing a region of interest (B) and examining the decay curve (C) along with 
visualising individual echos (D1-8) helps determine that this is a ‘blooming artefact’ from outside the 
heart that affects echos 4-8. These can be manually removed, forming a new decay curve (E) with 











decay curves and excluding echo times influenced by artefact  aided T2* curve 
fitting  (Figure 3.5). 
 
The advantage of MRI mapping techniques is that visual assessment and objective 
quantification can be made using the same image, and these are now entering clinical 
practice. It seems likely that if UPSIO-enhanced MR imaging is adopted into clinical 
practice to detect tissue inflammation, T2* mapping would be used for image 
interpretation. However based on my experiences, I would recommend caution in 
interpreting maps alone. Signal attenuation seen on the T2* map may be interpreted 
as tissue USPIO accumulation, but may be due to blooming artefact from nearby 
susceptibility effects, and close examination of the T2* decay curve, and individual 
echoes (if possible), is suggested in order to distinguish accurately between tissue 
USPIO accumulation and artefact. In theory, setting an r2 threshold as we did helps to 
exclude areas grossly affected by artefact. In practice however, regions with a 
seemingly acceptable r2 may still be influenced by artefact (Figure 3.5). Manual 
exclusion of later echoes (influenced by artefact) from the curve may result in an 
improvement in r2 (a measure of how well the data points fit the curve), however 
there is the danger that reducing the number of fitting points will in fact reduce the 
overall sampling accuracy. Clearly, automated software capable of detecting and 
excluding artefact would be advantageous. This could be achieved by excluding, or 
applying less weight, to later echo times especially data points at a large distance 
from the initial decay curve trajectory [He et al 2007; Shah et al 2011]. It should be 




breathing or movement artefact is generally non-interpretable and post processing 
using automated T2* decay curve fitting software is not likely to provide a remedy. 
 
Echo times in this study were specific for cardiac imaging and were selected 
appropriately. Therefore they were not optimal for imaging tissues with T2* values 
substantially higher or lower than myocardium. Native blood pool and post USPIO 
bone marrow (Figure 3.6) provide examples of low and high T2* values respectively 
that I had difficulty accurately fitting a T2* decay curve. With high T2* values, only 
a short part of the decay curve is plotted over the echo sampling time period, and 
often the signal has not decayed sufficiently for an accurate decay curve to be plotted. 
In contrast, regions with particularly short T2* decay times have decayed to a level 
expected from background noise before sufficient data sampling has been made. 
Therefore fitting a decay curve from a small number (i.e. 2-4) of echo times is 
clearly difficult, and often too much emphasis is placed upon data decayed to the 
baseline level of background noise in order to generate a decay curve. Allowances 
can be made for background noise but are of limited value in this instance. I strongly 
advise applying tissue-specific echo times tailored to the expected T2* value in order 















Figure 3.6.   Example of high and low T2* values. Regions of interest with excessively low or high 
T2* value (pre-contrast blood pool, A) and post USPIO bone marrow, B), respectively) can often be 
difficult to generate an accurate T2* decay curve. Imaging with tissue specific echo times will help 
generate more accurate T2* decay curves. USPIO - ultrasmall superparamagnetic particles of iron 












3.5.1   LIMITATIONS 
There are some limitations that should be taken into account when interpreting these 
data. First, this study has small numbers and a larger cohort of participants should be 
studied to further validate these normal values. Furthermore, due to geographical 
reasons, it was not feasible to scan the same participants at both centres so 
comparison cohorts at 1.5 T and 3 T were different. Despite this, both were healthy 
volunteers groups and displayed no differences at baseline so I do not feel this has 
impacted on the results. Finally, due to problems in interpreting high and low T2* 
values as mentioned above, I recommend caution in interpreting some high non-
cardiac R2* values; especially in the organs of the reticuloendothelial system at 3 T. 
In these organs, the spread of R2* data above the median value appears wide. This is 
possibly caused by artefact and most evident at 3 T, and may additionally explain 
why these regions have disproportionally high R2* values.   
 
3.5.2   CONCLUSION 
We have shown that ferumoxytol-enhanced MR imaging is feasible at both 1.5 T and 
3 T, and suggest a range of expected normal values post ferumoxytol in a range of 
tissues. Refinements of dose administration, optimisation of acquired echo times, 
careful image analysis, and development of post processing and analysis software 
capable of excluding common artefacts, are essential to ensure reliable and robust 



















ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF  
IRON OXIDE-ENHANCED T2* MAGNETIC RESONANCE IMAGING 
CAN BE USED TO DETECT AND SERIALLY MONITOR 
MYOCARDIAL INFLAMMATION AFTER MYOCARDIAL INFARCTION 













Objectives   Macrophages play a central role in the cellular inflammatory response 
to myocardial infarction and predict subsequent clinical outcomes. I aimed to assess 
temporal changes in cellular inflammation and tissue oedema in patients with acute 
MI using ultrasmall superparamagnetic particles of iron oxide-enhanced magnetic 
resonance imaging. 
Methods   Thirty-one patients were recruited following acute myocardial infarction 
and followed up for 3 months with repeated T2 and USPIO-enhanced T2* mapping 
MR imaging. Regions of interest were categorised into infarct, peri-infarct, and 
remote myocardial zones, and compared  to control tissues.  
Results   Following a single dose, USPIO enhancement was detected in the 
myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron 
and macrophages within the infarcted, but not the non-infarcted, myocardium. 
Following repeated doses, USPIO uptake in the infarct zone peaked at days 2-3, and 
greater USPIO uptake was detected in the infarct zone compared to remote 
myocardium until days 10-16 (p<0.05). In contrast, T2-defined myocardial oedema 
peaked at days 3-9 and remained increased in the infarct zone throughout the           
3-month follow up period (p<0.01).   
Conclusion			Myocardial macrophage activity can be detected using USPIO-
enhanced magnetic resonance imaging in the first 2 weeks following acute 
myocardial infarction. This observed pattern of cellular inflammation is distinct, and 
provides complementary information to, the more prolonged myocardial oedema 




non-invasive method of assessing and monitoring myocardial cellular inflammation 
with potential application to diagnosis, risk stratification and assessment of novel 




More than one person every minute suffers a myocardial infarction in the United 
States of America [Go et al 2014]. Despite improved interventional and medical 
treatments, mortality rates following MI remain high and many develop heart failure 
[Go et al 2014]. Post-infarct inflammation plays a key role in the recovery of cardiac 
function [Nahrendorf et al 2007; Nahrendorf et al 2010], and is a target for 
therapeutic manipulation to improve clinical outcomes.  
 
After early neutrophil infiltration, monocyte-derived macrophages dominate the 
cellular infiltrate in the first 2 weeks following MI and sequentially coordinate 
digestion of damaged tissue and promotion of infarct healing [Nahrendorf et al 2007; 
Nahrendorf et al 2010]. Optimal post-MI recovery is determined by the balance 
between proinflammatory and reparative macrophages, with uncontrolled early 
inflammation leading to adverse functional recovery [Nahrendorf et al 2007; 
Tsujioka et al 2009; Nahendorf  et  al 2010; Panizzi et al 2010]. 
  
Ultrasmall superparamagnetic particles of iron oxide consist of an iron oxide core 
surrounded by a carbohydrate or polymer coating and are small enough to 




by tissue-resident macrophages [Ruehm et al 2001]. Accumulation of USPIO 
reduces T2* decay time and creates signal deficits that can be quantified and 
visualised using T2* magnetic resonance imaging [Alam et al 2012;                 
Yilmaz et al 2013]. Thus USPIO-enhanced MRI can detect tissue-resident 
macrophage activity and  identify cellular inflammation within tissues. 
 
In current practice, T2-weighted MRI is used to evaluate myocardial oedema after 
MI [Abdel-Aty et al 2004; Kellman et al 2007]. However these imaging techniques 
assess myocardial free water content and not active cellular inflammation. 
Development of a reliable non-invasive imaging technique capable of directly 
detecting myocardial cellular inflammation would be a major advance and could 
potentially facilitate risk stratification and therapeutic targeting of macrophages 
immediately after MI. Furthermore, this technique could provide diagnostic 
information, serial disease monitoring and a measure of treatment response in other 
conditions mediated by inflammatory cell infiltration of the heart.  
 
In a recent proof-of-principle pilot study, Alam et al [2012], successfully detected 
inflammation following acute MI using USPIO-enhanced MRI. USPIO uptake, 
defined as the increase in R2* (1/T2*) 24 hours following administration, was seen 
in the infarct zone within the heart. In this present study, I hypothesised that I could 
track the time course of cellular inflammation in the 3-month period following acute 
MI using USPIO-enhanced MRI. My primary aims were firstly to determine the 
duration and distribution of USPIO enhancement in tissues following a single 




heart by tracking myocardial USPIO enhancement using repeated USPIO 





This was an open label observational cohort study. Patients were recruited within      
7 days of acute myocardial infarction. The study was performed in accordance with 
the Declaration of Helsinki, the approval of the Local Research Ethics Committee, 
and the written informed consent of all participants. 
 
4.3.1   SUBJECTS 
Participants were aged 18 to 80 years of age and had sustained a recent MI according 
to the Third Universal Definition of Myocardial Infarction [Thygesen et al 2012] 
with 12-hour plasma troponin I concentration ≥5000 ng/L (Architect STAT 
Troponin-I assay, Abbott Diagnostics). Exclusion criteria were known critical 
stenosis (>95%) of the left main stem, ongoing symptoms of angina, heart failure 
(Killip class ≥2), renal failure (estimated glomerular filtration rate <30 mL/min/1.73 
m2), and contraindication to MRI or ferumoxytol infusion. Results were also 
compared to ‘control’, healthy myocardium at 3 T, as described in the previous 
Chapter. 
 
4.3.2   USPIO 




immediately following the baseline magnetic resonance scan over at least 15 minutes 
using a concentration of 2-8 mg/mL, diluted in 0.9% saline or 5% dextrose. 
Haemodynamic monitoring was conducted throughout.  
 
4.3.3   STUDY PROTOCOL 
A variable study protocol was used that was purposely designed for imaging at 
different time points after acute MI. Over a 3-month period following MI, patients 
received up to 7 MRI scans and up to 3 infusions of USPIO. Two principal analyses 
were performed using data from the same participants.  
 
First, to assess the duration of a single dose of USPIO, R2* values of only the 
participants that first received USPIO within 7 days of MI (21/30) were included in 
this analysis. They were followed on all subsequent MRI scans prior to receiving any 
further doses of USPIO (Figure 4.1a). Upon receiving further USPIO, data were 
censored from the point of the second USPIO administration, hence the reduction in 
numbers over the course of the study.   
 
Second, to assess the duration of myocardial macrophage activity, USPIO uptake 
was compared using repeated USPIO infusions over the 3-month follow up period. 
All patients were included in this analysis. USPIO uptake was calculated by 
subtracting the baseline R2* value from values obtained at 24 hours following 
USPIO infusion (Figure 4.1b). This allowed repeated assessment of myocardial 





Following clinical guidance for the administration of ferumoxytol, participants were 
allowed a maximum of two doses of USPIO in a 1-month period, and a total of three 
over the 3-month follow up period to prevent iatrogenic iron overload. Therefore, 
USPIO-enhanced data was collected up to three times for each patient and it was not 





Figure 4.1a.   Duration and distribution of USPIO enhancement after single-dose administration in 
the first week after MI.  USPIO - ultrasmall superparamagnetic particles of iron oxide;  h - hours;       






Figure 4.1b.   Repeated myocardial uptake of USPIO following MI. USPIO - ultrasmall 
superparamagnetic particles of iron oxide; MRI - magnetic resonance imaging; d - days; LGE - late 



















Finally, to assess myocardial oedema, T2 values were compared on unenhanced 
scans (prior to and at least 7 days following USPIO administration). All patients 
were included in this analysis. 
 
4.3.4    MAGNETIC RESONANCE IMAGING PROTOCOL 
MR imaging was performed using a 3 T scanner and a Siemens 32-channel cardiac 
array. All images were acquired with electrocardiogram gating using expiration 
breath-holds. Routine steady state free precession sequences were used to acquire 
long and short axis cine images of the heart (TR 85.8 ms, TE 1.45 ms, flip angle 50º, 
matrix 173x256, FoV 400 mm, slice thickness 8 mm, 2 mm gap). Quantitative 
USPIO imaging was performed again in similar slice positions using a prototype              
T2*-weighted multi-gradient-echo acquisition using a volumetric shim applied over 
the entire heart volume (TR 996 ms, TE 2.13, 4.3, 6.4, 8.6, 10.7, 12.8, 15.0, 17.1 ms, 
flip angle 18º, matrix 130x256, FoV 400 mm, slice thickness 6 mm, 4 mm gap). The 
T2*-weighted acquisitions included views through the liver, spleen and spine to 
allow quantification of USPIO accumulation within organs of the reticuloendothelial 
system. The same T2* protocol was used to quantify USPIO accumulation 24 hours 
after infusion allowing calculation of T2* relaxation rates before and after 
administration of USPIO. Oedema imaging was conducted using a Siemens T2 
mapping based on a prototype T2-prepared TrueFISP acquisition acquiring identical 
long and short axis slice positions (TR 219.3 ms, TE 1.07 ms, T2P durations 0, 25, 
50 ms, flip angle 70º, matrix 130x192, FoV 400 mm, slice thickness 6 mm, 4 mm 




allow for sufficient magnetisation recovery in between acquisitions. 
 
Immediately after the baseline T2 and T2*-weighted scan, participants received an 
intravenous administration of gadolinium contrast medium (0.1 mmol/kg) followed 
by breath held inversion recovery sequences in long axis and short axis planes to 
acquire late enhancement images. Gadolinium-enhanced imaging is the current gold 
standard for infarct detection using MR imaging. Optimal inversion time was 
determined on a slice-by-slice basis using standard late enhancement TI-scout 
protocols (TR 750 ms, TE 2.61 ms, flip angle 20º, matrix 173x256, FoV 400 mm, 
slice thickness 9 mm, 1 mm gap). The inversion recovery late enhancement 
short axis slices were acquired using similar slice positions as the T2-oedema and 
T2*-weighted imaging.  
 
4.3.5   IMAGE ANALYSIS 
All T2*-weighted multi-gradient-echo images for each patient were analysed using 
Circle CVI software. An experimentally determined threshold used in previous work 
[Alam et al 2012] for the coefficient of determination (r2>0.85) was used to exclude 
data that did not have an acceptable exponential decay when signal intensity was 
plotted against echo time. The relaxation rate, R2*, is the inverse of the mean T2*, 
and was calculated to assess the uptake of USPIO for each region of interest, where 
the higher the value, the greater the USPIO accumulation.  
 
Late gadolinium enhancement, ventricular volume and functional analyses were 





4.3.6   REGION OF INTEREST (ROI) SELECTION 
Late gadolinium enhancement images at the 3-month time point were used to 
determine the distribution and anatomy of the myocardial infarct, and served as 
reference images to which each series of T2 and T2* scans at each separate visit 
could be visually coaligned. This allowed myocardial ROIs to be selected on the 
reference short axis LGE images and manually applied to T2* images corresponding 
to (1) infarct zone (defined by the short axis slice showing greatest LGE volume), 
(2) peri-infarct zone (½ segment width immediately adjacent to LGE), and 
(3) remote myocardium (at least ½ segment width, opposite the infarct zone on the 
same short axis slice, and at least 1 full segment clear of any LGE). Other selected 
regions included (4) liver, (5) spleen, (6) bone marrow, (7) kidney, (8) blood pool, 
(9) aortic wall (inside arch) and (10) skeletal muscle. 
  
T2 values were measured immediately prior to USPIO administration. USPIO-
enhanced data were collected 24 hours following USPIO administration.  
 
4.3.7   HISTOLOGY  
Myocardial tissue samples were obtained from patients undergoing coronary artery 
bypass graft  surgery for treatment of their coronary disease within 2 weeks of their 
index myocardial infarction. USPIO was administered 24 hours prior to the biopsy, 
and a trucut myocardial biopsy sample was taken from the infarcted area, guided by 
the distribution of LGE on MR imaging, during the procedure. The biopsy sample 




architecture (haematoxylin and eosin), accumulation and distribution of USPIO 
(Prussian Blue) and macrophages (CD68). Patients that underwent CABG surgery 
were excluded from further MRI follow up. 
 
4.3.8   STATISTICAL ANALYSIS 
All statistical analysis was performed with GraphPad Prism, version 6. To assess 
duration of USPIO enhancement in tissues following single administration in the first 
week after myocardial infarction, R2* values on subsequent MRI scans (prior to any 
further USPIO dosing) were compared using one-way analysis of variance with 
Tukey’s post hoc test for multiple comparisons.  
 
To assess variation and duration of myocardial inflammation, USPIO uptake        
(R2* increase from pre to 24 hours following USPIO) was compared using one-way 
ANOVA with Tukey’s post hoc test for multiple comparisons (repeated measures 
where appropriate). As a further method to assess USPIO accumulation within the 
heart, post USPIO R2* 24 hours after administration (without baseline R2* 
subtraction) was compared in the same way.  
 
Finally, to assess variation and duration of myocardial oedema, T2 values for infarct, 
peri-infarct and remote myocardium were compared again using one-way ANOVA 
with Tukey’s post hoc test for multiple comparisons (repeated measures where 







Thirty-one patients were recruited although one patient was excluded due to 
claustrophobia. One hundred and forty-seven MRI scans and 54 infusions of 
ferumoxytol were completed over the course of the study. Administration of 
ferumoxytol was well tolerated with no adverse reactions reported during or 
immediately after administration. 
 
Participants were predominantly middle-aged males with current or previously 
diagnosed hypercholesterolaemia or smoking habit (Table 4.1). Around half of 
participants were hypertensive and had a family history of premature coronary heart 
disease. Twenty-five patients had ST segment elevation myocardial infarction, 
5 patients non ST segment elevation myocardial infarction, 26 underwent 
percutaneous coronary intervention and 4 coronary artery bypass graft surgery. The 
mean elevation  in plasma  troponin was 31,200 ng/L.   
 
4.4.1   ENHANCEMENT AFTER SINGLE USPIO DOSE 
Twenty-one of the thirty participants received USPIO in the first week after MI and 









TABLE 4.1   Participant Characteristics 
Number of Participants 30 
Age (years) 58.4±9.8  
Sex  
Male - 29 (97) 




Risk Factors  
    Hypertension 13 (43) 
    Diabetes mellitus 8 (27) 
    Hypercholesterolaemia 27 (90) 
    Family history 14 (47) 
    Current or ex-smoker 
 
26 (87) 
Infarct Characteristics  
STEMI  25 (83) 
    Anterior 10 (33) 
    Inferior 15 (50) 
    Lateral 0 (0) 
    Diagnostic ECG to reperfusion (STEMI, min) 72.5±16.8 
NSTEMI  5 (17) 
PCI 26 (87) 
Baseline ejection fraction (%) 48.5±11.2 
Infarct size (% of LV mass) 31.6±19.5 
Infarct volume (mL) 43.9±27.5 




mean±SD, N (%). 
STEMI - ST elevation myocardial infarction; NSTEMI - non ST elevation myocardial infarction; PCI - 








Ultrasmall superparamagnetic particles of iron oxide were detected by an increase in 
R2* in all myocardial regions, blood pool, kidney and aortic wall until 24 hours, 
being cleared by 4-9 days (Figure 4.2 and Table 4.2). USPIO were detected in bone 
marrow until days 4-9, and liver and spleen until days 13-21. There was no change in 
R2* following USPIO infusion in skeletal muscle.  
 
Myocardial biopsies were taken from 3 of 4 patients undergoing CABG and revealed 
an abundance of inflammatory cells and early granulation tissue in keeping with a 
region of healing myocardium from around the infarct zone. Histological staining 
revealed colocalisation of the presence of iron (Prussian Blue) and macrophages 
(CD68). No staining for iron or  macrophages was seen within the adjacent regions 
of healthy myocardium (Figure 4.3). 
 
4.4.2   TIME COURSE OF ENHANCEMENT WITH REPEATED USPIO ADMINISTRATION 
There were no differences in baseline (pre USPIO) R2* value between infarct and 
remote myocardium at all time points. Time course variation in USPIO uptake was 
seen in the infarct zone over the 3-month period, peaking at days 2-3 (Figure 4.4a) 
and (Table 4.3a). There was no time course variation in USPIO uptake in the peri-












Figure 4.2.   USPIO enhancement after single-dose administration in the first week following MI. 
Following single-dose administration, USPIO enhancement was detected in all myocardial regions, kidney, blood 
pool and aortic wall at 24 hours. USPIO was detected in bone marrow until days 4-9, and spleen and liver until 
days 13-21. There was no change in R2* in skeletal muscle following USPIO infusion (p>0.05) (**** = 
p<0.0001, *** = p<0.001, * = p<0.05). n = 21 (baseline, 24 h) 11 (days 4-9), 15 (days 13-21), and 5 (days 78-99). 
USPIO - ultrasmall superparamagnetic particles of iron oxide; MI - myocardial infarction; h - hours;           














































































































































































































































































































Figure 4.3.   Histology section of trucut biopsy from infarcted myocardium. A) Haematoxylin and 
eosin (x5 magnification) stain displaying a thin region of viable healthy myocardium (strip of dark 
pink) surrounded by infarcted myocardium (lighter pink). Infarcted myocardium shows an abundance 
of inflammatory cells and early granulation formation (D). B) Prussian Blue (x5) staining revealing 
intracellular iron (E x20 and G x50), not seen in the region of healthy myocardium. C) CD68 (x5) 
staining revealing macrophages within the infarcted myocardium (F x20 and H x50), again not seen in 
healthy myocardium. G+H show colocalisation of iron within macrophages. CD - cluster of 

















Figure 4.4a.   USPIO uptake in myocardium after MI with repeated USPIO administration. Time 
course variation in USPIO uptake was seen in the infarct zone peaking at days 2-3. No variation of 
USPIO uptake was seen in peri-infarct and remote myocardium. Compared to remote myocardium, 
increased USPIO uptake was seen in the infarct zone until days 10-16 post MI  (**** = p<0.0001,  
*** = p<0.001, ** = p<0.01 * = p<0.05). USPIO - ultrasmall superparamagnetic particles of iron 
oxide; MI - myocardial infarction; d - days. 





Figure 4.4b.   R2* 24 hours  following USPIO (without subtraction of baseline values). Compared to 
remote myocardium, greater post USPIO R2* was seen in the infarct zone until days 10-16 post MI 
(*** = p<0.001, ** = p<0.01, * = p<0.05). USPIO - ultrasmall superparamagnetic particles of iron 
oxide; d - days; h - hours; MI - myocardial infarction. 














































































Compared to remote myocardium, greater USPIO uptake was seen in the infarct zone 
until days 10-16 (mean +56 seconds (s)-1; 95% confidence interval (CI) 33 to 79; 
p<0.001, +47 s-1; 95% CI 31 to 62; p<0.0001, and +33 s-1;  95% CI 4 to 61; p<0.05 at 
days 2-3, days 4-7 and days 10-16 respectively) but not thereafter (Figure 4.4a and 
Figure 4.5). Similarly, comparing R2* 24 hours following USPIO (without baseline 
R2* subtraction), greater USPIO uptake was again evident in infarcted myocardium 
compared to remote myocardium until days 10-16 (mean +60 s-1; 95% CI 33 to 86; 
p<0.01, +49 s-1; 95% CI 21 to 77; p<0.01, and +45 s-1; 95% CI 2 to 87; p<0.05 at 
days 2-3, days 4-7 and days 10-16 respectively, (Figure 4.4b and Table 4.3b).  
 
There was a negative correlation between infarct size and USPIO uptake within the 
infarct zone in the first 2 weeks of MI (r=-0.51, p<0.01, n=26), particularly within 
the first 2-3 days (r=-0.73, p<0.01, n=11). Nine patients had imaging evidence of 
microvascular obstruction (MVO). There was no statistically significant difference in 
USPIO accumulation between the non-MVO group when compared to the MVO 
group (mean R2* change 94 vs. 79 s-1, p=0.14).  
 
4.4.3   ASSESSMENT OF MYOCARDIAL OEDEMA USING T2 MAPPING 
Following acute MI, time course variation in infarct and peri-infarct T2 value was 
seen (Figures 4.5, 4.6 and Table 4.4). No time course variation in T2 value was seen 
in remote myocardium. Compared to remote myocardium, greater myocardial T2 
value was detected in the infarct zone and remained present throughout the 3-month 
follow up period (mean +12 ms; 95% CI 7 to 18; p<0.001, +14 ms; 95% CI 9 to 18; 




+6 ms; 95% CI 2 to 9; p<0.01 at days 1-2, days 3-9, days 10-16, days 17-24 and 
days 77-98 respectively). 
 
4.4.4   TIME COURSE OF ENHANCEMENT WITH REPEATED USPIO ADMINISTRATION 
COMPARED WITH HEALTHY VOLUNTEERS (FROM CHAPTER 3) 
Compared to healthy volunteer myocardium, greater USPIO uptake was seen in the 
infarct zone until days 10-16 (mean +51 seconds (s)-1; 95% confidence 
interval (CI) 28 to 75; p<0.0001, +49 s-1; 95% CI 26 to 73; p<0.0001, and +28 s-1;  
95% CI 4 to 52; p<0.05 at days 2-3, days 4-7 and days 10-16 respectively) but not 
thereafter (Table 4.5). No significant difference in USPIO uptake existed between 
peri-infarct or remote myocardial infarction tissue and healthy volunteer control 












Figure 4.5.   Examples of myocardial oedema and USPIO enhancement in the infarct zone after MI. 
Three examples of MI (1: anteroseptal, 2: lateral and 3: inferior) illustrating LGE, USPIO 
enhancement (R2* map) and oedema (T2 map), at early (up to 10 days) and late (3 months) time 
points. Early inflammation and oedema seen on R2* (dark region) and T2 maps (light region) 
respectively has improved or resolved by 3 months. LGE - late gadolinium enhancement; USPIO -
ultrasmall superparamagnetic particles of iron oxide; MI - myocardial infarction. 
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Figure 4.6.   T2 value in the myocardium after MI. Time course variation in infarct and peri-infarct 
T2 was seen in the 3-month period following MI, both peaking at days 3-9. Compared to remote 
myocardium, higher T2 was seen in the infarct zone throughout the duration of the study, and in the 
peri-infarct zone until days 17-24 (**** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05).           
n = 15 (days 1-2), 14 (days 3-9 and 77-98), 8 (days 10-16) and 10 (days 17-24). MI - myocardial 










































TABLE 4.2  USPIO enhancement after single-dose administration in the first week following MI 
 Baseline 24h 4-9d 13-21d 78-99d 
Infarct 49 [34-76] 141 [112-164] 73 [52-94] 54 [45-70] 57 [37-75] 
Peri-infarct 36 [25-49] 85 [67-101 44 [30-69] 43 [39-58] 40 [39-64] 
Remote 47 [41-59] 83 [75-89] 52 [34-63] 48 [40-60] 50 [38-60] 
Liver 67 [53-83] 333 [278-370] 175 [172-178] 145 [115-185] 116 [95-166] 
Spleen 56 [40-91] 400 [364-476] 208 [111-323] 137 [104-170] 66 [52-162] 
Bone marrow 278 [230-308] 526 [456-625] 435 [400-526] 333 [294-400] 323 [238-334] 
 
TABLE 4.3a  USPIO uptake (change in R2*, s-1) in myocardium after MI with repeated USPIO 
administration 
 2-3d 4-7d 10-16d 17-25d 78-99d 
Infarct 83 [77-110] 81 [74-104] 60 [44-85] 38 [29-65] 43 [28-49] 
Peri-infarct 46 [28-63] 46 [30-64] 24 [15-46] 28 [23-45] 33 [19-48] 
Remote 36 [22-41] 42 [19-50] 31 [26-39] 36 [23-40] 38 [32-49] 
 
TABLE 4.3b   R2* (s-1) 24 hours following USPIO (without subtraction of baseline values) 
 2-3d 4-7d 10-16d 17-25d 78-99d 
Infarct 147 [109-167] 141 [116-161] 121 [81-168] 99 [82-110] 99 [82-110] 
Peri-infarct 87 [77-102] 81 [61-99] 59 [51-69] 81 [64-89] 78 [67-105] 
Remote 83 [74-86] 83 [77-109] 78 [72-82] 85 [80-104] 86 [83-104] 
 
TABLE 4.4  T2 value (ms) in the myocardium after MI 
 1-2d 3-9d 10-16d 17-24d 77-98d 
Infarct 53 [48-65] 59 [56-64] 58 [54-71] 57 [50-66] 48 [45-55] 
Peri-infarct 52 [45-55] 54 [47-56] 49 [47-53] 48 [46-51] 46 [44-48] 
Remote 44 [42-48] 45 [41-48] 46 [45-47] 44 [43-47] 44 [42-46} 
median [IQR] 





TABLE 4.5  USPIO uptake (change in R2*, s-1) in myocardium after MI with repeated USPIO 
administration compared to Healthy Volunteers (Chapter 3) 
 2-3d 4-7d 10-16d 17-25d 78-99d 
Infarct 83 [77-110]**** 81 [74-104]**** 60 [44-85]* 38 [29-65] 43 [28-49] 
Peri-infarct 46 [28-63] 46 [30-64] 24 [15-46] 28 [23-45] 33 [19-48] 
Remote 36 [22-41] 42 [19-50] 31 [26-39] 36 [23-40] 38 [32-49] 
 
Healthy Control  35 [31-38]                  35 [31-38]                 35 [31-38]                35 [31-38]               35 [31-38] 
 
Compared to healthy control myocardium, increased USPIO uptake was seen in the infarct zone until 
days 10-16 post MI  (**** = p<0.0001, * = p<0.05).  There is no significant difference in USPIO 
uptake between peri-infarct or remote myocardial infarction tissue and healthy volunteer control tissue 
at any of the time points.  
 
median [IQR] 







For the first time, I have simultaneously investigated cellular inflammation and tissue 
oedema for 3 months following acute myocardial infarction using USPIO-enhanced 
T2* and T2 mapping magnetic resonance imaging. I have demonstrated that whilst 
tissue oedema persists for at least 3 months, cellular inflammation in the infarct zone 
is transient and lasts for only 2 weeks following MI. The time course of USPIO 
uptake following MI demonstrates a pattern of macrophage inflammation that is 
distinct to tissue oedema caused by loss of capillary integrity. This suggests that 
whilst capillary integrity may take several months to resolve, cellular inflammation 
and specifically macrophage activity predominates in the first 2 weeks following 
myocardial infarction. 
 
Ultrasmall superparamagnetic particles of iron oxide can be used as an MRI contrast 
agent as it is immediately apparent in the blood pool following intravenous 
administration [Taylor et al 1999]. Tissue enhancement with USPIO following 
inflammation has been suggested to occur as a result of either partitioning of USPIO 
into the tissues because of loss of capillary integrity alone or as a result of 
macrophage phagocytic activity clearing tissue resident particles [Yilmaz et al 2013]. 
I here provide confirmatory evidence that USPIO enhancement predominantly 
occurs as a result of cellular inflammation within the myocardium. I used T2 
mapping to describe loss of capillary integrity following myocardial infarction. 
Using this comparator, I demonstrated that there is a discontinuity between the 




(first 2 weeks) T2*-defined time limited cellular inflammation. This observed 
USPIO uptake in the infarct zone for up to 2 weeks following MI is consistent with 
data from previous studies demonstrating that tissue-resident macrophages are active 
and predominate within the infarcted myocardium in the first 2 weeks after MI 
[Tsujioka et al 2009; Nahrendorf et al 2010]. Additionally, I obtained myocardial 
biopsies in patients undergoing coronary artery bypass graft surgery within 2 weeks 
of myocardial infarction and 24 hours after USPIO administration. I demonstrated 
marked colocalisation of iron staining with tissue-resident macrophages in infarcted 
but not non-infarcted tissue. It is not possible to resolve specific USPIO on histology 
and I cannot discount the possibility that there is some contribution from post-infarct 
hemosiderin staining. However, I would contend that the majority of iron staining is 
attributable to USPIO uptake given the selective, transient and marked R2* 
enhancement on MRI, and the relatively constant contribution from hemosiderin 
over the period of assessment. Moreover, I did not detect substantial quantities of 
iron that were free in the extracellular space and were not associated with areas of 
macrophage infiltration. 
 
Following a single infusion in the first week after MI, USPIO enhancement is seen in 
all regions of the myocardium, but greatest within the infarct zone, after 24 hours. 
USPIO enhancement is also observed until days 4-9 in bone marrow, and until       
days 13-21 in the liver and spleen. Therefore the duration of USPIO enhancement is 
longest in the mononuclear phagocyte rich reticuloendothelial system. It is likely that 
resident phagocytes within these organs ingest USPIO from circulating blood. Efflux 




reticuloendothelial system T2* signal. Ultimately, once within macrophages, the iron 
oxide core is broken down by lysosomes, providing a supply of iron ions for 
haemoglobin synthesis [Van Beers et al 2001; Thorek et al 2006]. 
  
The observed duration of enhancement following a single infusion of USPIO in 
tissues helped guide the minimum time interval between repeated USPIO 
administrations. Complete washout of the previous dose of USPIO, allowing baseline 
R2* to return to normal, is required to reassess uptake of USPIO accurately, without 
influence from previous USPIO administration. I have shown that USPIO is no 
longer detectable in the myocardium at 1-week following intravenous administration 
and I suggest that 1-week is the minimum interval between repeated doses of USPIO. 
 
USPIO is detectable in the peri-infarct and remote myocardium, kidney and aortic 
wall at 24 hours following administration. However the amplitude of R2* change is 
less than that of blood pool, suggesting this is likely to be due to a diluted effect of 
blood pool USPIO and not macrophage uptake of USPIO within these tissues. 
Although there appears a trend to suggest that the peri-infarct zone displays an early 
relative increase in USPIO uptake compared to remote myocardium, this failed to 
reach statistical significance. 
 
Previous studies have suggested that the remote myocardium may exhibit USPIO 
and macrophage accumulation [Alam et al 2012; Lee et al 2012; Yilmaz et al 2013]. 
I have here shown that there is no time course variation in USPIO uptake in remote 




USPIO is likely to be reflective of intravascular capillary bed blood pool USPIO 
rather than more widespread macrophage activity throughout the myocardium. This 
is confirmed with no significant difference between USPIO uptake in remote 
myocardium and healthy control myocardium (Chapter 3 and Table 4.5). 
 
Although no patients in this study displayed imaging evidence of myocardial 
haemorrhage, I was able to account for the presence of microscopic iron due to 
haemorrhage by subtracting baseline R2*. Therefore, any R2* increase detected is 
due to accumulation of USPIO and not iron from myocardial haemorrhage. I 
acknowledge that intramyocardial haemorrhage occurring between the pre and          
24 hours post USPIO scans could theoretically increase R2*, but the earliest I 
imaged patients was at least 24 hours after myocardial infarction, by which time 
haemorrhage is likely to have taken  place. 
 
The weak negative correlation between infarct size and USPIO uptake within the 
infarct zone in the first 2 weeks of MI is interesting and deserves mention. This was 
likely driven by microvascular obstruction in patients with large infarcts that 
prevented USPIO accessing infarcted tissue. However when we compared subgroups 
of patients with and without MVO, although no statistically significant difference in 
USPIO uptake existed, there may be a suggestion that the MVO group had less 
USPIO uptake. This study lacked power to detect differences in USPIO uptake 
between subgroups of patients with and without MVO. An increased sample size will 






I chose T2 mapping to assess myocardial oedema as it provides improved sensitivity 
and addresses some of the problems with subjective image interpretation using 
traditional T2-weighted techniques [Giri et al 2009; Verhaert et al 2011]. The 
finding of ongoing myocardial oedema in the infarct zone at 3 months after MI may 
at first appear surprising. However several groups have described the long lasting 
presence of myocardial oedema, often up to 6 months after MI [Nilsson 2001; 
Dall’Armellina et al 2011]. This suggests that it may take many months for complete 
resolution of injury and return of normal vascular homeostasis and function.  
 
What are the clinical applications of my technique? I have here used the ‘model’ of 
acute myocardial infarction and demonstrated the predicted time course of tissue-
resident macrophage uptake using USPIO. I therefore suggest that this technique has 
utility in defining the extent of myocardial cellular inflammation that has potential 
utility in risk stratification. Perhaps more importantly, USPIO-enhanced MRI may 
prove a useful tool to assess the response to novel anti-inflammatory interventions 
targeted at reducing myocardial cellular inflammation to improve clinical outcomes. 
Such a study was carried out at our centre and has recently been published [Alam et 
al 2015]. Currently, there is no USPIO licensed as a contrast agent for routine 
clinical MR imaging, which limits its widespread use. However the most exciting 
application would be to extend this technique to help diagnose, monitor disease 
progression and assess therapeutic intervention in myocardial diseases associated 
with and mediated by macrophage infiltration. Such diseases include myocarditis, 




currently underway to assess this (EUDRACT 2013-002336-24). This would be 
important given the lack of simple definitive diagnostic tests in these conditions, the 
challenges of unreliable cardiac biopsies, and the need for rapid assessments of 
disease progression and  therapeutic interventions.  
 
In conclusion, I have successfully imaged, quantified and validated macrophage 
inflammation and myocardial oedema over 3 months in patients following MI using 
USPIO-enhanced T2* MR imaging and T2 mapping. This technique can provide a 
non-invasive method for the diagnosis and monitoring of tissue inflammatory 
macrophage activity in the heart. It also provides a potential platform on which to 
assess existing and novel therapeutic interventions that might modify the 
inflammatory process, not only after MI but also in other inflammatory processes 









CHAPTER  5 
 
 
FERUMOXYTOL-ENHANCED MAGNETIC RESONANCE IMAGING 
 














5.1 SUMMARY  
 
Background   Ultrasmall superparamagnetic particles of iron oxide-enhanced 
magnetic resonance imaging can detect tissue-resident macrophage activity and 
identify cellular inflammation within tissues. I hypothesised USPIO-enhanced MRI 
would provide a non-invasive imaging technique that would improve the diagnosis 
and management of patients with acute myocarditis. 
Methods   Ten volunteers and 14 patients with suspected acute myocarditis 
underwent T2, T2* and late gadolinium enhancement 3 T MR imaging, with further 
T2* imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) infusion, at baseline 
and 3 months. Myocardial oedema and USPIO enhancement were determined within 
areas of LGE as well as throughout the myocardium. 
Results   Myocarditis was confirmed in 9 of the 14 suspected cases of myocarditis. 
There was greater myocardial oedema in regions of late gadolinium enhancement in 
patients with myocarditis when compared to healthy volunteer myocardium            
(T2 value, 57.1±5.3 versus 46.7±1.6 ms; p<0.0001). There was no demonstrable 
difference in USPIO enhancement between patients and volunteers even within 
regions displaying LGE (change in R2*, 35.0±15.0 versus 37.2±9.6 s-1; p>0.05). 
Imaging after 3 months in myocarditis patients revealed a reduction in volume of 
LGE, a reduction in oedema measures within regions displaying LGE, and 
improvement in ejection fraction (LGE mean -19.7 mL; 95%  CI  -0.5 to -40.0 mL, 
T2  -5.8 ms;  95%  CI   -0.9  to  -10.7 ms,   and   EF   +6%;  95%   CI   0.5  to  11.5% 
respectively;  p<0.05 for all). 
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Conclusion   In patients with acute myocarditis, USPIO-enhanced MRI does not 
provide additional clinically relevant information to LGE and T2 mapping MRI. This 
suggests that tissue-resident macrophages do not provide a substantial contribution to 




Acute myocarditis comprises a wide clinical spectrum from subclinical disease to 
severe heart failure, and is a major cause of sudden death in young adults [Drory et 
al 1991]. Pathologically, it is characterised by inflammatory cell infiltration of the 
myocardium with evidence of myocyte necrosis that is not characteristic of an 
ischaemic aetiology [Aretz et al 1987]. Causes of myocarditis include infections, 
immune-mediated injury, and toxins (such as anthracyclines) although frequently no 
cause is identified [Caforio et al 2013]. 
  
A variety of inflammatory cells infiltrate the myocardium during myocarditis. In 
viral myocarditis, the infiltrate is predominantly lymphocyte rich, but other cells 
including plasma cells, neutrophils, eosinophils, giant cells, and macrophages are 
also present [Aretz et al 1987; Feldman and McNamara 2000; Magnani and Dec 
2006; Li et al 2009; Barin et al 2012; Sagar et al 2012; Jaquenod et al 2015]. 
Monocytes differentiate into macrophages at sites of myocarditis, suggesting they 




Endomyocardial biopsy is considered the gold standard investigation for diagnosis. 
However this is prone to sampling error and is uncommon in routine clinical practice 
[Caforio et al 2013]. Cardiac magnetic resonance imaging plays a key role in the 
diagnosis and shows typical appearances on T2-weighted and LGE imaging 
according to the Lake Louise Criteria [Friedrich et al 2009]. More recently, 
quantitative mapping techniques appear to improve diagnostic accuracy further 
[Luetkens et al 2015]. 
  
Iron oxide nanoparticles are generating interest as an MRI contrast agent able to 
detect macrophages, and clinical applications are now emerging [Trivedi et al 2004; 
Tang et al 2006; Trivedi et al 2006; Tang et al 2009; Richards et al 2011; Alam et al 
2012; Yilmaz et al 2013; McBride et al 2015; Stirrat et al 2016 and 2017]. 
Ultrasmall superparamagnetic particles of iron oxide consist of an iron oxide core 
surrounded by a carbohydrate or polymer coating. They are small enough to 
extravasate passively through capillaries, where they are engulfed by tissue-resident 
macrophages [Ruehm et al 2011], and are detectable by T2*-weighted MR imaging. 
Thus USPIO-enhanced MRI can identify tissue-resident macrophage activity and 
identify cellular inflammation within tissues.  
 
In a promising preclinical study of autoimmune myocarditis [Moon et al 2012], iron 
nanoparticles were ingested by inflammatory cells and improved distinction of areas 
with severe inflammation on MRI compared to conventional T2-weighted and 
gadolinium-enhanced MRI. I aimed to assess and to quantify myocardial USPIO 
enhancement in acute myocarditis, and to correlate enhancement with clinical 
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measures of inflammation and oedema using T2 mapping and LGE MR imaging and 
compare these measures with healthy volunteers [Stirrat et al 2016]. I hypothesised 
that USPIO-enhanced MRI would detect myocardial macrophage activity in 
myocarditis and provide a cellular specific non-invasive imaging technique that may 




Patients were recruited from a single centre as part of an open label observational 
multicentre cohort study (NCT02319278). The study was performed in accordance 
with the Declaration of Helsinki, the approval of the Scotland A Research Ethics 
Committee, and the written informed consent of all participants. The Medicines and 
Healthcare products Regulatory Agency of the United Kingdom gave Clinical Trial 
Authorisation for the study (EUDraCT 2013-002336-24). 
 
5.3.1   STUDY POPULATIONS 
Adult (>18 years of age) patients with suspected acute myocarditis were recruited 
into the study. The clinical diagnosis was made by an independent clinical 
cardiologist based on the history, electrocardiogram, serum troponin (ARCHITECT 
STAT troponin I assay, Abbott Diagnostics), and other available imaging modalities. 
The diagnosis of myocarditis was verified from casenote review by an independent 
cardiologist and retained for analysis if the MRI scan (reported and agreed by two 
independent radiologists) showed imaging features of myocarditis on LGE and/or T2 
mapping [Friedrich et al 2009]. Healthy volunteers had no clinically significant past 
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medical history. Exclusion criteria were contraindication to MRI or ferumoxytol 
infusion, any other inflammatory comorbidity, renal failure (estimated glomerular 
filtration rate <30 mL/min/1.73 m2), pregnancy, breastfeeding and women of 
childbearing potential without reliable contraception. 
 
5.3.2 STUDY PROTOCOL 
Patients with suspected myocarditis and healthy volunteers underwent paired MRI 
scans at baseline, and patients were invited to return for repeat imaging after 
3 months.  
 
5.3.3   MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging was performed using a Magnetom Verio 3 T MRI 
scanner running software version VB17, with a dedicated cardiac array coil. All 
images were acquired using electrocardiogram-gated breath-holds. Routine steady 
state free precession sequences were used to acquire long axis and short axis images 
of the heart. Oedema imaging was conducted using a Siemens T2 mapping based on 
a prototype T2-prepared TrueFISP acquisition acquiring identical long and short axis 
slice positions. Quantitative USPIO imaging was performed in similar slice positions 
using a prototype T2*-weighted multi-gradient-echo acquisition using a volumetric 
shim applied over the entire heart volume. Standard cardiac slice widths (6 mm 
width with 4 mm gap) and 8 echo times (2.1-17.1 ms range) with matrix size of 
256×115 were acquired for T2* maps. The in-plane resolution differed as required 
for larger or smaller objects; generally, a field of view of 400×300 mm was used 
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with an in-plane resolution of 2.6×1.6 mm. T2* relaxation times were calculated 
before and after administration of USPIO.  
 
Immediately after the baseline T2, T2* and SSFP cine imaging, breath held inversion 
recovery sequences in long axis and short axis planes were used to acquire late 
enhancement images following an intravenous administration of gadolinium contrast 
medium (0.1 mmol/kg). Optimal inversion time was determined on a slice-by-slice 
basis using standard late enhancement TI-scout protocols. The inversion recovery 
late enhancement short axis slices were acquired using similar slice positions as the 
T2 and T2* imaging.  
 
5.3.4   USPIO 
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg) was performed immediately 
following the baseline magnetic resonance scan over 15 minutes using a 
concentration of 2-8 mg/mL, diluted in 0.9% saline or 5% dextrose. Haemodynamic 
monitoring was conducted  throughout.  
 
5.3.5   IMAGE ANALYSIS 
All T2*-weighted multi-gradient-echo images for each patient were analysed using 
Circle CVI software. An experimentally determined threshold used in previous work 
[Alam et al 2012] for the coefficient of determination (r2>0.85) was used to exclude 
data that did not have an acceptable exponential decay when signal intensity was 
plotted against echo time. Individual images affected by artefact were excluded. The 
inverse of the mean T2* (R2*) for each ROI was then calculated to assess the uptake 
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of USPIO, where the higher the value, the greater the USPIO accumulation.  
 
T2 maps, late gadolinium enhancement, ventricular volume and functional analyses 
were also performed using Circle CVI software. T2 and T2* data were collected 
immediately prior to USPIO administration. USPIO-enhanced T2* data were 
collected 24-25 hours following ferumoxytol administration.  
 
5.3.6   REGION OF INTEREST (ROI) SELECTION 
Regions of interest were drawn using the standard 16-segment cardiac model 
[Cerqueira et al 2002], and pan-myocardial values averaged using all 16 segments. 
As a final method of analysis to focus on inflamed myocardium, regions with 
contiguous LGE >1 cm2 on a single short axis slice were retained and visually         
coaligned with corresponding T2 and T2* images. These corresponding coaligned 
regions were then averaged to form  LGE+ T2 and T2* regions. 
 
5.3.7   STATISTICAL ANALYSIS 
All statistical analysis was performed with GraphPad Prism, version 6. Shapiro-Wilk 
normality testing was carried out prior to testing. To compare USPIO uptake and 
myocardial oedema in patients and volunteers, R2* and T2 values were compared 
using paired and unpaired t-tests, Mann-Whitney, and Wilcoxon tests depending on 
pairing and normality of data. To compare results at 3 months with baseline, a paired 






Ten volunteers and 14 patients with suspected myocarditis were recruited. Nine 
patients had confirmed myocarditis according to imaging criteria and independent 
review. Baseline imaging was conducted within a week of diagnosis. Four patients 
had alternative diagnoses (tako-tsubo cardiomyopathy (n=2), lung cancer (n=1), 
polymyositis (n=1)) and 1 patient had an incidental finding of an unknown chest wall 
metallic implant. These 5 patients were excluded from further analysis. All 9 patients 
retained for analysis had typical features of myocarditis on late gadolinium 
enhancement imaging. Of these 9 patients, 1 patient did not return at baseline for the 
24 hour post USPIO scan. Seven of the 9 patients returned at 3 months for repeat  
imaging. 
  
The healthy volunteer group was older with greater ejection fraction than the 
myocarditis group at baseline (p<0.001 for both; Table 5.1). Patients with 
myocarditis had greater neutrophil count, CRP and serum troponin concentrations 
than volunteers (p<0.05, p<0.01 and p<0.0001 respectively). There were no other 
significant differences between participant groups at baseline. 
 
Administration of ferumoxytol was well tolerated with no adverse reactions reported 













Number 10 9 7 
Female 6 1 1 
Age (years) 50 (45-53) 28 (24-34)*** 25 (23-35) 
Body mass index (kg/m2) 26 (23-29) 25 (22-29) 25 (22-27) 
Left ventricular ejection 
fraction (%) 
61.1±4.1 51.0±4.9*** 57.1±4.3 
Late gadolinium 
enhancement (mL) 
Nil 30.3±19.3 16.3±12.3 
ECG n/a 9/9  
    ST elevation   7  
    T wave inversion   1  
    Normal  1  
Coronary Angiogram  n/a 4/9  
    Normal  4  
Echo n/a 8/9  
    Wall motion 
    abnormality 
 4  
    Normal  4  
Blood Tests    
    White cell count (x109/L) 5.8 (4.2-7.1) 7.1 (6.1-8.9) 5.1 (4.6-5.6) 
    Neutrophil count (x109/L) 3.2 (2.2-4.2) 4.4 (3.7-5.2)* 2.8 (2.7-3.5) 
     Lymphocyte count (x109/L) 1.7 (1.4-2.1) 1.8 (1.3-2.2) 1.8 (1.2-1.9) 
    Monocyte count (x109/L) 0.4 (0.3-0.7) 0.6 (0.5-0.8) 0.4 (0.3-0.5) 
    C-reactive protein (mg/L) 1.0 (1.0-2.5) 38 (14-63)** 2.0 (1.0-2.0) 




Mean±SD or median (interquartile range).  
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 (compared to volunteers at baseline). 




5.4.1   USPIO ENHANCEMENT 
At baseline, there were no differences in R2* values between healthy volunteers and 
patients with myocarditis (pan-myocardium and LGE+ regions; Figures 5.1 and 5.2). 
After USPIO administration, the R2* in all three groups increased but there was no 
difference in either the change in, or post USPIO, R2* between the groups       
(Figure 5.2 and Table 5.2). 
 
5.4.2   MYOCARDIAL OEDEMA 
There was no difference in pan-myocardial T2 between volunteers and patients with 
myocarditis. Regions displaying LGE in myocarditis patients had higher T2 than 
pan-myocardial values for both healthy volunteers and patients with myocarditis 
(p<0.0001 and  p<0.01 respectively; Figure 5.2 and Table 5.2). 
 
5.4.3   BASELINE VERSUS 3-MONTH IMAGING IN MYOCARDITIS PATIENTS  
There were no changes in myocardial USPIO uptake between baseline and 3 months 
either on pan-myocardial analysis (mean +7.6 s-1; 95% CI -4.8 to 19.9) or in regions 
with LGE (mean -4.2 s-1; 95% CI -21.9 to 13.5; p>0.05 for both; Figure 5.3). Pan-
myocardial T2 did not change over 3 months (mean -1.1 ms; 95% CI -5.8 to 3.5;  
p>0.05). Volume of LGE and T2 within regions displaying LGE reduced over the   
3-month period (mean -19.7 mL; 95% CI -0.5 to -40.0 and mean -5.8 ms; 95% CI     
-0.9 to -10.7 respectively; p<0.05 for both). Ejection fraction increased over the         







Figure 5.1.   Images of a patient with myocarditis. Three chamber and basal short axis images of a 
patient with myocarditis displaying patchy posterolateral LGE (white regions, arrowed) that 
correspond to oedematous regions of myocardium on the T2 map (lighter regions, arrowed). There is 
no uptake of USPIO in the post USPIO R2* maps; corresponding regions may even have lower R2* 
in this patient. Myocardial oedema appears to normalise but subtle LGE remains at 3 months.        
LGE - late gadolinium enhancement; h - hours; USPIO - ultrasmall superparamagnetic particles of 
iron oxide.  
	 	 	 	 	Baseline 	 	 	 	 	 	 	 		
				LGE 																				T2 					 		24h	Post	USPIO	R2*	
	 	 	 	 	3months 	 	 	 	 	 	 	 		









A B  
Figure 5.2.   Myocardial USPIO enhancement versus oedema at baseline. Changes in myocardial R2* 
due to USPIO accumulation (A, left) and myocardial oedema by T2 mapping (B, right) are shown in 
healthy volunteers (HV) and patients with myocarditis (M) using pan-myocardial average, and further 
limited to regions displaying LGE in patients with myocarditis (M LGE+). There were no significant 
differences in ΔR2* due to USPIO accumulation between all groups (p>0.05 for all). There was no 
difference in pan-myocardial T2 between volunteers and patients with myocarditis. Myocardial 
regions displaying LGE (M LGE+) had greater T2 than the pan-myocardial value for healthy 
volunteers and myocarditis patients (**** = p<0.0001 and ** = p<0.01 respectively). USPIO -  

















































****p<0.0001 (compared to volunteers). LGE - late gadolinium enhancement; USPIO - ultrasmall 
superparamagnetic particles of iron oxide. 
  







USPIO R2* (s-1) 
46.9±4.1 43.7±5.3 51.8±8.3 
Pan-myocardial post 
USPIO R2* (s-1) 
84.2±12.4 75.6±11.3 86.1±15.3 
Pan-myocardial  
ΔR2* (s-1) 
37.2±9.6 31.4±7.5 35.0±15.0 





A   B  
C   D  
E   F  
 
Figure 5.3.   Changes on repeat imaging at 3 months in patients with myocarditis. There was no 
significant (ns) difference in USPIO uptake between baseline and 3 months in both pan-myocardium 
(A) and in regions displaying LGE (B). There was no difference in pan-myocardial T2 (C) over 
3 months. T2 in regions displaying LGE (D) reduced, as did the volume of LGE (E) over the 3-month 
period There was an increase in ejection fraction (EF) between baseline and 3 months (F)                






















































































































For the first time, I report the combined assessment of myocarditis using late 
gadolinium enhancement, T2 mapping and USPIO-enhanced T2* MRI. USPIO-
enhanced T2* MRI has previously been used in man to assess cardiovascular 
inflammation in a range of different conditions [Tang et al 2009; Richards et al 
2011; Alam et al 2012; Yilmaz et al 2013], with preliminary positive results from a 
rodent model of myocarditis. This raised hope that USPIO-enhanced T2*MRI might 
add useful cell-specific clinical information in patients with myocarditis. However, 
whilst I found typical features of myocarditis using standard imaging with LGE and 
T2 mapping CMR, I did not detect USPIO enhancement within the myocardium of 
our patients. This suggests that USPIO-enhanced MRI provides no additional 
diagnostic value in these patients and that tissue-resident macrophages are not a 
major contributor to the cellular inflammation following acute myocarditis.  
 
My case study population of 9 patients were excellent examples of myocarditis. They 
were young, with significantly elevated levels of systemic inflammatory markers, 
including neutrophil count, CRP and cardiac specific high-sensitivity troponin, and 
all had typical features of myocarditis on CMR reported by two independent clinical 
radiologists. Most patients had ECG changes suggesting significant myocyte injury 
and several had normal coronary angiograms. All patients that did not have a 
coronary angiogram did not have any risk factors for coronary artery disease. I 
detected MRI features of myocarditis in every patient. Late gadolinium enhancement 
was discontinuous in nature and generally epicardial and subepicardial in distribution, 
but could be found in the midwall and occasionally in the subendocardium. LGE was 
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never found in the subendocardium alone or confined to one coronary territory that 
would be more suggestive of myocardial infarction. In keeping with the typical 
distribution of myocarditis, most patients displayed LGE in the inferior, posterior 
and lateral walls. We are therefore confident that the diagnosis of myocarditis was 
robust in all patients, and an independent cardiologist verified this. 
 
Myocardial oedema was easily visualised, and indeed quantified, using T2 mapping 
(Figure 5.2). I found intense myocardial oedema in our myocarditis cohort with 
maximal T2 values approaching 70 ms on T2 mapping. Within regions displaying 
LGE (LGE+), there was a profound increase in T2 when compared to volunteers. 
This signal was so powerful that a trend remained evident when comparing           
pan-myocardial T2 values to those of volunteers, although the difference was not 
statistically significant. Seven patients returned for repeat imaging assessment at 
3 months, where we recorded an improvement in clinical features: a reduction in the 
volume of LGE (by around 50%); a reduction in oedema within inflamed (LGE+) 
regions, and an overall improvement in ejection fraction.  
 
I was unable to detect USPIO accumulation in our cohort of patients with 
myocarditis. I know that macrophages can be present in myocarditis, although they 
are generally not the predominant cell type. It is possible that patients within my 
group had predominantly lymphocytic or neutrophil rich cell infiltrate, and the 
finding of greater levels of neutrophils in patients with myocarditis at baseline may 
support the latter. The clinical care team did not feel that endomyocardial biopsy was 
justified in any of the cases, and lack of histological data is clearly a limitation. In 
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recent work, I have detected USPIO-laden macrophages in patients with recent 
myocardial infarction and demonstrated macrophage uptake of USPIO in biopsies 
taken at the time of cardiac surgery [Stirrat et al 2017]. I therefore acknowledge that 
while some USPIO-laden macrophages may have been present in patients with 
myocarditis, there were either insufficient numbers of macrophages or USPIO 
engulfment was inhibited or deficient. Ultimately USPIO-enhanced T2* CMR was 
unable to demonstrate increased macrophage activity and lacked sensitivity for 
detecting myocarditis. 
 
A further contributory reason for failure to detect USPIO enhancement within 
inflamed regions may be due to difficulties encountered in USPIO-enhanced T2* 
imaging. These are discussed in greater detail elsewhere [Stirrat et al 2016] but 
artefact due to breathing and in particular, ‘blooming’ artefacts from the vascular 
organs of the lungs, liver and stomach can be problematic. This can make analysis 
more challenging by having to exclude the affected later echo times from T2* decay 
curve fitting. Indeed, blooming artefacts from nearby tissues and organs most 
commonly affect the inferior and lateral walls, which is the usual site of 
inflammation in myocarditis. Therefore the myocardial regions of greatest interest 
were often the most difficult to analyse although this can usually be overcome 
[Stirrat et al 2016]. This may go some way to explain why there is greater spread of 
R2* data in patients with myocarditis, especially in LGE+ regions. Finally, patients 
with myocarditis often had symptoms of pleurisy and pericarditis, and despite 
adequate analgesia, often found the long breath-holding required for                       
T2* imaging difficult.    
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5.5.1   LIMITATIONS 
Some final limitations also deserve mention. First, the sample size was small, but 
numbers in this pilot study were sufficient to show that USPIO-enhanced T2* CMR 
fails to add clinically relevant information to CMR imaging parameters of LGE and 
T2 mapping for individual patients. Second, the control volunteer group was not age 
or sex matched but we have no reason to believe that this influenced the results. 
Lastly, myocardial geometry is affected by several factors that vary between scans 
such as presence of tissue oedema, heart rate and blood volume status, and accurate 
co-registration can be challenging.  
 
Despite these results, USPIO-enhanced imaging still holds promise as a non-invasive 
imaging method for the diagnosis and monitoring of tissue inflammatory 
macrophages in the heart. We have recently found that USPIO-enhanced MRI can 
detect and serially monitor macrophages after myocardial infarction [Stirrat et al 
2017] and work is underway at our centre as part of this project (NCT02319278) to 
assess the value of this technique in diagnosing cardiac sarcoidosis and cardiac 
transplant rejection. If successful, USPIO-enhanced MRI may provide a platform on 
which to assess existing and novel therapeutic interventions that might modify the 
inflammatory process, not only after MI but also in other inflammatory processes 






5.5.2   CONCLUSION 
In conclusion, I have shown that in patients with acute myocarditis, USPIO-
enhanced T2* MRI does not provide additional clinically relevant information to that 
of LGE and T2 mapping MRI. This suggests that tissue-resident macrophages do not 























6.1 SUMMARY  
 
Background   Ultrasmall superparamagnetic particles of iron oxide-enhanced 
magnetic resonance imaging can detect cellular inflammation within tissues and may 
help non-invasively identify cardiac transplant rejection. Here, I aimed to determine 
the normal reference values for USPIO-enhanced MRI in patients with a prior 
cardiac transplant, and examine whether USPIO-enhanced MRI could detect 
myocardial inflammation in patients with transplant rejection. 
Methods   Ten volunteers and 11 patients with cardiac transplant underwent T2, T2* 
and late gadolinium enhancement 1.5 T MRI, with further T2* imaging at 24 hours 
after USPIO (ferumoxytol, 4 mg/kg) infusion, at baseline and  3 months.  
Results   Ten patients with clinically stable cardiac transplantation and nine healthy 
volunteers were retained for analysis. Myocardial T2 values were higher in patients 
with cardiac transplant versus healthy volunteers (53.8±5.2 versus 48.6±1.9 ms 
respectively; p=0.003). There were no differences in the magnitude of USPIO-
induced change in R2* in patients with transplantation (change in R2*, 
26.6±7.3 versus 22.0±10.4 s-1 in healthy volunteers; p=0.28). After 3 months, 
patients with transplantation (n=5) had unaltered T2 values 
(52.7±2.8 versus 52.12±3.4 ms; p=0.80) and changes in R2* following USPIO 
(29.42±8.14 versus 25.8±7.8 s-1;  p=0.43). 
Conclusion   Stable patients with cardiac transplantation have increased myocardial 
T2 values, consistent with resting myocardial oedema or fibrosis. In contrast, 
USPIO-enhanced MRI is normal and stable over time suggesting the absence of 










Cardiac transplantation is a life prolonging treatment for end stage cardiac disease. 
Transplant rejection is a major threat to the allograft, occurring in 20-30% of 
recipients in the first year [Hertz et al 2009], but can occur at any stage after 
transplantation and causes significant morbidity and mortality. Rejection is 
notoriously difficult to diagnose using existing non-invasive imaging methods 
necessitating repeated surveillance myocardial biopsies. 
 
Most cases of acute rejection are due to cellular rejection with antibody-mediated 
rejection less prevalent. Rejection severity is classified according to histological 
findings, and although the cellular infiltrate in acute cellular rejection is 
predominantly lymphocytic, macrophage infiltration has a key role [Stewart et al 
2005; Mannon 2012]. The importance of macrophages in acute cardiac allograft 
rejection was recently emphasised in a rodent study that showed depletion of 
circulating macrophages protected the allograft against rejection, raising the 
possibility of therapeutic targeting of macrophages as a novel treatment strategy  
[Wu et al 2013].  
 
Iron oxide nanoparticles are generating interest as an MR imaging contrast medium 





infarction, are now emerging [Trivedi 2004; Tang et al 2006; Trivedi 2006; Tang et 
al 2009; Richards et al 2011; Alam et al 2012; Yilmaz et al 2013; McBride et al 
2015; Stirrat et al 2017]. Ultrasmall superparamagnetic particles of iron oxide consist 
of an iron oxide core surrounded by a carbohydrate or polymer coating. They are 
small enough to extravasate passively through capillaries, where they are engulfed by 
tissue-resident macrophages [Ruehm et al 2001], and are detectable by T2*-weighted 
MRI. Thus USPIO-enhanced MRI can identify tissue-resident macrophage activity 
and help to identify cellular inflammation within tissues.  
 
Promising preclinical studies have shown USPIO-enhanced MRI is able to detect 
acute cardiac and renal allograft rejection with USPIO signal correlating with 
macrophage distribution, rejection severity on histology, and impaired cardiac 
function. Moreover, this approach can also be used to assess treatment response with 
rodent models demonstrating less USPIO enhancement following initiation of 
immunosuppression [Kanno et al 2001; Johansson et al 2002; Penno et al 2005; Wu 
et al 2009; Wu et al 2013; Alam et al 2015]. A future role of USPIO includes a 
‘theranostic’ strategy whereby imaging is combined with therapy. For example,    
Guo et al recently conjugated an iron nanoparticle to a CD3 antibody and a therapy 
gene, allowing imaging and targeting of T cells that play a central role in acute 
cardiac allograft rejection [Guo et al 2012].  
 
In this study, I aimed to assess and quantify myocardial USPIO enhancement in 
stable patients with cardiac transplantation and patients with cardiac transplant 





oedema including T2 mapping MRI; a quantitative imaging method assessing 
myocardial oedema in transplant rejection [Giri et al 2009; Thavendiranathan et al  
2012]. I hypothesised that USPIO-enhanced MRI would detect myocardial 
macrophage activity in the inflamed myocardium of rejecting transplanted hearts, but 
not in stable healthy cardiac allografts, and provide a cellular-specific non-invasive 




This was an open label observational multicentre cohort study (NCT02319278). The 
study was performed in accordance with the Declaration of Helsinki, the approval of 
the Scotland A Research Ethics Committee (13-SS-0111), and the written informed 
consent of all participants. The Medicines and Healthcare products Regulatory 
Agency of the United Kingdom gave Clinical Trial Authorisation for the study 
(EUDraCT 2013-002336-24). 
 
6.3.1   STUDY POPULATIONS 
Adult (>18 years of age) patients with a history of cardiac transplantation (including 
suspected allograft rejection) were recruited into the study. Healthy volunteers had 
no clinically significant past medical history. Exclusion criteria were 
contraindication to MR imaging or ferumoxytol infusion, any other inflammatory 
comorbidity, renal failure (estimated glomerular filtration rate <30 mL/min/1.73 m2), 






6.3.2   STUDY PROTOCOL 
Patients with cardiac transplantation and healthy volunteers underwent paired MRI 
scans at baseline, and patients were invited to return for repeat imaging after 
3 months. At the time of scanning, blood samples were collected for clinical 
haematology and biochemistry measurements. The troponin assay used was the 
Elecsys® high sensitivity Troponin T assay (Roche Diagnostics). 
 
6.3.3   MAGNETIC RESONANCE IMAGING 
MRI was performed using a MAGNETOM Avanto 1.5 T MRI scanner, with a 
dedicated cardiac array coil. All images were acquired with electrocardiogram gating 
using expiration breath-holds. Routine steady state free precession sequences were 
used to acquire long and short axis cine images of the heart (TR 85.8 ms, TE 1.45 ms, 
flip angle 50º, matrix 173x256, FoV 400 mm, slice thickness 8 mm, 2 mm gap). 
Quantitative USPIO imaging was performed in similar slice positions using a 
prototype T2*-weighted multi-gradient-echo acquisition with a volumetric shim 
applied over the entire heart volume (TR 996 ms, TE 2.13, 4.3, 6.4, 8.6, 10.7, 12.8, 
15.0, 17.1 ms, flip angle 18º, matrix 130x256, FoV 400 mm, slice thickness 6 mm, 
gap 4 mm). The T2*-weighted acquisitions included views through the liver, spleen 
and spine to allow quantification of USPIO accumulation within organs of the 
reticuloendothelial system. The same T2* protocol was used to quantify USPIO 
accumulation 24 hours after infusion allowing calculation of T2* relaxation rates 
before and after administration of USPIO. T2 mapping was conducted using a 
Siemens prototype T2-prepared TrueFISP acquisition acquiring identical long and 





flip angle 70º, matrix 130x192, FoV 400 mm, slice thickness 6 mm, 4 mm gap). 
T2P-TrueFisp images are acquired at intervals of at least 3 RR intervals to allow for 
sufficient magnetisation recovery in between acquisitions. 
 
Immediately after the baseline T2 and T2*-weighted scan, participants received an 
intravenous administration of gadolinium contrast medium (0.15 mmol/kg) followed 
by breath held inversion recovery sequences in long axis and short axis planes to 
acquire late enhancement images. Optimal inversion time was determined on a slice-
by-slice basis using standard late enhancement TI-scout protocols (TR 750 ms, TE 
2.61 ms, flip angle 20º, matrix 173x256, FoV 400 mm, slice thickness 9 mm, gap 
1 mm). The inversion recovery late enhancement short axis slices were acquired 
using similar slice positions as the T2 oedema and T2*-weighted imaging.  
 
6.3.4   USPIO 
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg; Rienso®) was performed 
immediately following the baseline magnetic resonance scan over 15 minutes  using 
a concentration of 2-8 mg/mL, diluted in 0.9% saline or 5% dextrose. 
Haemodynamic monitoring was conducted throughout and participants were 
observed for a further 30 minutes  to ensure no hypersensitivity reactions. 
 
6.3.5   IMAGE ANALYSIS 
All T2*-weighted multi-gradient-echo images for each patient were analysed using 
Circle CVI software. An experimentally determined threshold used in previous work 





data that did not have an acceptable exponential decay when signal intensity was 
plotted against echo time. Individual images affected by artefact were excluded. The 
inverse of the mean T2* (R2*) for each ROI was then calculated to assess the uptake 
of USPIO, where the higher the value, the greater the USPIO accumulation.  
 
T2 maps, ventricular volume and functional analyses were also performed using 
Circle CVI software. T2 and T2* data were collected immediately prior to USPIO 
administration. USPIO-enhanced T2* data were collected 24-25 hours following 
ferumoxytol administration. Regions of interest were drawn on T2 and T2* images 
in the septum at mid cavity level between anterior and inferior right ventricular (RV)  
insertion points (Figure 6.1). Septal myocardial regions only were selected to reduce 














Figure 6.1.   Post USPIO R2* and T2 maps for a healthy volunteer (A), patient with cardiac 
transplant (B) and myocardial infarction (C). Myocardial oedema is displayed as brighter signal in the 
T2 colour map corresponding to higher T2 value. Cardiac transplant myocardium (B) displays no 
USPIO accumulation but high T2, in contrast to USPIO accumulation and high T2 in myocardial 















6.3.6   HISTOLOGY  
Myocardial tissue samples were obtained from one patient with cardiac 
transplantation undergoing surveillance biopsies without suspicion of transplant 
rejection. USPIO was administered 24 hours prior to the biopsy, and a trucut 
myocardial biopsy sample was taken from the myocardium. The biopsy sample was 
fixed in formalin, embedded in paraffin, sectioned, and stained to look at architecture 
(haematoxylin and eosin), accumulation and distribution of USPIO (Prussian Blue) 
and macrophages (CD68).  
 
6.3.7   STATISTICAL ANALYSIS 
All statistical analysis was performed with GraphPad Prism, version 6. Shapiro-Wilk 
or D’Agostino and Pearson tests were used to test normality of distribution. To 
compare participant characteristics, USPIO uptake and myocardial oedema in 
patients and volunteers, R2* and T2 values were compared using Chi-squared, 
unpaired t-tests, and Mann-Whitney tests depending on normality of data. To 
compare results at 3 months with baseline, paired t-test and Wilcoxon test was used 
depending on normality of distribution. Statistical significance was defined as two-









Ten volunteers and 11 patients with cardiac transplantation were recruited. One 
volunteer was excluded from analysis due to the presence of late gadolinium 
enhancement as described previously [Stirrat et al 2016]. At the time of recruitment, 
all transplant patients were assessed to be clinically well with no firm evidence of 
allograft rejection. One patient with prior cardiac transplant was excluded due the 
finding of LGE consistent with myocardial infarction that may influence the 
USPIO enhancement data [Alam et al 2012; Stirrat et al 2017]. No other patient with 
cardiac transplant displayed LGE. Five of the 10 cardiac transplant patients returned 
at 3 months for repeat imaging. Administration of ferumoxytol was well tolerated 
with no adverse reactions reported during or immediately after administration in any 
of the participants.  
 
Volunteers were predominantly female and patients with cardiac transplant were 
predominantly male (Table 6.1). Transplant patients had smaller indexed end-
diastolic ventricular volumes (p<0.01) and higher baseline plasma high-sensitivity 
troponin concentrations (p<0.05). There were more males in the transplant group 
(p<0.05) but there were no other differences between groups at baseline.  
 
6.4.1    T2 AND  R2* MAPPING 
Patients with cardiac transplantation had a higher T2 value than volunteers (53.8±5.2 









TABLE 6.1   Participant Characteristics 
 Healthy Volunteers Patients with Cardiac 
Transplant 
Number 9 10 
Female 6 1* 
Age (years) 52 (45.5-61.5) 60  (52.75-64.5) 
Time since transplantation (months)  59 (19-159) 
Body mass index (kg/m2) 22.9 (20.1-26.9) 25.9 (24.0-27.9) 




Left ventricular ejection 
 fraction (%) 
 
63.6±4.9 65.0±7.1 
Blood Tests   
    White cell count (x109/L) 6.5±1.5 6.1±2.5 
    C-reactive protein (mg/L) 1.9±2.0 2.1±2.1 
    Plasma troponin (ng/L) 3.1±2.8 14.1±20.9* 
Mean±SD or median (interquartile range). 













Figure 6.2.   Comparison of T2 (ms) and R2* (s-1) measurements at baseline in healthy volunteers 
(HV, blue) and cardiac transplant patients (Tx, black). Transplant patients have higher T2 than healthy 
volunteers, but no other significant differences exist between groups (** = p<0.01). USPIO - 








































































TABLE 6.2   Septal myocardial R2* and T2 values in healthy volunteers and patients 




** p<0.01 (compared to volunteers).  USPIO - ultrasmall superparamagnetic particles of iron oxide; SD - standard 
deviation. 
  




Pre USPIO R2* (s-1) 31.6±5.9 34.0±10.1 
Post USPIO R2* (s-1) 58.2±7.5 56.0±10.2 
ΔR2* (s-1) 26.6±7.3 22.0±10.4 





There were no differences in R2* between patients with cardiac transplantation and 
volunteers at baseline (31.6±5.9 versus 34.0±10.1 s-1; p=0.84), at 24	hours after 
USPIO administration (58.2±7.5 versus 56.0±10.2 s-1; p=0.60), or in the magnitude 
of change in R2* due to USPIO (26.6±7.3 versus 22.0±10.4 s-1; p=0.28; Figures 6.1 
and 6.2, and Table 6.2).  
 
There were no differences in either T2 (52.7±2.8 versus 52.12±3.4 ms;  p=0.80) or 
the change in R2* due to USPIO (29.42±8.14 versus 25.8±7.8 s-1; p=0.43) between 
baseline and 3 months in patients with cardiac transplant (Figure 6.3). The 
myocardial biopsy 24 hours after USPIO administration revealed normal myocyte 
architecture with no evidence of increased numbers of inflammatory macrophages or 
the presence of USPIO (Figure 6.4). 
 
6.4.2   CARDIAC TRANSPLANT PATIENT WITH RECENTLY SUSPECTED ALLOGRAFT 
REJECTION 
One patient was recruited to the study 3 days following admission with non specific 
malaise. This was the only patient in my cohort that had a previous history of 
previous acute cellular rejection (2 years before). On this occasion, the myocardial 
biopsy showed grade 1a rejection (i.e. no evidence of recurrence of rejection or 
cellular infiltration) and the patient was reassured, but subsequently recruited to the 
study. This patient had the highest plasma high-sensitivity troponin I in the cohort at 
71 ng/L. Other blood tests were normal including white cell count (4.3x109/L) and 
C-reactive protein (<1 mg/L). The T2 value for this subject was the highest in our 





50.6 s-1 24 hours after USPIO: change in R2* was 23.8 s-1. Despite censoring this 
patient from analysis, patients with cardiac transplantation continued to have a higher 
T2 value than volunteers (52.4±2.8 versus 48.6±1.9 ms; p=0.0056). This patient did 
not undergo gadolinium-enhanced imaging at the request of the attending clinician 
due to mild renal impairment. 
 
A  B  
 
Figure 6.3.   Repeated imaging in patients with cardiac transplant. There were no differences in 
myocardial T2 ms (A) or the change in R2* s-1 (B) due to USPIO between time points (n=5).       




Figure 6.4.   Biopsy from patient with cardiac transplant. A) Haematoxylin and eosin (x100) staining 
showing normal myocyte architecture with no evidence of significant inflammatory cell infiltration.     
B) CD68 staining (x200) showing only very few scattered macrophages (brown). C) Prussian Blue 

















































For the first time, I report the combined assessment of T2 mapping and USPIO-
enhanced T2* MR imaging in patients with prior cardiac transplantation and healthy 
volunteers. This technique is feasible, safe and well tolerated in this group of patients. 
I demonstrate that whilst myocardial T2 is increased, there is no evidence of ongoing 
or chronic cellular inflammatory uptake as detected by USPIO enhancement. Further 
assessments of these measures are now needed in patients with acute cardiac 
transplant rejection. 
 
USPIO-enhanced T2* MRI has previously been used in man to assess cardiovascular 
inflammation in a range of different conditions [Tang et al 2009; Richards et al 
2011; Alam et al 2012; Yilmaz et al 2013; Stirrat et al 2017], and preclinical models 
suggest this technique may be useful in assessing human patients with transplant 
rejection [Kanno et al 2001; Johansson et al 2002; Penno et al 2005; Wu et al 2009; 
Wu et al 2013; Alam et al 2015]. In my cohort of stable patients with cardiac 
transplantation, I did not detect greater USPIO enhancement within the myocardium, 
but this contrasted with the increased measures of myocardial T2 found in transplant 
patients compared to volunteers.  
 
Why did I detect higher T2 values in transplant patients compared to controls in the 
absence of USPIO accumulation? There are several plausible explanations. First, 
chronic residual low grade inflammation or oedema without tissue-resident 





USPIO. In the absence of histological data, I cannot confirm the presence of 
lymphocytes, but in a stable group of patients who are clinically well this explanation 
appears unlikely. Second, higher T2 values in the myocardium of cardiac allografts 
may simply be due to increased water content, possibly related to expansion of the 
myocardial vasculature and blood content. The finding of greater measures of R2* 
(both at baseline and after USPIO), which measures iron within the blood pool, 
would support this mechanism. This explanation may suggest intriguing differences 
in the behaviour of resting myocardial vascular integrity in patients with stable 
cardiac allografts. Third, the relatively low field strength of the MRI scanner (1.5 T) 
may be contributory since it has poorer sensitivity in detecting sparse myocardial 
USPIO compared to higher field strength 3 T scanners. However, in my single 
myocardial biopsy, substantial numbers of macrophages were not evident. Finally, 
the most plausible explanation for greater measures of T2 in cardiac allografts may 
in fact reflect a change in myocyte architecture caused by myocardial fibrosis, or 
scarring. High T2 value is usually solely attributed to myocardial oedema, but has 
previously been found to inversely correlate with LV function in patients with dilated 
cardiomyopathy that did not have any evidence of inflammation or other reasons for 
myocardial oedema [Nishii et al 2014]. This may suggest higher T2 values reflect 
myocardial fibrosis, similar to results using T1 mapping approaches. Furthermore, 
higher T2 has also been found in patients with hepatic fibrosis [Guimaraes et al 
2016]. I therefore contend that elevated T2 in the myocardium of cardiac allografts 
may reflect intrinsic changes to the cellular architecture, such as the presence of 
myocardial fibrosis, and not myocardial oedema in this cohort. As such, it may prove 





Crucially I lacked adequate access to sufficient histology or T1 mapping in order to 
prove whether subtle myocardial fibrosis, not detected by LGE imaging, is a 
causative factor in the high T2 value found. Most patients had undergone 
transplantation many years ago (Table 6.1) so using historical postoperative 
surveillance biopsies would not provide an accurate assessment of current myocyte 
architecture and we chose not to use these for histological correlation. 
 
Irrespective of the aetiology, greater T2 in stable transplant patients is an interesting 
finding. Previous small studies have found that T2-weighted and T2 mapping MRI 
assists in diagnosis and prognosis estimation in patients with cardiac transplant 
rejection [Marie et al 2001; Usman et al 2012; Bonnemains et al 2014]. Following 
on from these studies, the DRAGET study [Bonnemains et al 2015], a large 
multicentre multinational study, is now prospectively recruiting patients in the first 
year after transplantation to assess the performance of T2 mapping in diagnosing 
transplant rejection. The findings of this study are awaited with interest, but clearly if 
the T2 value in myocardium of stable cardiac allografts is high, this increases the 
likelihood of false positive diagnoses of allograft rejection and ultimately reduces the 
specificity and precision of the test.  
 
A further study by Miller et al examined 22 patients with cardiac transplantation in 
the early post-operative period with CMR and cardiac biopsy. Unsurprisingly, they 
found that myocardial T2 and T1 was higher in the patients that displayed graft 
rejection (n=5) compared to those unaffected. In patients without biopsy evidence of 





volunteers suggesting greater measures of myocardial oedema even in clinically well 
patients without biopsy evidence of inflammation. T1 and T2 measures improved 
over the 22 week follow-up period, but there remained significantly greater T1 
values at the end of the follow up period in the non-rejecting transplant patients 
compared to volunteers. These findings are in keeping with my results and suggest 
that T1 and T2 measures may be elevated, even in ‘healthy’ transplant patients. It is 
unfortunate the Miller et al did not follow these patients for longer to see if MRI 
measures normalised.   
 
One patient had very high myocardial T2 and deserves special mention. This was the 
only patient with a previous history of biopsy proven acute cellular rejection 2 years 
previously. At the time of recruitment the patient was recovering from a non specific 
illness and recurrent episode of rejection had been discounted on the basis of 
negative endomyocardial biopsies 3 days previously. Based upon the studies 
mentioned previously, myocardial T2 value of this magnitude suggests severe 
rejection. Serial imaging with T2 mapping, both prior and subsequent to this episode, 
would have been useful in determining the time course and fluctuation in T2 to 
assess whether it is chronically elevated, which may suggest stable myocardial 
fibrosis, or not. This patient in fact had T1 maps acquired as part of imaging biobank 
retention (the only one in my study) and septal values were elevated at 1018 ms 
(normal values 950±21 ms) [Dabir et al 2014].  
 
Whether or not this patient had allograft rejection (with a negative biopsy) or not 





medical therapy, making an episode of rejection less likely. If myocardial fibrosis 
and active rejection or inflammation is not the cause of elevated T2 then why was the 
T2 value so high in this patient? A high T2 value of this magnitude in the absence of 
rejection would cast serious doubt on the precision of T2 mapping to diagnose and 
exclude cardiac allograft rejection and diminish its potential utility in clinical 
practice. The DRAGET study will be well placed to answer this [Bonnemains et al 
2015]. 
 
6.5.1   LIMITATIONS 
There are some limitations that deserve mention. Participant numbers were small, but 
sufficient for a pilot study testing the feasibility of USPIO-enhanced MRI in this 
population. From my recent work in patients with myocardial infarction, I  know that 
this technique works, and is capable of identifying and tracking myocardial 
macrophage accumulation [Stirrat et al 2016]. In this study, myocardial macrophage 
infiltration is either not a chronic feature of transplantation or at levels too low to be 
detected.  
 
My aim was to recruit a range of patients with cardiac transplantation, from chronic 
stable patients, to patients with suspected allograft rejection. Unfortunately, I was 
only able to recruit one patient with recently suspected transplant rejection, and this 
was excluded clinically, with the remaining patients being stable and well. Small 
study numbers and absence of patients with florid transplant rejection clearly limit 
my findings and this technique now needs to be tested in patients with proven acute 






6.5.2   CONCLUSION 
I have shown that stable patients with cardiac transplantation have greater measures 
of myocardial T2, which may suggest myocardial oedema or fibrosis, compared with 
control volunteers. Ferumoxytol-enhanced MR imaging does not add clinically 
relevant information in this group of stable patients but may provide additional 





















Novel molecular and cellular imaging techniques capable of non-invasively 
examining metabolic and biological processes would be valuable in a range of 
cardiovascular diseases to aid understanding of disease pathogenesis, provide 
diagnostic information, predict disease progression, and guide therapeutic 
intervention. It would therefore be a major clinical advance if a reliable non-invasive 
imaging technique capable of detecting tissue inflammation could be developed. 
 
Magnetic resonance imaging has a number of advantages including excellent 
discrimination of soft tissue components, good spatial resolution and in particular, 
absence of ionising radiation, an important consideration if serial imaging is 
envisaged. T2* imaging for assessing iron accumulation has successfully been used 
for over a decade in diagnosing and grading the severity of iron accumulation in 
patients with transfusion-dependent thalassaemia major, helping provide serial 
disease monitoring and guide therapy that improves prognosis [Anderson et al 2001; 
Anderson et al 2004]. In this disease, T2* MRI has improved sensitivity in detecting 
early myocardial iron accumulation compared to serum iron sampling [Anderson et 
al 2001]. T2* MRI in the assessment of iron accumulation is easily quantifiable, well 
validated, highly reproducible, clinically robust, and is achievable in a single breath-
hold [Westwood et al 2003a; Westwood et al 2003b; Tanner et al 2006; Carpenter et 




Iron oxide nanoparticles initially generated interest as an MRI blood pool contrast 
agent, but recent studies have revealed them to be an effective tracer, highlighting 
inflammatory tissue macrophages, and clinical applications have started to emerge 
[Trivedi 2004; Tang et al 2006; Trivedi 2006; Tang et al 2009; Richards et al 2011; 
Alam et al 2012; Yilmaz et al 2013; McBride et al 2015]. Following administration, 
USPIO are small enough to migrate passively across the vessel wall [Wang et al 
2001] especially in regions of inflamed vasculature where there is loss of endothelial 
integrity. Cells of the reticuloendothelial system, particularly tissue macrophages, 
identify, internalise and concentrate iron oxide nanoparticles generating markedly 
reduced T2 and T2* MRI relaxation times. Thus USPIO-enhanced MRI can identify 
tissue-resident macrophage activity and identify cellular inflammation within tissues.  
 
In the studies presented in my thesis, I first determined a range of normal T2* values 
at 1.5 Tesla and 3 Tesla in healthy volunteers before and after USPIO, detailing 
methodology used and describing commonly encountered imaging 
problems (Chapter 3). I went on to assess whether USPIO-enhanced T2* MRI can 
detect and serially monitor myocardial inflammation after myocardial infarction 
using single and repeated USPIO administration (Chapter 4). Thereafter I compared 
USPIO enhancement in the myocardium of volunteers with patients affected with 







7.2 SUMMARY OF THESIS FINDINGS 
 
7.2.1   A RANGE OF NORMAL TISSUE VALUES FOR USPIO-ENHANCED T2* MRI WAS 
DETERMINED AT 1.5 TESLA AND 3 TESLA 
Following USPIO administration in healthy volunteers, USPIO was detected by 
changes in R2* from baseline at 24 hours in myocardium, skeletal muscle, kidney, 
liver, spleen and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and 
bone at 3 T. Myocardial changes in R2* due to USPIO were 26.5±7.3 s-1 at 1.5 T, 
and 37.2±9.6 s-1 at 3 T. Tissues showing greatest ferumoxytol enhancement were the 
reticuloendothelial system: the liver, spleen and bone marrow at both 1.5 and 3 T. 
  
Tissues with small increases in R2* after USPIO (i.e. less than that of the blood 
pool) can be explained by detection of USPIO within the intravascular space and 
include skeletal muscle (at 1.5 T only), myocardium and kidney. In contrast, R2* 
changes due to USPIO that are greater than the blood pool must be due to 
accumulation of USPIO, either through iron storage, uptake by macrophages or other 
phagocytes, or sequestered within tissue interstitium. As the most pronounced R2* 
changes were seen in the spleen, liver and bone marrow: organs of the 
reticuloendothelial system, it would appear likely that USPIO is incorporated quickly 
into tissue-resident phagocytes and macrophages.  
 
7.2.2   SOLUTIONS TO COMMONLY ENCOUNTERED PROBLEMS WITH USPIO-
ENHANCED T2* MR IMAGING WERE DETAILED 
Artefacts are commonly encountered with T2* imaging and made data analysis 
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challenging. Post USPIO contrast artefacts at the blood pool to myocardial interface 
were commonly seen and needed careful exclusion when selecting myocardial ROI. 
This limited the assessment of USPIO accumulation at the endocardium. Similarly, 
blooming artefacts from nearby organs with high iron or blood pool USPIO content, 
such as lung and liver, commonly created signal deficits within the myocardium. In 
this situation, examination of T2* decay curves and excluding echo times influenced 
by artefact aided T2* decay curve fitting. 
 
The advantage of MRI mapping techniques is that visual assessment and objective 
quantification can be made using the same image, and these are now entering clinical 
practice. However based on my experiences, I would recommend caution in 
interpreting maps alone. Signal attenuation seen on the T2* map may be interpreted 
as tissue USPIO accumulation, but may be due to blooming artefact from nearby 
susceptibility effects, and close examination of the T2* decay curve, and individual 
echoes is suggested in order to distinguish accurately between tissue USPIO 
accumulation and artefact. Setting a decay curve fitting acceptability threshold (r2), as 
I did, helps exclude areas grossly affected by artefact. In practice however, regions 
with a seemingly acceptable r2 may still be heavily influenced by artefact and there is 
no acceptable substitute for visualising decay curves and individual echo images.  
 
Finally, applying tissue specific echo times tailored to the expected T2* value should 
be used in order to achieve the most accurate decay curves possible. 
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7.2.3   ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE-ENHANCED 
T2* MR IMAGING CAN DETECT MYOCARDIAL MACROPHAGES AFTER MYOCARDIAL  
INFARCTION 
Following a single USPIO infusion in the first week after MI, USPIO enhancement is 
seen in all regions of the myocardium, but greatest within the infarct zone, after 
24 hours. USPIO enhancement is also observed until days 4-9 in bone marrow, and 
until days 13-21 in the liver and spleen. Therefore the duration of USPIO 
enhancement is longest in the mononuclear phagocyte rich reticuloendothelial 
system. It is likely that resident phagocytes within these organs ingest USPIO from 
circulating blood. Efflux of myocardial macrophages containing USPIO may also 
contribute to the reticuloendothelial system T2* signal seen after MI.  
 
7.2.4   USPIO-ENHANCED T2*  MR IMAGING CAN SERIALLY MONITOR MYOCARDIAL 
MACROPHAGES AFTER MI 
Following repeated doses, USPIO uptake in the infarct zone peaked at days 2-3, and 
greater USPIO uptake was detected in the infarct zone compared to remote 
myocardium until days 10-16. In contrast, T2-defined myocardial oedema peaked at 
days 3-9 and remained increased in the infarct zone throughout the 3-month 
follow up period.   
 
I have demonstrated a discontinuity between the prolonged (up to 3 months) T2-
defined time course of tissue oedema, and the brief (first 2 weeks) T2*-defined time 
limited cellular inflammation. This observed USPIO uptake in the infarct zone for up 
to 2 weeks following MI is consistent with data from previous studies demonstrating 
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that tissue-resident macrophages are active and predominate within the infarcted 
myocardium in the first 2 weeks after MI [Tsujioka et al 2009; Nahrendorf et al 
2010]. Furthermore, the finding of myocardial oedema within the infarct zone at 
3 months after MI may at first appear surprising, but long lasting myocardial oedema, 
often up to 6 months after MI, has previously been described [Nilsson et	al	2001; 
Dall’Armellina et al 2011]. 
 
7.2.5   USPIO ENHANCEMENT IN THE MYOCARDIUM OF PATIENTS WITH ACUTE 
MYOCARDITIS 
There was no demonstrable difference in USPIO enhancement between patients and 
volunteers even within regions displaying late gadolinium enhancement. However, 
there was greater T2 value in regions of LGE in patients with myocarditis when 
compared to healthy volunteer myocardium suggestive of myocardial oedema. This 
suggests that tissue-resident macrophages do not provide a substantial contribution to 
the myocardial inflammation in this condition, and that USPIO-enhanced MRI does 
not provide additional clinically relevant information to LGE and T2 mapping MRI 
in this condition.   
 
Imaging after 3 months in myocarditis patients was repeated and imaging evidence 
of recovery was found: a reduction in volume of LGE, a reduction in T2 value in 
regions displaying LGE, and improvement in ejection fraction.  
 




I determined that there were no differences in USPIO uptake in the myocardium of 
patients with transplantation compared to healthy volunteers. Therefore USPIO-
enhanced MRI is normal and stable over time suggesting the absence of chronic 
macrophage-driven cellular inflammation. However, in contrast, myocardial T2 
values were higher in patients with cardiac transplant versus healthy volunteers. This 
finding is intriguing and there are several explanations. Chronic residual low grade 
inflammation or oedema without tissue-resident macrophage infiltration                  
(or inadequate MRI magnetic strength to detect sparse USPIO-laden macrophages) is 
possible, but the raised T2 values found may simply relate to expansion of the 
myocardial vasculature after cardiac transplantation. Finally, the most plausible 
explanation for greater measures of T2 in cardiac allografts may in fact reflect a 
change in myocyte architecture caused by myocardial fibrosis, or scarring. Crucially 
I lacked adequate access to sufficient histology or T1 mapping in order to prove 
whether subtle myocardial fibrosis, not detected by LGE imaging, is a causative 
factor in the high T2 value found. 
 
7.3 FUTURE DIRECTIONS 
 
The conclusions of this thesis raises several questions regarding whether USPIO-
enhanced cardiac magnetic resonance will enter clinical practice to aid diagnosis, 
improve risk stratification and serial monitoring in inflammatory conditions driven 






7.3.1   IRON NANOPARTICLES TO AID DETECTION OF STEM CELLS  
Current research endeavours are increasingly focusing on stem cell therapy that 
attempts to restore function to organs with little or no regenerative capacity. This 
follows the discovery that pluripotent progenitor cells bear the capacity to 
differentiate into mature cardiac cells. There is therefore a need to non-invasively 
track the distribution and viability of administered stem cells. Cell labelling with iron 
nanoparticles has been proposed as it is relatively simple, fast, inexpensive and is 
well described, although there are few published studies using this technique. 
Tracking of stem cells labelled with iron nanoparticles using MR imaging is still at 
the preclinical stage but offers high spatial resolution, excellent soft tissue detail and 
avoids exposure to ionising radiation. 
 
Küsterman et al [2005] labelled cardiac progenitor cells expressing enhanced green 
fluorescent protein (EGFP) with ferumoxtran-10 (USPIO) and implanted the cells 
into murine myocardium injured through either cryocoagulation or coronary artery 
ligation. Colocalisation of USPIO and stem cells was confirmed by comparing the 
high-resolution MRI images with Prussian Blue staining (for iron) on histology, and 
immunohistochemistry for EGFP.  
 
Chapon et al [2009] combined MR imaging and positron emission tomography 
(PET), to track transplanted stem cells after myocardial infarction in rats providing 
anatomical, physiological and metabolic tissue information. They conjugated rat 
bone marrow-derived stem cells to CLIO. Stem cells were successfully detected on 
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MRI and histology for the 6-week duration of the study, although increased 
myocardial metabolic activity detected by PET (18F-fluorodeoxyglucose uptake) 
was only seen in the first week post stem cell implantation. This may represent a 
short-lived improvement in tissue viability after stem cell transplantation, but more 
likely may be due to early, localised inflammation from intramyocardial stem cell 
injection settling over time. A trend to an improvement in cardiac function was found 
after stem cell implantation, although this did not reach statistical significance.  
 
Imaging of stem cells using larger iron particles has also been conducted with 
success [Kraitchman 2003; Chung et al 2011; Lu et al 2012]. Of particular interest, 
Lu et al [2012] recently investigated the effects of culprit vessel intracoronary 
infusion of SPIO-labelled (ferucarbotran) autologous bone marrow-derived 
mesenchymal stem cells (MSCs) after acute myocardial infarction in pigs. One week 
after MI, SPIO-labelled MSCs were infused via the culprit coronary vessel and 
compared to a control infusion of phosphate buffer saline. The pigs were imaged 
immediately before and 3 days after cell transplantation. Detection of SPIO-labelled 
MSCs was observed on T2* MRI after cell transplantation. However, pronounced 
reduction in T2* values was found in the spleen, liver and kidney with 
immunohistochemistry confirming this to be the SPIO-MSC conjugate, suggesting 
the majority of the infused cells escaped into the systemic circulation, and were 
subsequently sequestered in the organs of the reticuloendothelial system. The major 
disadvantage of labelling MSCs in vitro prior to injection (as in this study), is that 
subsequent MRI would not detect any ‘offspring’ MSCs (having no SPIO attached) 
should the stem cell successfully proliferate.  
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As a solution to this problem of in vitro SPIO-labelled MSCs being unable to detect 
newly created stem cells, Chung et al [2011] made use of a clever reporter gene-
expressing antigen on the surface of the embryonic stem cells (ESCs). They 
separately injected SPIO-conjugated to a monoclonal antibody (SPIO-MAb) that 
targeted the antigen expressed by the reporter gene, allowing in vivo MRI 
quantification of viability, proliferation and teratoma formation of transplanted ESCs 
and their offspring. The advantage of this technique over direct stem cell labelling is 
that proliferated stem cells can now be tracked. Signal is enhanced when the stem 
cell successfully divides thus allowing successful detection of newly proliferated 
stem cells. 
  
These studies above suggest that iron nanoparticle enhanced MRI may be well 
placed to assess the viability and proliferation of implanted stem cells in future 
research. Clinical trials using this technique have yet to emerge but this may happen 
in the near future. Before this can take place, MRI detection limits for specific stem 
cell, iron nanoparticle, MRI scanner combinations are likely to be different and 
would have to be predetermined, although work has already begun on this 
[Mathiasen et al 2013]. 
 
7.3.2   IRON NANOPARTICLES TO AID DETECTION OF APOPTOSIS 
Targeting of various pathophysiological processes of interest becomes possible when 
contrast agents, including iron oxide particles, are conjugated to a specific antibody 
or peptide [McAteer et al 2010]. Like stem cells described above, iron nanoparticles 
can facilitate imaging of apoptosis, or cell death. Non-invasive detection of early, 
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reversible apoptosis might be useful clinically. During apoptosis, the phospholipid 
phosphatidylserine is externalised on the cell surface. Annexin V is an endogenous 
protein that binds with high affinity to phosphatidylserine, and when conjugated to 
CLIO, has successfully been able to identify apoptotic cells in vitro using              
MR imaging [Schellenbeerger et al 2002]. Sosnovik et al [2005] used this particle as 
a foundation to create a multimodality imaging nanoparticle when conjugated to 
cyanine 5.5 dye (AnxCLIO-Cy5.5) allowing co-identification of apoptosis with 
fluorescence microscopy and T2* MRI. In a murine model of ischaemia-reperfusion 
injury, a reduction in signal intensity on T2* MRI was observed in reperfused 
regions with AnxCLIO-Cy5.5 but not with unlabelled CLIO-Cy5.5. The area of 
signal loss correlated with the region of contractile dysfunction seen on MRI, and 
with areas of increased fluorescence intensity on near infrared fluorescence 
confirming that this was correctly identifying ischaemic myocardium. 
 
The same group then developed a novel dual contrast molecular MRI probe to help 
identify ischaemic ‘at-risk’, but viable, myocardium after ischaemia-reperfusion 
injury [Sosnovik et al 2009]. Using the same AnxCLIO-Cy5.5 particle described 
above, they identified cellular apoptosis in mice on MRI 4-6 hours after ischaemia-
reperfusion injury. However, to illustrate necrosis, gadolinium was also administered 
with late enhancement MRI. Gadolinium accumulates in regions of cell necrosis, 
with cell wall rupture and expansion of the extracellular volume. In apoptosis alone, 
the cell wall remains intact, and gadolinium does not accumulate. Interestingly, they 
found only 21% of regions displaying apoptotic myocardium (accumulation of 
AnxCLIO5.5) had evidence of necrosis (defined by late gadolinium enhancement). 
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This suggests that the majority of apoptotic cardiomyocytes remain viable 4-6 hours 
after ischaemia-reperfusion injury, and this was confirmed on fluorescence 
microscopy and immunohistochemistry revealing large numbers of apoptotic, but 
potentially viable, cardiomyocytes in the at-risk area (AnxCLIO-Cy5.5 positive, 
gadolinium negative areas). This imaging technique may provide an ideal imaging 
platform to trial strategies to salvage apoptotic, but not yet necrotic, myocardium 
after an ischaemic insult. 
 
Perhaps the most interesting role for iron nanoparticles in assessing apoptosis was 
illustrated by Dash et al [2011] in the setting of chemotherapy induced cardiotoxicity. 
They conjugated SPIO to recombinant human Annexin V (ANX-SPIO), and 
examined doxorubicin-induced cardiotoxicity in rat myocytes, cardiac fibroblasts, 
mesenchymal stem cells and also in mice in vivo. Areas of signal attenuation on T2* 
MRI correlated with iron accumulation and regions of apoptosis on histology, 
although myocardial structure appeared normal suggesting the detection of early 
apoptosis only. Perhaps more importantly, they demonstrated that treatment with 
A61603 (an alpha-1 adrenoreceptor agonist that prevents doxorubicin-induced 
cardiomyopathy), reversed apoptosis on histology and eliminated the ANX-SPIO 
signal on MRI. These findings suggest that this technique may have the ability to 
detect early myocyte injury, such as in patients with early chemotherapy-induced 






7.3.3   ASSESSMENT OF USPIO ENHANCEMENT WITH T2 MAPPING 
Imaging assessment of USPIO has historically been achieved with T2* MRI. T2* 
MRI measures the ‘true’ T2 of tissue in addition to magnetic field inhomogeneities 
due to imperfections of the scanner magnet itself or magnetic susceptibility effects 
within the patient or placed within the magnetic field (such as USPIO).                 
T2*-weighted imaging therefore requires high uniformity of the magnetic field. In 
spin echo T2 imaging, a refocusing pulse removes dephasing due to magnetic field 
inhomogeneities and susceptibility effects. In gradient echo T2* MRI there is no 
such refocusing pulse and the susceptibility effects of USPIO can be measured by 
reduction in T2*. Gradient echo has the advantages of shorter acquisition times but 
suffers from relatively reduced signal, artefacts in regions of tissue interfaces, and 
generally poorer image quality compared to T2 spin echo sequences.  
 
Accumulation of USPIO particles has two major effects: a predominant susceptibility 
effect mentioned above, but also direct T2 shortening caused by local field 
inhomogeneities that promotes transverse relaxation [Sanjay et al 2004]. As such, 
UPSIO can be detected on both T2 and T2* imaging, but T2* imaging is more 
sensitive in detecting USPIO than T2 imaging [Kaim et al 2002; Simon et al 2006]. 
The reduced sensitivity of T2 imaging in detecting USPIO may be in part due to 
prolonged T2 values of oedematous tissue opposing the USPIO-lowering T2 effects, 
especially when assessing areas of tissue inflammation. Observations of our data 
throughout this thesis show that the spread of T2* values, even in healthy tissue, is 
greater than that seen in T2 imaging. This is probably explained by artefact and 
poorer image quality of gradient echo T2* sequences compared to T2 imaging 
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described above. Larger spread of data within normal healthy tissue makes it more 
difficult to detect threshold levels of USPIO accumulation within inflamed tissue. 
This raises the question of whether T2 imaging could be used to assess USPIO 
accumulation. The answer lies with whether the sensitivity of T2 imaging for 
detecting tissue USPIO is good enough to swing the balance in favour of T2 
imaging. I am unable to answer this with results in this thesis but this could be 
readily addressed with pre and post USPIO T2 mapping.  
 
7.3.4   NOVEL INFLAMMATORY IMAGING WITH COMBINED MRI/PET 
18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely 
used to measure myocardial inflammation. As shown in this thesis, cardiac MRI with 
late gadolinium enhancement has become well established for detecting and 
differentiating myocardial injury in a range of conditions. The development of 
simultaneous PET/MR imaging now allows combination of these techniques 
alongside function assessment with advantages in terms of improved image             
co-registration and interpretation, and reduced radiation exposure. 
 
Sarcoidosis is a multisystem inflammatory disease. There is cardiac involvement in 
up to 27% of sarcoid cases and complications include atrial and ventricular 
arrhythmias, congestive cardiac failure and sudden cardiac death [Roberts et al 1977; 
Yazaki et al 2001; Banba et al 2007; Kandolin et al 2011]. The core inflammatory 
cells of sarcoid granulomas include monocytes and macrophages [Mitchell et al 
1977] and an imaging technique targeting these cells would be ideally placed to 
establish the diagnosis and to assess disease activity. 
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Hybrid MRI/PET has recently been found to be useful in detecting active myocardial 
sarcoidosis and acute myocarditis [Abgral et al 2017; Dweck et al 2017]. Patients 
with inflammatory cardiac conditions are now being recruited in our centre and it 
will be interesting to follow these results to assess the success of this novel technique 
in diagnosing and monitoring inflammatory cardiac conditions. 
 
As part of this series of research studies, we intended to recruit patients with active 
cardiac sarcoidosis. Despite having three recruiting centres across the UK (including 
the national sarcoid centre at the Royal Brompton hospital) we struggled to recruit 
sufficient numbers of patients. Twelve patients with systemic sarcoidosis were 
recruited and only 2 had evidence of active or previous myocardial involvement.  
This was insufficient for conclusions to be drawn and is not discussed further in this 
thesis. 
 
7.3.5   THINGS I WOULD DO DIFFERENTLY 
Completing a thesis such as this gives the opportunity for reflection. Naturally, there 
are things during the course of my research that, given the opportunity again, I would 
do slightly differently. I feel it is important to mention these at the end of a piece of 
work such as this. 
 
After myocardial infarction, I was able to detect macrophages in the infarct region 
during the expected time period of two weeks after myocardial infarction. However, 
as discussed in Chapter 4, two specific subsets of macrophages that have divergent 
functions operate during this period. To help guide future research studies, it would 
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have been helpful to determine whether or not both subsets of macrophages ingest 
USPIO. The time course of USPIO enhancement seen suggests both subgroups 
ingest USPIO, but the collection of peripheral blood for flow cytometry at the time 
of MRI would provide further information on circulating macrophages at the time of 
MRI.  
 
As part of a pilot study for an undergraduate medical student study, we collected 
blood for flow cytometry from a small number of patients (n=9) at some, but not all, 
of the MRI time points, Without access to original data, I was unable to include this 
into the results of this thesis, however we saw the expected early peak in classical 
monocytes with a later peak in non-classical monocytes. Collecting and measuring 
circulating monocytes in all patients at all MRI time points may help determine 
whether both subgroups ingest USPIO, and whether a correlation exists been 
particular monocyte subgroups and USPIO accumulation measured on MRI. 
 
In this chapter I have already mentioned the potential for USPIO measurement by T2 
mapping. However T1 mapping is entering clinical practice as an MRI marker for 
myocardial fibrosis and has also recently been proposed as a technique to assess intra 
cardiac iron deposition with good correlation with myocardial T2*, and may even 
have enhanced sensitivity in detecting myocardial iron compared to T2* [Abdel-
Gadir et al 2016].  However due to an already lengthy MRI scanning protocol, I was 
not able to add pre and post USPIO T1 mapping sequences to the protocol. This 




Running a multicenter imaging study in 3 sites in the UK, with the majority of 
participants recruited in the final year, meant that some areas I had considered for 
research were never reached. Further analysis could be carried out on stored blood 
samples, particularly for serial measurements of inflammatory markers and 
mediators, as well as biomarkers such as BNP. This could be considered at a later 
date. 
 
Finally, it is regrettable that I was not able to recruit sufficient numbers of patients 
with confirmed active cardiac transplant rejection and active cardiac sarcoidosis. The 
utility of USPIO-enhanced MRI in these groups of patients is unknown. 
 
7.4  CLINICAL PERSPECTIVE 
 
There is an unmet clinical need for reliable, non-invasive imaging techniques capable 
of detecting disease processes at a molecular and cellular level. Successful 
development of such techniques would improve diagnosis by detecting early disease 
states, help understand disease pathophysiology, provide serial monitoring and risk 
stratification, and help guide therapeutic intervention. For these reasons, there is 
currently considerable research interest into the development of novel molecular 
imaging techniques. 
Magnetic resonance imaging  has the particular advantage of having excellent spatial 
resolution and being free from ionising radiation. Following administration, USPIO 
is taken up by macrophages and can be detected on T2* MRI. Therefore USPIO-
enhanced MRI is able to detect tissue-resident macrophages and provide information 
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on cellular and tissue inflammation in inflammatory myocardial diseases mediated 
by macrophage infiltration. 
 
Following myocardial infarction, maladaptive macrophage accumulation can lead to 
adverse functional recovery. USPIO-enhanced MRI may be of value in diagnosing 
active myocardial inflammation and quantifying macrophage accumulation. 
Ultimately, this technique may aid risk stratification after MI, provide serial 
assessment, and act as a platform on which to assess existing and novel therapeutic 
anti-inflammatory interventions that might modify the inflammatory process. 
 
Acute myocarditis and cardiac transplant rejection, other conditions where 
inflammation affects the myocardium, cause considerable clinical concern and rapid 
assessment is vital. These conditions remain a diagnostic challenge and suffer from a 
lack of simple definitive diagnostic tests, where gold standard cardiac biopsies are 
unreliable, associated with risk and are rarely carried out. Following my experiments, 
USPIO-enhanced MRI provided no additional diagnostic value in acute myocarditis 
or in assessing stable patients with cardiac transplantation, and that tissue-resident 
macrophages do not appear to be a major contributor to the cellular inflammation in 
these conditions. Of considerable interest, stable patients with cardiac transplantation 
have increased resting myocardial T2 values, consistent with myocardial oedema or 
fibrosis. This suggests that T2 assessment of myocardial oedema alone in this 
condition may lead to false positive diagnoses of active tissue inflammation and 
cause unnecessary treatment interventions. Results from my experiments could not 
determine whether USPIO-enhanced MRI is able to diagnose and monitor acute 
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cardiac allograft rejection, findings suggested in preclinical models, and this patient 
group requires further examination [Kanno et al 2001; Johansson et al 2002; Penno 
et al 2005; Wu et al 2009; Wu et al 2013]. 
  
Although USPIO-enhanced MRI failed to detect tissue macrophages in clear cases of 
acute myocarditis, this does not mean it provides no value. We know this technique 
can detect macrophages after MI. It may be simply that there were no macrophages 
to detect in acute myocarditis. Further assessments in patients with macrophage 
infiltration of the myocardium should now take place; such as acute cardiac 
transplant rejection. Furthermore, USPIO-enhanced MRI appears well placed to be 
involved in regenerative medicine in assessing the viability, distribution and 
proliferation after stem cell therapy, and also in detecting preclinical stages of 
chemotherapy-induced cardiotoxicity, where rapid detection and early intervention 
may improve clinical outcomes for cancer patients.  
 
Continued refinements to image acquisition and analysis processes, with particular 
emphasis on reducing T2* imaging artefacts will ensure reliable and robust 
quantification of tissue enhancement. T2 mapping in the assessment of USPIO 
should also be considered. 
 
In summary, I have outlined and developed robust methodologies, and demonstrated 
current and future clinical applications for USPIO-enhanced MRI to assess 
myocardial macrophage-driven myocardial inflammation. This technique has the 
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potential as an invaluable clinical tool, and results from future studies will determine 
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Abstract Superparamagnetic iron oxide-based contrast
agents enhance and complement in vivo magnetic resonance
imaging (MRI) by shortening T2 and T2* relaxation times.
They are able to highlight areas of cellular inflammation,
being detected and engulfed by cells of the reticuloendothelial
system, and can be targeted to specific cellular processes or
subtypes using antibody or ligand labeling. These agents have
been used preclinically for the assessment of cardiac trans-
plant rejection, cardiomyocyte apoptosis, myocardial infarc-
tion, myocarditis, and stem and endothelial cell imaging, with
clinical applications now emerging. We here review recent
studies using iron oxide particles to image cardiac inflamma-
tion, and highlight the potential of these agents for future
clinical and research applications.
Keywords Cardiac .MRI . Iron oxide nanoparticles .
Inflammation .Molecular imaging
Introduction
Overview of Iron Oxide Nanoparticles
In many inflammatory diseases of the myocardium,
endomyocardial biopsy is the ‘gold standard’ diagnostic in-
vestigation. However, this does carry the potential for life-
threatening complications [1], and false negative or inconclu-
sive results are not uncommon due to the focal nature and
spatial heterogeneity of the underlying inflammatory disease
process. Development of a reliable noninvasive imaging tech-
nique capable of detecting myocardial inflammation would be
extremely beneficial and a major advance. This could provide
a diagnosis in patients displaying early signs suggestive of
myocardial inflammation or with subclinical disease, creating
an opportunity to prevent the disease process from become
established or limit its progression. Furthermore, this could
provide a surrogate measure of treatment response and facil-
itate serial disease monitoring.
Iron oxide nanoparticles can be used for molecular and
cellular imaging [2], and thereby enhance the sensitivity of
magnetic resonance imaging (MRI) to detect and characterize
various pathologic processes [3]. They rely on the principle
that accumulation of superparamagnetic iron oxide particles
within tissues causes local magnetic field inhomogeneities
that shorten T2 and T2* relaxation times. They generally
consist of an iron oxide core surrounded by a carbohydrate
or polymer coat that prevents aggregation and oxidation of
the iron, and provides a surface for conjugation of drug
molecules and targeting ligands. A range of particles exists
and they vary in size and coating. These 2 properties of iron
nanoparticles are the key determinants of their biodistribution,
magnetic behavior and, thus, the potential applications of the
particle [4, 5].
Iron oxide particles can be categorized according to their
size (Table 1): nano-sized very small (VSPIO, <20 nm in
diameter), ultrasmall (USPIO, 20–50 nm in diameter) and
small (SPIO, 60–250 nm in diameter) superparamagnetic par-
ticles of iron oxide, and micrometer-sized (MPIO, 1–8 μm in
diameter) particles of iron oxide. The ‘superparamagnetic’
particles become magnetic within a strong external magnetic
field such as exists within an MRI scanner, but do not retain
their magnetism once removed from the field.
Iron oxide particles were initially used as contrast agents
for imaging of the gastrointestinal tract [6], the Kupffer cells
of the liver and spleen [7], and lymph nodes [8], as well as a
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blood-pool contrast agent for the evaluation of cerebral, myo-
cardial, and renal perfusion [9–11]. Here, we focus on its
application to image cardiac inflammation with an emphasis
on recent findings, and comment on future applications.
USPIO and VSPIO
The VSPIO particle is the smallest of the iron particles and the
USPIO particle is only slightly larger; hence, these agents are
often classified together as USPIO. Their clinical application
makes use of their ability to escape immediate phagocytosis
by cells of the reticuloendothelial system, conferring a con-
siderably longer half-life within the blood pool (up to 24 hours
[12]) compared with larger particles. Both VSPIO and USPIO
have been used successfully as contrast agents for MR coro-
nary angiography [13, 14] because they have a longer blood
pool circulating time compared with standard MR angio-
graphic agents such as Gadolinium. Although USPIO remain
predominantly within the blood pool, they are small enough to
migrate passively across the endothelium [2] especially in
regions of the vasculature where there is loss of endothelial
integrity. Once present within tissues, resident macrophages
with enhanced phagocytic activity engulf and concentrate
these nanoparticles. This colocalization and concentration of
nanoparticles enhances their superparamagnetic effects mark-
edly shortening the T2* value and creating local signal deficits
that appear dark on T2- and T2*-weighted images (Fig. 1). It
is these magnetic effects of USPIO that allow their use to
detect capillary leakiness and tissue-resident inflammatory
cell activity, thereby highlighting areas of tissue inflammation.
SPIO
SPIOs are larger than USPIOs, and as such are more rapidly
phagocytosed by cells of the reticuloendothelial system in the
liver, spleen, bone marrow, and lymph nodes (Fig. 2). They
are rapidly cleared from the blood pool after injection having a
short blood pool half-life of less than 15 minutes [15] in rats
and around 2 hours in humans [16]. After intracellular uptake,
SPIOs are degraded into a nonsuperparamagnetic form of iron
that becomes incorporated into the body’s iron stores [2]. The
coating of the particle also has to be metabolized, and coating
with dextran confers the advantage that it is biodegradable and
excreted in urine and feces [17].
MPIO
The largest of the iron particles discussed, MPIOs, are often
used for molecular imaging of endovascular targets. As a
result of their large size MPIOs have a very short blood pool
half-life of <1 minute in mice [18] and <2 minutes in rats [19].
Following intravenous administration phagocytic cells within
the blood pool and the lymphoreticular system identify them
rapidly. However, until they are cleared, they are less suscep-
tible than smaller particles to migrate across endovascular
borders or be incorporated into endothelial cells, and are
confined to the intravascular compartment [20]. For this rea-
son, MPIOs are often used to provide a platform for quantita-
tive targeted molecular imaging of vascular endothelial tar-
gets. By labeling cells ex vivo with MPIO, single cell detec-
tion has been shown in vivo [21]. Importantly, MPIO contain
significantly more iron oxide than USPIO or SPIO and con-
sequently fewer MPIO are required for detection. Indeed, they
create such an effect on local magnetic field homogeneity that
the spatial extent of the change in signal intensity on T2- and
T2*-weighted imaging can be up to 50 times its own physical
diameter. This so-called “blooming effect”markedly enhances
sensitivity such that MPIOs can detect even sparse endothelial
molecular targets [22], but spatial information may be
compromised.
Table 1 Summary of superparamagnetic particles of iron oxide
Particle Name Particle Size (diameter) Agent Name Coating Clinical/ Preclinical Application Reference
USPIO 20–50 nm n/a Dextran Preclinical Allograft rejection [25]
n/a Dextran Preclinical Allograft rejection [26]
n/a Polymer Preclinical Allograft rejection [27•]
Ferumoxytol Dextran Clinical Myocardial Infarction [35••, 36••]
CLIO 30–50 nm n/a Dextran Preclinical Apoptosis [32, 33]
SPIO 60–250 nm Ferumoxides Dextran Preclinical Apoptosis [29]
n/a PEG/silica Preclinical Myocarditis [39]
Ferumoxides Dextran Preclinical Stem Cells [40]
Ferucarbotran Carbodextran Preclinical Stem Cells [41]
n/a Polysaccharide Preclinical Stem cells [42•]
MPIO 1–8 μm ME03F Polymer Preclinical Myocardial Infarction [18, 34]
MyOne n/a Preclinical VCAM-1 [37]
n/a n/a Preclinical VCAM-1 [43]
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Imaging Using Iron Particles
Early preclinical imaging work took advantage of the
ability of inflammatory cells of the reticuloendothelial
system to engulf iron particles enabling the iron particles
to act as a tracer localizing to areas of inflammation.
Cardiac pathologies examined include cardiac transplanta-
tion, cardiomyocyte apoptosis, myocardial infarction (MI),
and myocarditis. The use of iron particles has also been
employed to examine cellular apoptosis and tracking of
stem cells. Histologic validation is important and tissue
can be stained with Prussian Blue or Perl’s stain for iron
(Fig. 3) and colocalization can be confirmed if the same
tissue is subsequently stained for inflammatory cells such
as macrophages (CD68 immunohistochemistry).
Cardiac Transplant Rejection
Cardiac transplantation is a major treatment option for end-
stage cardiac disease, but is challenged by the development of
transplant rejection in 20%–30% of recipients in the first year
[23]. This causes significant morbidity and mortality.
Transplant rejection can occur at any stage after transplanta-
tion and is notoriously difficult to diagnose noninvasively. It is
characterized histologically using the International Society for
Heart and Lung Transplantation (ISHLT) classification system
and graded into 1 of 3 groups depending on the presence of
interstitial and perivascular mononuclear cell infiltrates,
myocyte damage, edema, hemorrhage, or vasculitis [24].
Endomyocardial biopsy is undertaken routinely for rejec-
tion surveillance following transplantation, although this pro-
cedure can be associated with serious complications that in-
clude damage to the underlying cardiac structure, bleeding,
arrhythmia, and death [1]. Kanno et al. [25] detected organ
rejection using MRI and dextran-coated USPIO in rats with
evidence of cardiac allograft rejection. Histopathology not
only confirmed active rejection, but also confirmed UPSIO
uptake was confined to tissue-resident macrophages that ac-
cumulated within the rejecting cardiac allograft. Interestingly,
in rats that had more prolonged immunosuppression, they also
Fig. 1 Patient imaged 5 days
after an anterior myocardial
infarct with T2*-weighted
magnetic resonance imaging.
Images show T2* maps of
baseline pre-iron scan (left), and
24 hours following ferumoxytol
(USPIO) administration (right).
Iron uptake is seen in the dark
myocardial regions in the region
of the anterior infarct (arrow)
Fig. 2 Perl’s iron stain reveals aggregates of SPIO within the cytoplasm
of human mononuclear cells labeled with SPIO ex vivo
Fig. 3 Perl’s iron stain of the aortic wall from a patient with an abdominal
aortic aneurysm. Tissue samplewas acquired during operative repair 4 days
following the administration of USPIO. USPIO is seen to have accumu-
lated within macrophages in an inflamed region of the tunica media
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observed a decline in the rate of signal intensity reduction,
suggesting less inflammation and indicating that successful
treatment response could also be monitored by this method.
Wu et al. [26] studied a rat model of heart-lung transplant
rejection involving the implantation of an additional intra-
abdominal heart and lung allowing the native heart to support
life despite severe rejection in the transplanted organs. USPIO
was administered 1 week following transplantation. One day
after USPIO administration, hypointense areas appeared on
T2*-weighted images of allograft hearts that were not present
within the control native hearts and immediate histology after
graft explantation revealed accumulation of iron particles
mostly within macrophages.
Targeting of various pathophysiological processes of inter-
est becomes possible when contrast agents, including iron
oxide particles, are conjugated to a specific antibody or pep-
tide [12]. Recent work by Guo et al. [27•] targeted T cells that
play a central role in acute rejection in most cardiac allografts.
They built on work performed using ligand targeting of cells
to employ a “theranostic” strategy, combining diagnostic im-
aging with administration of therapy within the 1 system.
They targeted T cells in the endocardium of abdominally
implanted rejecting rat hearts using a CD-3 antibody–targeted
multifunctional polymeric nanocarrier. This polyplex nano-
particle was further conjugated to a therapy gene (pDNA-
DGKalpha) enabling simultaneous imaging of primary T cells
expressing CD-3 and achieving their immune modulation via
gene therapy.
Cardiomyocyte Apoptosis
Apoptosis is the process of programmed cell death in an
organism and in the myocardium confers a survival advantage
to the organism over necrosis, which induces inflammation
and leads to scarring. During apoptosis the phospholipid
phosphatidylserine is exteriorized and displayed on the cell
surface. Annexin V is an endogenous protein that binds with
high affinity to phosphatidylserine. Narula et al. [28] used
99mTechnetium-labelled Annexin V to image apoptosis in
cardiac allograft rejection in humans. Myocardial
99mTechnetium-labelled Annexin V binding was observed in
5 out of the 18 human patients with cardiac allografts. All 5 of
these patients displayed at least moderate rejection histologi-
cally and demonstrated caspase-3 staining, a marker for apo-
ptosis. In contrast, none of the 13 patients with no annexin
uptake displayed histologic signs of necrosis.
Dash et al. [29] developed a molecular MRI probe using
SPIO conjugated to recombinant human Annexin V (ANX-
SPIO). Using T2*-weighted MRI, they were able to detect
doxorubicin-induced early apoptosis in mouse hearts in vivo.
There was a spatial correlation between areas of signal atten-
uation on T2*-weighted images and histologic evidence of
iron accumulation and apoptosis (caspase activity), although
myocardial structure was normal suggesting only early apo-
ptosis. They were also able to detect apoptosis in cultured
ex vivo neonatal rat ventricular myocytes much earlier than
TUNEL staining: the latter detects DNA fragmentation and is
a late terminal event in the apoptotic sequence. Perhaps more
importantly, they were able to use ANX-SPIO to demonstrate
that the alpha-1 adrenoreceptor agonist, A61603, could pre-
vent doxorubicin-induced cardiomyopathy. They documented
early apoptosis through increased caspase activation and re-
duction in myocardial T2* value that could be eliminated by
A61603 treatment.
The development of cross-linked particles of iron oxide
(CLIO) [30] was exploited for targeted imaging of apoptosis
again conjugated to annexin V [31]. Cross-linking and
amination of the USPIO dextran chains encourages circum-
ferential adherence of the dextran coat to the iron nanoparticle
providing chemical stability and improved conjugation [30].
This allowed Sosnovik et al. [32] to develop a CLIO particle
conjugated not only to annexin V, but also to cyanine 5.5 dye
to allow co-identification with fluorescence microscopy and
T2*-weighted MRI. In a murine model of ischemia reperfu-
sion injury, a reduction in signal intensity on T2*-weighted
imaging was observed with AnxCLIO-Cy5.5 but not with
unlabeled CLIO-Cy5.5. The area of signal loss correlated with
the zone of contractile dysfunction suggesting uptake of
AnxCLIO-Cy5.5 was within the injured and apoptotic myo-
cardium. This was further confirmed by near infra-red fluo-
rescence where increased fluorescence intensity co-localized
to regions of reduced signal intensity on MRI.
More recently, Sosnovik et al. employed a similar concept
in developing a novel dual-contrast molecular MRI technique
to image both cardiomyocyte apoptosis and necrosis in mice
with ischemia reperfusion injury in vivo [33]. They used a
similar protocol to identify apoptosis and followed this with
injection of a novel magnetofluorescent gadolinium chelate
(Gd-DTPA-NBD), with subsequent gadolinium delayed en-
hancement MRI. Interestingly, they found that only 21 % of
apoptotic myocardium (accumulation of AnxCLIO5.5) had
evidence of necrosis (defined by delayed enhancement with
Gd-DTPA-NBD). This was confirmed on fluorescence mi-
croscopy and immunohistochemistry revealing the presence
of large numbers of apoptotic, but potentially viable,
cardiomyocytes in the ‘at-risk’ area (AnxCLIO-Cy5.5 posi-
tive, Gd-DTPA-NBD negative areas). The authors concluded
by remarking that strategies to salvage apoptotic, but not yet
necrotic, myocardium should be explored now that these areas
could be successfully imaged.
Myocardial Infarction
Yang et al. [18] imaged inflammatory cell infiltration in a
murine left anterior descending coronary artery ligation model
of myocardial infarction. Micrometer-sized particles of iron
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oxide (MPIO) were administered and T2* signal attenuation
was seen in the infarct zone of these mice when compared
with control groups of mice that (I) were administered MPIO
and had a “sham’ operation, or (II) were subjected to MI but
did not receive MPIO. Unsurprisingly, they noted increased
signal attenuation in the infarct area, illustrating MPIO accu-
mulation secondary to increased inflammatory cell infiltra-
tion. This correlated functionally with a reduction in left
ventricular ejection fraction.
In a subsequent study by the same group [34], they ex-
plored the dose and timing of MPIO administration and MRI
scanning. The investigators concluded that an optimal tempo-
ral scanning window of 7–14 days post-MI, and an optimal
dose of 9.1–14.5 μg of iron per gram bodyweight to image
myocardial inflammation.
Alam et al. [35••] used USPIO to image inflammation
dynamics following acute myocardial infarction (MI).
Within 48 hours following acute MI, patients received an
infusion of ferumoxytol (USPIO) and underwent MRI scan-
ning at baseline (pre-USPIO) and for 3 days. The infarct zone
was defined using a late gadolinium enhancement (LGE)
scan. Following USPIO administration, there was a significant
increase in R2* (R2*=1/T2*) in the infarct zone, with smaller
changes observed in the peri-infarct zone (surrounding LGE)
and even in remote myocardium when compared with control
tissue (skeletal muscle). The authors suggested that this was a
reflection of peri-infarct and remote myocardial inflammation,
although there were no histologic data to confirm this.
Notably, the R2* value was greatest 24 hours following
USPIO (ferumoxytol) infusion, and had declined by 48 hours
suggesting that 24 hours postinfusion is the most sensitive
imaging time point in this group of patients.
In a similar study, Yilmaz et al. [36••] also detected a
reduction in T2* value in the infarct as well as in the peri-
infarct region, the remote myocardium and the
lymphoreticular system. In imaging the first 3 patients at 6,
24, 48, and 96 hours after ferumoxytol administration, they
attempted to find the optimal time to characterize inflamma-
tion kinetics within the myocardium. From these data, they
suggest that signal attenuation was maximal at 24 hours but
that the best combination of T2-weighted (hypoenhancement
seen) and T2*-weighted images were obtained at 48 hours.
Unfortunately, neither Yilmaz nor Alam had access to
histologic samples. Such data would address the outstanding
questions regarding the exact distribution of USPIOwithin the
myocardium, and the potential contribution to the changes in
T2* or R2* of extracellular iron accumulation within the
interstitium, capillary bed, or tissue resident macrophages.
The finding of T2* signal void in remote myocardium in
the above articles is an interesting observation suggesting a
pan-myocardial inflammatory response in the context of a
smaller, highly localized infarct. This finding is in agreement
with Grieve et al. [37] who used a rat model of ischemia-
reperfusion injury, and examined endovascular inflammation
using a targeted MPIO tracer. They found MPIO signal in the
myocardium and pericardium in segments remote from the
ischemia-reperfusion injury. In a mouse model of myocardial
infarction, remote inflammation after myocardial infarction
has also been demonstrated [38]. An increase in inflammatory
mediators was found not only within the remote myocardium,
but also within renal glomeruli suggesting that inflammation
is not only confined to the myocardium, but extends to distal
sites and tissues.
Myocarditis
Transplant rejection and myocardial infarction are not the only
inflammatory myocardial processes to be scrutinized by mo-
lecular imaging employing iron particles. Like transplant re-
jection, myocarditis suffers from the lack of a reliable nonin-
vasive diagnostic test, and again patients are subjected to the
risk of biopsy procedures that have a lower diagnostic sensi-
tivity than clinicians would wish.
Moon et al. [39] recently examined a rat model of experi-
mental autoimmune myocarditis. They made use of
superparamagnetic and fluorescent “magneto-fluorescent
nanoparticles” (MNPs) consisting of a SPIO core with a
rhodamine isothiocyanate (RITC)-incorporated silica coating
of approximately 20 nm thickness, and polyethylene glycol
(PEG) conjugated onto the silica coating. They compared
MNP (10 mg Fe/kg) contrast MRI with unenhanced conven-
tional MRI protocols using T2-weighted, T1-weighted and
early and late gadolinium enhancement sequences. The degree
of inflammation was also assessed histologically. MNP-
enhanced T2*-weighted CMR more accurately detected
scattered foci of inflammation within the myocardium of rats
with autoimmune myocarditis and improved visualization of
small and less-severe myocardial inflammation than conven-
tional CMR imaging. Areas detected by MNP-enhanced T2*-
weighted CMR correlated with inflammatory foci and macro-
phage accumulation on histology as well as MNP-derived
fluorescence signals on fluorescence microscopy. However,
MNP-enhanced MRI ultimately proved unable to detect mild
histologic grades of myocardial inflammation, and this may
limit its clinical applicability.
Stem Cells
Current research endeavors are increasingly focusing on stem
cell therapy in an attempt to restore function to organs that
were previously felt to have no or little regenerative capacity.
There is, therefore, a clear need to track stem cells when
administered for therapeutic and regenerative purposes so that
the distribution and fate of administered cells can be deter-
mined. Kraitchman et al. [40] labeled mesenchymal stem cells
(MSC) with SPIO in order to detect and track them
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noninvasively using MRI in a swine model of myocardial
infarction. Labeling did not appear to affect the viability of
the MSCs, and hypointense regions were seen on MRI within
infarcted myocardium after intramyocardial SPIO-MSC injec-
tion, suggesting uptake of the SPIO-MSC conjugate.
Lu et al. [41] recently investigated the effects of culprit
vessel intracoronary infusion of SPIO-labeled autologous
bone marrow-derived MSCs after acute myocardial infarction
in pigs. One-week postmyocardial infarction SPIO-labeled
MSCs were infused via the culprit coronary vessel and com-
pared with a control infusion of phosphate-buffer saline. The
pigs were imaged immediately before and 3 days after cell
transplantation. A reduction in myocardial T2* value was
observed after cell transplantation in the study group com-
pared with the control group. However, the majority of the
infused cells were found in the spleen, liver, and kidney,
resulting in a more pronounced reduction in T2* values in
those organs. Immunohistochemistry confirmed this to be the
SPIO-MSC conjugate, suggesting the majority of the infused
cells escaped into the systemic circulation. There was no
difference seen between groups in terms of global or regional
cardiac function or myocardial viability although the follow-
up in this group was too short to see any functional recovery.
The authors acknowledge a weakness of this method is that
signal may be “diluted” if the stem cells subsequently prolif-
erate. Furthermore, this cell tracking method could create
misleading results. Although not demonstrated by this study,
the iron nanoparticle could become detached from the stem
cell allowing it to be taken up by another cell, or left behind in
the tissue.
In a murine model of myocardial infarction, Chung et al.
[42•] studied cell viability and teratoma formation after em-
bryonic stem cell (ESC) transplantation. They made use of a
reporter gene designed to express antigens on the surface of
embryonic stem cells (ESCs). By employing SPIO-
conjugated targeted monoclonal antibody (SPIO-MAb)
against these reporter antigens, the viability, proliferation,
and teratoma formation of transplanted ESCs could be quan-
tified in vivo with MRI. The advantage of this reporter gene
technique over direct stem cell labeling, is that the signal is
enhanced when the stem cell successfully divides, thus,
allowing quantification of subsequent stem cell proliferation.
Endothelium
Although the majority of preclinical endothelial imaging
using iron oxide has examined large vessel vascular endothe-
lium, which is beyond the scope of this review, there has been
some recent work in the heart. Dall’Armellina et al. [43]
employed a targeted system in characterizing the role of
vascular cell adhesion molecule-1 (VCAM) that is known to
play a crucial role in promoting endothelial inflammation after
ischemia-reperfusion injury [44]. They described T2*-
weighted MRI signal drop out with antibody-conjugated
MPIO targeting VCAM-1 in mouse hearts following coronary
artery ligation.
Grieve et al. [37] followed this work by adopting a similar
protocol conjugating MPIO with monoclonal VCAM anti-
bodies in a rodent model of MI. Extensive foci of signal voids
were observed within the infarcted area on ex vivo T2*-
weighted MRI corresponding to MPIO deposition on histolo-
gy. Supporting previous evidence of pan-myocardial inflam-
mation after myocardial infarction, signal void was also de-
tected in remote myocardium and pericardium.
Conclusion and Future Applications
Important and recent research has demonstrated that
superparamagnetic particles of iron oxide can be used to
detect cardiac inflammation in preclinical models of myocar-
dial infarction, cardiac transplant rejection, myocarditis, as
well as targeted imaging in stem cell therapy and apoptosis.
These agents are able to provide a platform for both imaging
and modulation of the disease process. Molecular MRI using
iron nanoparticles, therefore, has the potential to develop into
a powerful tool in diagnosing and treating inflammatory car-
diac conditions in clinical medicine.
Recent translation of preclinical studies has already led to
clinical applications examining myocardial inflammation fol-
lowing myocardial infarction. There have been concerns over
the safety profile of iron oxide particles in the past, and at
present there is only 1 iron oxide particle preparation available
for clinical use: ferumoxytol (Rienso), a USPIO measuring
17–30 nm. Interestingly Rienso is indicated for the intrave-
nous treatment of iron deficiency anemia in adult patients with
chronic kidney disease (CKD), and not its imaging properties.
Previous clinical preparations of superparamagnetic parti-
cles of iron oxide have not had a particularly successful track
record. Another USPIO, ferumoxtran-10 (Sinerem), was pre-
viously approved in some European countries, but the manu-
facturer discontinued development due to concerns over un-
acceptably high false positive rate of detecting lymph node
metastasis in patients with prostate cancer [45]. Other iron
oxide nanoparticles including NC100500 (Clariscan),
ferumoxides (Feridex in USA, Endorem in Europe), and
ferucarbotran (Resovist) have all been discontinued over re-
cent years. The latter 2 agents were the only 2 clinically
approved SPIO agents for MRI, and it remains to be seen
whether commercial companies will consider it economically
viable to develop further iron oxide based agents for human
imaging.
The natural progression following limited clinical studies
using ferumoxytol, would be to characterize kinetics and
dynamics of inflammatory cell recruitment to the myocardium
not only following MI but also in other inflammatory
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myocardial processes including cardiac transplant rejection,
myocarditis, and active cardiac sarcoidosis. If iron
nanoparticle-enhanced MRI was able to diagnose and charac-
terize inflammation in these diseases, it may eventually re-
place the need for cardiac biopsy. In conjugating iron oxide to
various peptide, antibody, or gene therapy platforms, a new
method of targeted therapy is a further potential opportunity
for the clinic. This novel imaging tool may therefore prove a
useful platform not only for diagnostic and disease monitoring
purposes, but may even provide a treatment approach in these
conditions.
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Abstract: Ultra-small superparamagnetic particles of iron oxide (USPIO) are iron-oxide based 
contrast agents that enhance and complement in vivo magnetic resonance imaging (MRI) by 
shortening T1, T2, and T2* relaxation times. USPIO can be employed to provide immediate 
blood pool contrast, or to act as subsequent markers of cellular inflammation through uptake by 
inflammatory cells. They can also be targeted to specific cell-surface markers using antibody 
or ligand labeling. This review will discuss the application of USPIO contrast in MRI studies 
of cardiovascular disease.
Keywords: cardiac, aortic, MRI, USPIO, carotid, vascular, molecular imaging
Introduction
Beyond the anatomical and morphological information afforded by standard clini-
cal cardiovascular imaging techniques, it is increasingly recognized that additional 
information regarding the underlying biological processes involved would be valuable 
in a range of cardiovascular diseases to aid understanding of disease pathogenesis, 
provide diagnostic information, predict disease progression, and to monitor response 
to treatment. Novel molecular and cellular imaging techniques can identify metabolic 
and biological processes that are critical to disease pathogenesis, and therefore have 
the potential to predict clinical events and guide therapeutic intervention.
A range of potential imaging modalities exists (Table 1). Magnetic resonance 
imaging (MRI) has a number of advantages including excellent discrimination of 
soft tissue components, good spatial resolution and avoidance of ionizing radiation, 
a particular consideration if serial imaging is envisaged.
Iron oxide particles are a group of MRI contrast agents that can be used for vascular, 
molecular and cellular imaging.1 Iron oxide particles can be categorized according to 
their size: nano-sized very small superparamagnetic particles of iron oxide (VSPIO, 
20 nm in diameter), ultra-small superparamagnetic particles of iron oxide (USPIO, 
20–50 nm in diameter), small superparamagnetic particles of iron oxide (SPIO, 
60–250 nm in diameter), and micro-sized particles of iron oxide (MPIO, 1–8 Mm in 
diameter). VSPIO and USPIO are often classified together (as USPIO) due to similar 
size. Superparamagnetism occurs when the size of the iron oxide crystal is smaller 
than that of ferromagnetic domains (approximately 30 nm). Under the influence of a 
strong external magnetic field, such as within an MRI scanner, iron oxide nanoparticles 
have a large magnetic moment, but unlike larger ferromagnetic particles, this magnetic 
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Figure 1 Patient imaged 3 days after an anterior myocardial infarct with T2*-
weighted magnetic resonance imaging.
Notes: Images show T2* maps of baseline pre-iron scan (A), and 24 hours following 
ferumoxytol (USPIO) administration (B). Iron uptake is seen as signal void (dark) in 
the region of the anterior infarct (arrow).
Abbreviation: USPIO, ultra-small superparamagnetic particles of iron oxide.
Table 1 Summary of commonly used molecular imaging modalities
Modality Spatial resolution Temporal resolution Sensitivity Penetration Radiation Cost
MRI 10–100 micron High Low Good No High
US 50 micron High Medium cm No Medium
SPECT 1–2 mm Low Medium Good Yes Medium
PET 1–2 mm Low High Good Yes High
Fluorescence 2–3 mm High High 1 cm Yes/no Low
Abbreviations: MRI, magnetic resonance imaging; US, ultrasound; SPECT, single-photon emission computerised tomography; PET, positron emission tomography.





USPIO generally consist of an iron oxide core surrounded 
by a coating, usually of carbohydrate or polymer construc-
tion, with a total particle diameter of less than 50 nm. The 
purpose of the coating is to prevent aggregation, to retain 
particles within a colloidal suspension and to provide a sur-
face for conjugation of drug molecules and targeting ligands. 
A range of particles exists varying in size and coating; these 
two properties are the key determinants of biodistribution, 
magnetic behavior, and thus the potential applications of the 
particle.2,3 The majority of proposed applications for iron 
oxide nanoparticles utilize particles within the ultra-small 
and small size ranges.
Following administration, cells of the reticuloendothelial 
system including inflammatory macrophages internalize iron 
oxide nanoparticles. Neutrophils and structural endothelial 
and tumor cells also take up iron nanoparticles. Larger SPIO 
particles are identified and rapidly engulfed, principally by 
resident macrophages in the lymphoreticular organs including 
the liver, spleen, and lymph nodes. In contrast, USPIO par-
ticles are much smaller and therefore less readily recognized 
by cells, escaping immediate phagocytosis and resulting in 
a much longer half-life within the blood pool compared to 
larger particles (up to 36 hours for USPIO4 versus as low as 
2 hours for larger SPIO5 in humans). The biodistribution of 
USPIO is individual to each particle but a blood pool half-life 
of several hours is expected with distribution predominantly 
in the spleen, liver, bone marrow, and lymph nodes, before 
being cleared within a matter of a few days. Cytotoxicity data 
for iron nanoparticles is limited but is not found until exposure 
to high levels of iron and is also dependent on factors such as 
surface coating or its breakdown products, composition of the 
cell medium, and protein-iron nanoparticle interaction.6–9
Whilst circulating within the blood pool, USPIO are 
small enough to migrate passively across the endothelium1 
especially in regions of the vasculature where there is 
loss of endothelial integrity. Once present within tissues, 
nanoparticles are concentrated and engulfed by resident 
macrophages through phagocytosis and pinocytosis resulting 
in their concentration within inflamed tissues. This concen-
tration results in magnetic cooperativity, enhancing their 
superparamagnetic effects, markedly shortening the T2* 
relaxation time and creating local signal deficits on T2- and 
T2*-weighted images. Thus USPIO can highlight areas of 
tissue inflammation on MRI.10
Earlier studies using iron nanoparticles employed semi-
quantitative methods to calculate reduction in signal intensity 
consistent with iron accumulation, however this is liable 
to variations in signal across the image relative to proxim-
ity to surface coils between visits, and also assumes that 
signal intensity in the control tissue is consistent between 
both pre- and post-USPIO scans. Calculation of changes in 
T2 and T2* relaxivity values has been adopted for a more 
sensitive and objective approach. The T2 and T2* relaxivity 
values, are the initial decay constants for the exponential 
decay of signal intensity with increasing echo time. Calcula-
tion and comparison of decay constants for each region of 
interest allows for a more objective and quantitative analysis 
approach and thus accounts for problems caused by varia-
tions in relaxivity values between regions and also MRI coil 
sensitivity between subject visits. In the presence of USPIO 
the signal decays more rapidly and the T2 and T2* relaxivity 
values are reduced. On the resulting images, particularly on 
T2*-weighted images, a profound reduction in signal inten-
sity is evident as a region of signal void (hypointense region) 
where USPIOs have accumulated (Figure 1).
Precise blood suppression during USPIO-enhanced MRI 
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Table 2 Summary of USPIO studies discussed in this article
Agent name Iron oxide cored  
diameter, nm  
(total diameter)








































































































n/a n/a (27) Dextran 4.7 T Intravenous Preclinical Cardiac transplant  
rejection
24,27
n/a 6 (n/a) Polymer 1.5 T Intravenous Preclinical Cardiac allograft  
rejection
30











































n/a n/a (7.5) Amine silane 3 T Intracoronary Preclinical Stem cells 38
n/a 2–7 (15–40) Polysaccharide 1.5 T Intravenous Preclinical Atherosclerosis 49
Note: Rienso®; Takeda Italia S.p.A, Rome, Italy.
Abbreviations: USPIO, ultra-small superparamagnetic particles of iron oxide; AAA, abdominal aortic aneurysms; CLIO, cross-linked particles of iron oxide; n/a, not available.





which is often the region of interest under examination. 
 Magnetization transfer between the blood pool and myocar-
dium, and also flow-related blood pool artifact, may compro-
mise the quality of T2* data. Double inversion techniques 
are commonly used to suppress blood signal in most cardiac 
MRI examinations. However, double inversion techniques 
do not account for changes in blood pool USPIO related T1 
shortening. Therefore, more complicated inversion strategies 
(such as a quadrature inversion technique) may be required 
to fully null blood signal in both pre- and post-USPIO data, 
although these inversion techniques are less commonly avail-
able on clinical systems and so are not widely used.
Here, we focus on the use of USPIO in cardiovascu-
lar imaging, discussing their application as a blood pool 
contrast agent, a tracer highlighting inflammatory cells of 
the  reticuloendothelial system, and in targeted imaging 
 conjugated to a specific antibody or peptide (Table 2).
Cardiac imaging
Blood pool contrast
USPIO have been used successfully as coronary and ventricular 
MRI blood pool contrast agents for over a decade as they have 
longer blood pool circulating time compared to standard MRI 
angiographic agents such as gadolinium. In 1997, Stillman 
et al11 demonstrated improved myocardial to blood pool bor-
der definition with ferumoxtran-10 on T1-weighted MRI cine 
images. Image intensity gradients at the myocardial to blood 
pool interface increased significantly in both long and short axis 
views. At the time it was thought that ferumoxtran-10 would 
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This was soon followed up by Taylor et al12 who used an 
alternative USPIO agent, NC100150 (ClariscanTM) with a 
blood pool half-life of over 2 hours, to aid ventricular cavity 
edge detection using MRI. They administered NC100150 
to 18 healthy male volunteers and examined optimized cine 
imaging sequences. At higher doses (3 and 4 mg Fe/kg) 
a reduction in signal intensity was seen in the blood pool 
enabling enhanced detection of the left ventricle blood pool 
to myocardial interface thus improving functional assessment 
of the left ventricle. The finding that NC100150 improves 
myocardial blood pool definition has since been repeated in 
other human studies.13–15
NC100150 has been used extensively as a coronary 
contrast agent for MRI coronary angiography (MRCA) with 
mixed results. Johansson et al compared invasive X-ray 
angiography with T1-weighted MRCA using NC100150 in 
pigs with coronary artery stenosis.16 Although the sample 
size was small (n6), the location and severity grading of 
stenoses on MRCA correlated well with X-ray angiography 
findings in all animals. Within a few years, Sandstede et al17 
carried out a feasibility study using the same contrast agent 
in patients with coronary artery disease. Proximal segments 
of coronary arteries could be visualized but distal visual-
ization was poor. Furthermore, no improvement in image 
quality was seen when an increased USPIO dose was used 
and only six of eight proximal coronary stenoses seen on 
conventional angiography were detected on the NC100150 
contrast enhanced scan.
Klein et al18 conducted an experiment comparing 
NC100150 enhanced MRI with unenhanced MRI imaging, 
again yielding mixed results. Although the visible length of 
mid and distal portions of the coronary artery improved on 
USPIO-enhanced imaging, there was no improvement when 
assessing the proximal portion of the artery. Furthermore, 
only eight of the eleven significant coronary stenoses (50%) 
were detected on USPIO-enhanced MRI compared to six on 
the unenhanced scan.
Soon after the development of USPIO as a blood 
pool contrast agent for ventricular cavity and coronary 
imaging, attempts were made to illustrate myocardial 
viability with conflicting results. Kroft et al19 administered 
 ferumoxtran-10 (AMI-227, Sinerem®) in a pig model 
of myocardial infarction (MI) and then imaged using 
T1-weighted MRI with a 1.5 T scanner. Interim imaging 
failed to detect USPIO in the viable myocardium, likely due 
to low dose, fast elimination time of the contrast agent, and 
a low field strength scanner. Increasing the magnetic field 
strength provides improved signal-to-noise ratio, greater 
spatial resolution, and higher sensitivity for detecting 
lower concentrations of iron, which is advantageous in the 
detection of USPIO.
Bjerner et al20 had more success using NC100150 in a 
similar model. Using T1-, T2-, and T2*-weighted imaging, 
they found that T1-weighted MRI with doses of 4 and 8 mg 
Fe/kg produced the best evaluation of perfused myocardium 
after histological validation against areas of fluorescein stain 
uptake on ex vivo histological analysis.
The use of USPIO as a myocardial tissue contrast agent 
was extended to a model of ischemia-reperfusion in rats to 
evaluate microvascular injury in reperfused myocardium. 
Krombach et al21 employed coronary ligation for 45 minutes 
and 3 hours of reperfusion, and administered NC100150, to 
help define regions of microvascular injury and obstruction 
after MI. USPIO distributes by diffusion in the extravas-
cular space of injured myocardium with damaged, leaky 
vasculature. They found that USPIO-enhanced imaging 
provided some indication of transmural and non-transmural 
microvascular injury. This imaging approach tended to 
overestimate the area of true infarction when compared to tri-
phenyltetrazolium chloride stain, and underestimate the area 
of myocardium deemed “at risk” of infarction determined 
by redo coronary ligation and intravenous phthalocyanine 
blue dye injection.
Inflammation
Endomyocardial biopsy is the “gold standard” diag-
nostic investigation for inflammatory diseases of the 
 myocardium. This does carry the potential for life-threatening 
complication,22 and sampling error is common due to the 
focal nature and spatial heterogeneity of underlying inflam-
matory processes. This procedure is rarely performed outside 
specialist tertiary referral centers.
Transplant rejection
Cardiac transplantation is a life prolonging treatment option 
for end-stage cardiac disease. Transplant rejection is a major 
threat to the allograft, occurring in 20%–30% of recipients in 
the first year.23 Rejection can occur at any stage after trans-
plantation and causes significant morbidity and  mortality. 
Serial surveillance myocardial biopsies are routinely under-
taken as rejection is notoriously difficult to diagnose using 
existing non-invasive imaging methods.
Kanno et al24 exploited the finding that iron nanopar-
ticles accumulated within the cytoplasm of macrophages, 
and detected organ rejection using MRI and dextran-coated 
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Histopathology confirmed active rejection and identified 
USPIO uptake confined to macrophages that had accumulated 
within the rejecting cardiac allograft. Rats that received more 
prolonged immunosuppression had a decline in the rate of 
signal intensity reduction, suggesting less inflammation and 
indicating that treatment response could be monitored with 
this method.
Subsequent studies have confirmed the value of using 
USPIO to detect acute cardiac rejection in rats,25–27 although 
ferumoxtran-10 proved inferior to NC100150 at detecting 
rejection26 and was unable to detect acute cardiac rejection 
in rats in another study.28 In the latter study, ferumoxtran-10 
was given at two doses of 2 mg and 11 mg Fe/kg with T2*-
weighted MRI conducted using a 1.5 T scanner at postop-
erative day 7, 24 hours after USPIO administration. The 
failure to detect USPIO was thought to be due to the low 
field strength magnet of the MRI scanner.
Iron oxide particles can be conjugated to a specific anti-
body or peptide to target pathophysiological processes.29 
Recent work by Guo et al30 targeted T cells that play a cen-
tral role in acute cardiac allograft rejection. They built on 
work performed using ligand targeting of cells to employ a 
“theranostic” strategy, combining diagnostic imaging with 
administration of therapy within the one system (Figure 2). 
They targeted T cells in the endocardium of rejecting rat 
hearts using a CD-3 antibody-targeted multifunctional poly-
meric nanocarrier. This polyplex nanoparticle was further 
conjugated to a therapeutic gene (pDNA-DGKalpha) enabling 
simultaneous imaging and immune modulation of CD-3 
expressing T cells.
MI
The development of cross-linked particles of iron oxide 
(CLIO)31 allowed targeted cardiac inflammatory imaging. 
Cross-linking and amination of the USPIO dextran chains 
encourages circumferential adherence of the dextran coat 
to the iron nanoparticle providing chemical stability and 
improved conjugation.31 Sosnovik et al32 conjugated CLIO 
with cyanine 5.5 dye creating a “magnetofluorescent” particle 
allowing co-registration of MRI and fluorescence molecular 
tomography data. They administered CLIO-Cy5.5 48 hours 
after left coronary artery ligation in a mouse model of MI 
with dual modality imaging 48 hours later. The accumulation 
of CLIO-Cy5.5 within infarcted regions of myocardium was 
clearly seen on fluorescence and MRI images that were not 
present on control mice (mice injected with CLIO-Cy5.5 but 
a “sham” operation). In vivo imaging findings were subse-
quently confirmed with histology. Examination of infarcted 
myocardium revealed a high degree of co-localization 
between inflammatory cell infiltrates on hematoxylin and 
eosin staining, increased signal intensity on fluorescence 
microscopy, and an abundance of macrophages on immu-
nohistochemistry staining. This is consistent with uptake 
of CLIO-Cy5.5 by macrophages infiltrating the infarcted 
myocardium.
Clinical applications of USPIO in highlighting myocardial 
inflammation after MI have since emerged following the dis-
covery that inflammation around the time of MI affects both 
the extent of myocardial salvage and recovery of left ventricular 
function. Our group33 used USPIO to image myocardial inflam-
mation following acute MI. Within 48 hours following acute 
MI, patients underwent MRI scanning at baseline (pre-USPIO) 
before receiving an infusion of ferumoxytol (USPIO) with 
subsequent serial MRI scans thereafter. The infarct zone was 














Figure 2 Schematic diagram of therapeutic process of magnetic targeting polyplex 
scAbCD3-PEG-g-PEI-SPION in vitro and in vivo.
Notes: Reprinted with permission from Guo Y, Chen W, Wang W, et al. 
Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart 
transplantation model using a T-cell-targeted theranostic nanosystem. ACS Nano. 
2012;6(12):10646–10657. Copyright © 2012 American Chemical Society.30 
Abbreviations: ScAb-CD3, CD3 single chain antibody; PEG, polyethylene glycol; 
PEI, polyethylenimine; SPION, superparamagnetic iron oxide nanoparticles; pDNA, 
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USPIO administration, there was a significant increase in 
R2* (R2*  1/T2*) in the infarct zone, with smaller changes 
observed in the peri-infarct zone (surrounding areas of delayed 
enhancement) and even in remote myocardium when com-
pared with control tissue (skeletal muscle). This suggested 
peri-infarct and remote myocardial inflammation, although 
no histological data were available to confirm this. Notably, 
the R2* value was greatest 24 hours following USPIO (feru-
moxytol) infusion, and had declined by 48 hours suggesting 
that 24 hours post-infusion is a more sensitive imaging time 
than 48 hours post-infusion in this group of patients.
Yilmaz et al34 also detected a reduction in T2* value in 
the infarct as well as in the peri-infarct region, the remote 
myocardium, and the lymphoreticular system. On imag-
ing the first three patients at 6, 24, 48 and 96 hours after 
ferumoxytol administration, they attempted to find the opti-
mal time window to characterize inflammation within the 
 myocardium. From these data, they suggest that signal attenu-
ation was maximal at 24 hours but that the best combination 
of T2-weighted (hypoenhancement seen) and T2*-weighted 
images was obtained at 48 hours.
Histological data are required to address the outstand-
ing question regarding distribution of USPIO within the 
myocardium and the relative contribution to changes in T2* 
of extracellular iron accumulating within the interstitium, 
capillary bed, and inflammatory macrophages.
The finding of T2* signal void in remote myocardium 
suggests a pan-myocardial inflammatory response in the 
context of a focal infarct. Grieve et al35 confirmed this finding 
in remote segments in a rat model of ischemia-reperfusion 
injury examining endovascular inflammation using a targeted 
larger iron oxide tracer (MPIO).
Other cardiac imaging
Stem cells
Current research endeavors are increasingly focusing on 
stem cell therapy following the discovery that pluripotent 
progenitor cells bear the capacity to differentiate into mature 
cardiac cells, in an attempt to restore function to organs with 
no regenerative capacity. There is a need to track stem cells 
following administration so that their distribution and fate 
can be determined. Cell labeling with iron nanoparticles is 
relatively simple, fast, inexpensive and is well described, 
although there have been few published studies using USPIO 
in cardiac stem cell imaging. Tracking of stem cells labeled 
with iron nanoparticles using MRI is still at the pre-clinical 
stage but offers high spatial resolution, excellent soft tissue 
detail, and avoids exposure to ionizing radiation.
Küstermann et al36 labeled cardiac progenitor cells 
expressing enhanced green fluorescent protein with 
 ferumoxtran-10 and implanted the cells into murine myo-
cardium injured through cryocoagulation or coronary 
artery  ligation. Co- registration of USPIO and stem cells 
was confirmed by comparing high-resolution MRI images 
with Prussian Blue stain for iron on histology, and immuno-
histochemistry for enhanced green fluorescent protein. Dif-
ficulties were encountered using this approach as the signal 
attenuation of unlabeled ischemic myocardium was similar 
to that induced by USPIO-labeled cells in T2*-weighted 
images making detection of labeled cells within infarcted 
regions difficult. However, the authors subsequently found 
that the combination of proton density- and T2*-weighted 
MRI sequences identified regions of myocardial injury and 
USPIO-labeled cells respectively – the larger area of signal 
attenuation in the T2*-weighted images was caused by infil-
tration of the iron-labeled cells.
Chapon et al37 combined MRI and positron emission 
tomography to track transplanted stem cells after MI in rats 
providing anatomical, physiological, and metabolic informa-
tion. They conjugated rat bone marrow-derived stem cells to 
CLIO and fluorescein dye enabling co-localization of stem 
cells to be assessed by in vivo MRI and ex vivo magnetic 
resonance  spectroscopy. Stem cells were successfully detected 
on MRI and histology for the 6 week duration of the study, 
however positron emission tomography signs of metabolic 
activity (18F-fluorodeoxyglucose uptake) was only seen in the 
first week post-stem cell implantation. This may have been due 
to early, localized inflammation from stem cell injection or 
more likely death of the stem cells. A trend to an improvement 
in cardiac function was found after stem cell implantation, 
although this did not reach statistical significance.
Ma et al38 compared the ability of USPIO and MPIO in 
tracking stem cells via intracoronary injection, as opposed to 
a direct intramyocardial route, in a swine model of ischemia-
reperfusion injury. They found that similar labeling efficiency 
was found in both particles, and differentiation and prolif-
eration of mesenchymal stem cells (MSCs) in vivo were 
not affected by labeling with either iron particle, confirmed 
by immunohistochemical assays showing similar protein 
expression. Hypointensity was seen in infarcted regions with 
both particles on T2*-weighted MRI at 4 and 8 weeks and 
co-localized with regions of iron uptake seen on Prussian 
Blue staining. However there was no hypointensity detected 
in 2/7 of the MPIO labeled pigs and the authors suggested 
that USPIO labeling was more suited to intracoronary injec-
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Mathiasen et al39 recently sought to determine the MRI 
detection limits of CLIO labeled human MSCs using gel-
phantoms in a clinical 1.5 T MR scanner. They determined 
the detection limit to be 250,000 MSCs using a 21 hours’ 
incubation time and 10 Mg USPIO/105 MSCs. At lower incu-
bation times and doses of USPIO, significantly more cells 
were needed for detection. They confirmed their findings 
in ex vivo porcine myocardium by visualizing the USPIO-
labeled MSCs.
USPIO-enhanced MRI appears well placed to provide 
future clinical research opportunities to detect and track stem 
cells following implantation. However, to enhance sensitiv-
ity, detection limits for stem cell number and administered 
iron concentration for a particular MRI scanner would need 
to be determined in advance.
Apoptosis
During apoptosis, or programmed cell death, the phospho-
lipid phosphatidylserine is externalized on the cell surface. 
Annexin V is an endogenous protein that binds with high 
affinity to phosphatidylserine, and when conjugated to CLIO, 
has successfully been able to identify apoptotic cells in vitro 
using MRI.40 Sosnovik et al41 used this particle as a founda-
tion to create a multimodal nanoparticle further conjugated 
to cyanine 5.5 dye – AnxCLIO-Cy5.5 – allowing co-identifi-
cation with fluorescence microscopy and T2*-weighted MRI. 
In a murine model of ischemia reperfusion injury, a reduction 
in signal intensity on T2*-weighted imaging was observed in 
reperfused regions with AnxCLIO-Cy5.5 but not with unla-
beled CLIO-Cy5.5 suggesting uptake of AnxCLIO-Cy5.5 
within the injured and apoptotic myocardium. The area of 
signal loss correlated with the region of contractile dysfunc-
tion seen on MRI, and subsequently with areas of increased 
fluorescence intensity on near infra-red fluorescence.
More recently, Sosnovik et al employed a similar approach 
in developing a novel dual-contrast molecular MRI probe 
capable of detecting cardiomyocyte apoptosis and necrosis 
in mice with ischemia reperfusion injury in vivo.42 Using the 
same AnxCLIO-Cy5.5 particle to identify cellular apoptosis 
on MRI 4–6 hours after ischemia-reperfusion injury, they 
also administered a novel magnetofluorescent gadolinium 
chelate with subsequent gadolinium delayed enhancement 
MRI to illustrate necrosis. Interestingly, they found that 
only 21% of apoptotic myocardium (accumulation of Anx-
CLIO-Cy5.5) had evidence of necrosis (defined by delayed 
gadolinium enhancement) suggesting that the majority of 
apoptotic cardiomyocytes remain viable 4–6 hours after 
ischemia-reperfusion injury. This was confirmed on fluores-
cence microscopy and immunohistochemistry revealing the 
presence of large numbers of apoptotic, but potentially viable, 
cardiomyocytes in the “at-risk” area (AnxCLIO-Cy5.5 posi-
tive, Gd-DTPA-NBD negative areas). The authors remarked 
that strategies to salvage apoptotic, but not yet necrotic, 
myocardium should be explored now that these areas could 
be successfully imaged.
Carotid atherosclerosis
Carotid atherosclerosis and stroke are a major cause of dis-
ability and death. In the United States it is estimated that 
around 750,000 people become victims of stroke  annually.43 
Over one million Americans live with disabilities caused by 
stroke and 28% of strokes occur in people under the age of 
65.44
Although the traditional imaging marker of disease bur-
den has been stenosis, this is a poor marker of disease activity. 
It is now accepted that atherosclerosis is an inflammatory 
disorder45–47 involving recruitment of inflammatory cells 
into the lipid-rich plaque core. In atherosclerotic plaques, 
high macrophage density is a feature of vulnerability and 
correlates with risk of plaque rupture and clinical events.48 
Modern techniques are now able to assess the composition 
and pathobiology of the arterial wall itself, and identification 
of vulnerable plaques at high risk of rupture is therefore key. 
USPIO-enhanced MRI is well placed to evaluate inflamma-
tion within plaques and will be discussed in this section.
Kresse et al49 first demonstrated USPIO uptake in athero-
sclerosis in vivo. They administered atherosclerotic rabbits 
custom-made iron oxide nanoparticles, visualizing these on 
MRI and confirming histologically with Prussian Blue staining. 
This study was uncontrolled and no attempt was made at quan-
titative analysis. Ruehm et al50 soon followed this with a more 
robust protocol. They administered USPIO to hyperlipidemic 
atherosclerotic rabbits and performed MRI scans at multiple 
time points. They noted extensive but patchy signal voids along 
the length of the aortic wall in atherosclerotic rabbits, but not 
in controls. Aortae were harvested for histological assessment 
and electron microscopy. Hyperlipidemic rabbits given USPIO 
showed extensive iron deposition in the subintima demonstrated 
by Prussian Blue staining, and on electron microscopy, iron 
inclusions were noted within plaque macrophages.
Hyafil et al51 examined hypercholesterolemic rabbits fol-
lowing iatrogenic aortic injury from balloon angioplasty and 
conducted MRI sequences at various time points following 
ferumoxtran-10 administration. At 5 days post-infusion, signal 
voids were seen in injured aortae on in vivo MRI, extending both 
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creating a “pseudostenosis” appearance. There was significantly 
more signal void in balloon-injured aortae  compared to control 
aortae (uninjured aortic regions or rabbits administered saline 
instead of USPIO). Regions of signal void correlated with 
iron and RAM-11 staining (a rabbit macrophage marker), and 
a close correlation was also noted between the distribution of 
iron and RAM-11 staining. Extensive histological iron staining 
was seen in the balloon-injured aortae.
The first demonstration of the feasibility of atherosclero-
sis imaging using USPIO in humans was reported by Schmitz 
et al52 in a small study of patients with pelvic malignancy 
undergoing MRI for assessment of lymphatic metastasis 
using the USPIO ferumoxtran-10, which was at the time 
licensed for this indication. They retrospectively examined 
the aortic bifurcation and detected new focal areas of subinti-
mal signal drop out in seven of 20 patients on T2*-weighted 
imaging that had not been present on the pre-USPIO images. 
The authors speculated that the presumed accumulation 
of subintimal USPIO was a consequence of dysfunctional 
endothelium and that this technique might function as an 
assay of endothelial integrity.
Kooi et al53 performed the first prospective human study 
evaluating atherosclerosis using USPIO (ferumoxtran-10) in 
a carotid endarterectomy model. Eleven patients scheduled to 
undergo carotid surgery following a symptomatic neurovascular 
event were imaged with T2*-weighted MRI at three time points: 
pre-USPIO, 24 and 72 hours post-USPIO. Semi-quantitative 
image analysis was undertaken by calculating the relative 
signal intensity in quadrants with visible signal changes and 
comparing to reference tissue (skeletal muscle). Following sur-
gery, carotid plaque was processed for immunohistochemical 
analysis and electron microscopy. Significant iron staining was 
noted in nine of ten plaques eligible for analysis, and regions 
co-localized with CD68 staining for macrophages. Electron 
microscopy confirmed this, demonstrating abundant USPIO-
sized intra-cytoplasmic inclusions within macrophages, which 
on energy-dispersive X-ray analysis were confirmed to be 
composed of iron. On magnetic resonance analysis, reduction 
in relative signal intensity was confined to areas of plaque that 
demonstrated positive histological iron staining. Maximum 
difference in pre- versus post-USPIO signal intensity occurred 
at 24 hours, with the 72 hour window failing to reach signifi-
cance, suggesting that this time point was too late to image 
USPIO uptake.
Trivedi et al54 conducted a small study of eight patients 
scheduled for carotid endarterectomy, performing multi-
sequence MRI at various time points (before, 24, 36, 48, and 
72 hours after ferumoxtran-10 administration). Only segments 
of plaque staining positive for iron revealed signal void on MRI 
which was clearest on qualitative review of the T2*-weighted 
images at the 36 and 48 hour time points. This finding was 
replicated in the quantitative analysis (employing relative sig-
nal intensity) revealing greatest relative signal loss between 24 
and 48 hours. Histological and electron microscopy analysis 
revealed most plaque sections demonstrated iron staining and 
that there was co-localization of iron and macrophage staining 
(MAC387), but there were regions with large populations of 
macrophages in the absence of iron staining. Electron micros-
copy confirmed the presence of USPIO-sized particles within 
macrophages.
In a subsequent study by the same authors,55 30 patients 
awaiting carotid endarterectomy for severe carotid stenosis 
were imaged before and 36 hours post-USPIO, in line with the 
findings of their previous work. MRI analysis was similar and 
more extensive histological validation was undertaken. Areas 
of reduced relative signal intensity were seen in 24/27 patients 
(three excluded for excessive artifact) that corresponded to 
USPIO/macrophage positive histology, and most samples 
(23/30) revealed iron staining within the plaque. There was 
a significant correlation between the presence of USPIO 
(based upon change in relative signal intensity) on MRI and 
iron staining in plaques with focal but not diffuse distribution 
of signal void. Co-localization of iron staining with CD68 
and MAC387 was seen but only modestly correlated (there 
were areas seen to stain for iron and not macrophages and 
vice versa), and in some sections there was extracellular iron 
staining around small neo-vessels, possibly indicating that 
these immature and leaky vessels may represent an entry 
port for USPIO.
The authors speculated that possible reasons for the 
weak correlation between iron and macrophage staining 
was a lack of sensitivity of Perls’ stain for USPIO, delayed 
kinetics of ferumoxtran-10 in inflammatory tissue, and that 
macrophage subtypes might have differing uptake kinetics 
for USPIO. This latter theory has been given some experi-
mental traction recently in a study which has shown that M1 
and M2 macrophages take up USPIO at different rates.56 
M1 polarized (pro-inflammatory/destructive) macrophages 
appear to take up relatively less USPIO than M2 polarized 
(anti-inflammatory/pre-healing) macrophages.
In 2006, Tang et al57 used a more objective analysis 
approach by calculating adjusted mean change in relative 
signal intensity. Instead of investigator selected regions of 
interest that are prone to bias, the mean change in relative 
signal intensity was calculated using multiple sample data 
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between signal loss in different quadrants within a slice and 
different slices within a plaque. They recruited 20 patients 
due to undergo carotid surgery and compared symptomatic 
to contralateral asymptomatic carotid artery plaques (mean 
stenosis 77% versus 46% respectively). They found that 
all symptomatic plaques demonstrated signal void and 
interestingly, 19/20 patients displayed regions of inflamma-
tion on the contralateral asymptomatic side. Symptomatic 
lesions did, however, have a greater percentage of positive 
quadrants (72% versus 51%, P0.007), and a significant 
reduction in adjusted mean relative signal intensity 
(10.9%p4.3%, P0.02) that was not apparent on the con-
tralateral side. They also observed that, as seen in previous 
studies, several asymptomatic “stable” plaques actually 
showed enhancement (signal increase) in the fibrous cap. 
The authors concluded that the results demonstrate the 
systemic nature of atherosclerotic inflammation and that 
this technique may aid risk-stratification of asymptomatic 
plaques in the future.
The notion of systemic inflammation in atherosclero-
sis was explored further in another study by Tang et al.58 
Ten patients awaiting coronary artery bypass graft surgery 
for active coronary disease with incidental asymptomatic 
carotid stenosis (50%) were compared to ten individuals 
with similar severity of asymptomatic carotid stenosis but 
no known coronary artery disease. Plaques from patients 
awaiting coronary artery bypass graft surgery showed a sig-
nificant mean signal intensity attenuation of 16.4% versus an 
increase (ie, enhancement) of 8.4% in the truly asymptomatic 
group making a true difference of 24.9% (95% confidence 
interval 16.7% to 33.0%; P0.001) between groups. These 
data support the hypothesis that vascular inflammation is a 
systemic phenomenon measurable by USPIO accumulation 
and that signal enhancement may indicate a more stable 
plaque phenotype.
The same authors59 sought to clarify the relationship 
between traditional radiological markers of stroke risk and 
USPIO uptake in 71 individuals with asymptomatic carotid 
stenosis of varying severity. USPIO uptake on T2*W MRI 
was compared to luminal stenosis measurements of North 
American Symptomatic Carotid Endarterectomy Trial 
(NASCET)60 and European Carotid Surgery Trial (ECST)61 
methods, and normalized wall index. The group also made an 
attempt to model the USPIO data with respect to increasing 
stenosis severity. As with their previous work, no relation-
ship was evident between either measurement of stenosis 
severity and plaque inflammation, and both are independent 
risk factors providing valuable and completely different 
pathological information. To further assess this, a prospective 
trial examining outcome data in patients stratified by USPIO 
uptake would be required.
The ATHEROMA (Atorvastatin THerapy: Effects on 
Reduction Of Macrophage Activity) trial was designed 
to evaluate the effects of statin therapy on carotid plaque 
inflammation.62 Forty-seven patients with carotid stenosis of 
greater than 40% who demonstrated plaque USPIO uptake 
were randomized to low (10 mg) or high-dose (80 mg) 
atorvastatin for 12 weeks with USPIO-enhanced MRI at 
6 and 12 weeks. Twenty patients completed 12 weeks of 
treatment in each study arm. The primary end point was 
met with a significant reduction in USPIO uptake observed 
in the high-dose treatment arm at both 6 and 12 weeks. No 
such difference was evident in the low dose arm. Unsur-
prisingly, beneficial effects were noted on plasma lipid 
profiles but of greater interest was that microembolic load 
assessed by transcranial Doppler was significantly reduced. 
Furthermore, enhancement was seen in the fibrous cap and 
subintima in the high-dose but not the low-dose cohort, 
supporting previous observations that such enhancement 
may be associated with a more stable plaque phenotype. 
This study represents progress in developing a reliable 
imaging-based biomarker of atherosclerotic disease activity 
and inflammation. However, hard clinical outcomes are still 
lacking. Degnan et al63 performed a retrospective analy-
sis of all participants screened for the ATHEROMA trial 
(n62) who received USPIO-enhanced MRI, and recorded 
the occurrence of stroke, transient ischaemic attack, MI or 
cardiovascular death during a median follow-up of 4 years. 
Although those who had events did appear to have greater 
mean change in relative signal intensity on MRI, there were 
small absolute differences that did not reach statistical sig-
nificance (P0.07). When the population was divided into 
USPIO-positive or -negative plaque groups, survival curves 
did not diverge significantly. The authors conclude that their 
study was not powered to assess outcome but that there were 
perhaps encouraging signs emerging from the data.
Abdominal aortic aneurysms
Abdominal aortic aneurysms (AAAs) are defined as focal 
dilatations of the aorta, where aortic diameter is 1.5 times 
normal. They affect 5% of men over the age of 65, and within 
this group cause 2%–3% of deaths annually.64,65 The vast 
majority of these deaths occur as a result of aortic rupture, 
which has a mortality rate of 65%–85% even in those reaching 
hospital alive.66,67 Currently, aneurysm diameter alone is the 
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AAAs have a diameter less than the 55 mm intervention 
threshold and many patients have larger aneurysms without 
symptoms.68,69 The implementation of aneurysm screening has 
reduced aneurysm-related mortality by up to 53%64 but will 
increase the number of patients under long-term surveillance. 
Due to the unpredictability and non-linearity of aneurysm 
growth, improvements to the prediction of aneurysm rup-
ture are required. Accordingly, there is a shift in focus from 
anatomical and morphological imaging to novel cellular and 
molecular techniques that evaluate lesion vulnerability on the 
basis of inflammatory and biological activity.
A prominent histological feature of AAAs is infiltration of 
T and B lymphocytes, macrophages, neutrophils, and natural 
killer cells.70–73 These inflammatory cells regulate the release 
of cytokines, resulting in the expression of cell adhesion mol-
ecules, protease production, and release of reactive oxygen spe-
cies that in turn cause degradation of the extracellular matrix 
through alterations in the balance of matrix metalloprotein ases 
and tissue inhibitors of matrix metalloproteinases.74,75 In addi-
tion, inflammation and hypoxia lead to new vessel formation 
and loss of vascular smooth muscle cells, and it is these 
mechanisms that predispose to aortic dilatation and increased 
risk of AAA rupture. Inflammation within the aortic wall is 
often focally distributed and it is these hotspots of pathological 
activity that have been the focus of much investigation.
Howarth et al were the first to report USPIO uptake in 
AAA in man. They described simultaneous USPIO uptake 
within atheroma of both the internal carotid artery and a 
56 mm, asymptomatic AAA.76 Truijers et al later described 
USPIO (ferumoxtran-10) uptake in the wall of a small num-
ber of asymptomatic AAAs (n6).77 They found significantly 
more USPIO-positive quadrants in aneurysm patients than 
in age-matched controls, and the patient with the larg-
est number of USPIO-positive quadrants had the largest 
diameter aneurysm although there was a wide variation in 
USPIO uptake. A subsequent pilot feasibility study by Sadat 
et al (n14) quantified USPIO uptake in the AAA wall by 
using calculated T2 and T2* values.78 They found significant 
correlation between imaging sequences pre- and 36 hours 
post-USPIO infusion, and both imaging methods were able 
to detect the presence of USPIO uptake.
Our group evaluated the potential for this technique to 
predict aneurysm expansion. Twenty-nine asymptomatic 
patients with AAAs underwent baseline MRI scans followed 
by intravenous administration of USPIO and repeat MRI 
scans 24–36 hours later. A similar technique was used to 
assess iron accumulation; the percentage change in T2* 
value was calculated following USPIO administration, but 
additionally, a threshold of significance for change was 
applied. By applying this threshold based on repeatability 
data for calculation of the T2* value in vascular tissue of 
subjects not receiving USPIO, we were able to distinguish 
changes in T2* associated with USPIO accumulation from 
artifact. All patients demonstrated non-specific peri-luminal 
USPIO accumulation, likely reflecting USPIO uptake in the 
fresh, highly cellular component of the thrombus. Thrombus 
within AAAs is structurally complex and is known to consist 
of a continuous network of interconnected canaliculi.79 This 
network may support transportation of inflammatory cells 
from lumen into the thrombus, and further into aortic wall as 
seen in some patients. Importantly, despite similar aneurysm 
sizes, it is these patients with mural USPIO uptake who had 
evidence of aneurysm growth rates three-fold higher (6.6 
mm/year) than patients with no mural USPIO uptake, sug-
gesting that this technique may be used to identify patients 
at greater risk of aneurysm growth. Aortic tissue was col-
lected from patients undergoing open surgical aneurysm 















Figure 3 T2*-weighted color maps showing alongside the corresponding T2-weighted anatomic images from patients with abdominal aortic aneurysms (AAA).
Notes: The color scale represents the magnitude of the change in T2* value, with blue indicating minimal change and red indicating a large change in T2* value using a 
previously defined threshold above which changes in T2* value can be attributed to ultra-small superparamagnetic particles of iron oxide (USPIO) accumulation. Only changes 
in T2* value above the threshold are presented on the graduated (yellow-red) color scale; data below the threshold appear blue. (A) shows a change in T2* value confined 
to the peri-luminal area; (B) diffuse patchy changes in T2* throughout the intraluminal thrombus but no distinct focal area of USPIO uptake affecting the aortic wall; and (C) 
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of USPIO with CD68 staining for macrophages.80 An 
observational surveillance study is currently underway 
in our center (MA3RS study) examining whether USPIO-
enhanced MRI is able to predict the likelihood of rupture 
or need for surgery (Figures 3 and 4).
Conclusion and future applications
USPIO can detect inflammation in cardiac, carotid, and 
aortic disease, whilst providing targeted imaging in stem 
cell therapy and apoptosis. It is a technique that holds major 
promise for translation into the clinic.
The development of iron nanoparticle-enhanced MRI 
has been greatly affected by the discontinuation of several 
agents in recent years. Ferumoxtran-10 (Sinerem®), was 
discontinued due to a high false-positive rate of detecting 
lymph node metastasis in patients with prostate cancer.81 
NC100500 (Clariscan™) was discontinued over concerns 
regarding long-term liver retention,82 and the larger SPIO fer-
umoxides (Feridex® in United States, Endorem™ in Europe), 
and ferucarbotran (Resovist®) have also been discontinued; 
the latter two agents were the only two clinically approved 
SPIO agents for MRI. At present there is only one iron oxide 
particle preparation available for clinical use:  ferumoxytol 
(Rienso®; Takeda Italia S.p.A, Rome, Italy), a 17–30 nm 
USPIO. Rienso is marketed for the intravenous treatment of 
iron deficiency anemia in adult patients with chronic kidney 
disease, but is currently not licensed for imaging.
There are several clear opportunities for the develop-
ments of USPIO-enhanced MRI as a clinical research tool 
and our group is using ferumoxytol-enhanced MRI success-
fully in several clinical research studies. We are attempting 
to characterize myocardial inflammation following MI in 
humans: using the assessment of cellular myocardial inflam-
mation as a biomarker for therapeutic interventions. We are 
also piloting USPIO-enhanced MRI as a diagnostic test in 
other inflammatory myocardial diseases such as sarcoidosis 
and myocarditis. At the same time, we are exploring whether 
USPIO-enhanced MRI can identify patients with high-risk 
atherosclerotic plaques and AAAs who require early medical 
or surgical intervention. There are also clear opportunities 
for USPIO-enhanced MRI in the development of stem cell 
therapy.
It is difficult to predict where USPIO-enhanced MRI 
will make a breakthrough into clinical practice but there 
are clear applications in a range of cardiovascular and non-
cardiovascular diseases. This exciting imaging technique 
has great potential and results of research studies in coming 
years will determine its place in the clinic.
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Figure 4 Histology from an abdominal aortic aneurysm wall.
Notes: (A) Hematoxylin and eosin staining at s20 – inflammatory cell infiltrates seen in the endoluminal region with focal calcified atheroma. (B) Perls’ stain for iron at s100 
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Ferumoxytol-enhanced magnetic resonance
imaging methodology and normal values
at 1.5 and 3T
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Abstract
Background: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging
(MRI) can detect tissue-resident macrophage activity and identify cellular inflammation. Clinical studies using this
technique are now emerging. We aimed to report a range of normal R2* values at 1.5 and 3 T in the myocardium
and other tissues following ferumoxytol administration, outline the methodology used and suggest solutions to
commonly encountered analysis problems.
Methods: Twenty volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2* and late gadolinium enhanced
(LGE) MRI was conducted at baseline with further T2* imaging conducted approximately 24 h after USPIO infusion
(ferumoxytol, 4 mg/kg). Regions of interest were selected in the myocardium and compared to other tissues.
Results: Following administration, USPIO was detected by changes in R2* from baseline (1/T2*) at 24 h in myocardium,
skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and bone at 3 T
(p < 0.05 for all). Myocardial changes in R2* due to USPIO were 26.5 ± 7.3 s-1 at 1.5 T, and 37.2 ± 9.6 s-1 at 3 T (p < 0.0001
for both). Tissues showing greatest ferumoxytol enhancement were the reticuloendothelial system: the liver, spleen and
bone marrow (216.3 ± 32.6 s-1, 336.3 ± 60.3 s-1, 69.9 ± 79.9 s-1; p < 0.0001, p < 0.0001, p = ns respectively at 1.5 T, and
275.6 ± 69.9 s-1, 463.9 ± 136.7 s-1, 417.9 ± 370.3 s-1; p < 0.0001, p < 0.0001, p < 0.01 respectively at 3 T).
Conclusion: Ferumoxytol-enhanced MRI is feasible at both 1.5 T and 3 T. Careful data selection and dose administration,
along with refinements to echo-time acquisition, post-processing and analysis techniques are essential to ensure reliable
and robust quantification of tissue enhancement.
Trial registration: ClinicalTrials.gov Identifier - NCT02319278. Registered 03.12.2014.
Keywords: Cardiac, MRI, Inflammation, USPIO
Background
Iron oxide nanoparticles are a class of magnetic reson-
ance imaging (MRI) contrast agents that are generating
interest as a method of detecting tissue inflammation.
Historically, these nanoparticles were initially used for
gastrointestinal, reticuloendothelial system and lymph
node imaging [1–3], and subsequently in hepatic and
cardiac imaging [4–7]. Recently however, it is in their
use as an MRI contrast agent for detecting tissue-
resident macrophages that clinical applications are now
emerging [8–15].
T2* MRI has been successfully used for over a decade
in diagnosing and grading severity of iron accumulation
in transfusion-dependent thalassaemia major, and has
been instrumental in guiding therapy that improves
prognosis, and allows serial disease monitoring [16, 17].
T2* MRI in the assessment of iron accumulation is easily
quantifiable, well validated, highly reproducible, clinically
robust, and is achievable in a single breath hold [18–22].
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Ultrasmall superparamagnetic particles of iron oxide
(USPIO) consist of an iron oxide core surrounded by a
carbohydrate or polymer coating. These particles can ex-
travasate through damaged capillaries, where they are
engulfed and concentrated by tissue-resident macrophages
[23]. Gradient echo T2*-weighted (T2*W) sequences are
highly sensitive to magnetic field inhomogeneities such as
susceptibility artifacts due to the presence of iron, includ-
ing USPIO. Accumulation of USPIOs in macrophages can
be quantified and visualized using T2*W MRI [8, 9] and
calculation of, and observing the reduction in, T2*
relaxation time due to the presence of iron. Thus USPIO-
enhanced MRI can detect tissue-resident macrophage ac-
tivity and identify localized cellular inflammation within
tissues.
In this present study we aimed to observe and quantify
the distribution ferumoxytol enhancement following
intravenous administration at 1.5 and 3 T MRI and es-
tablish a range of normal values for healthy myocardium
and other tissue. We also aimed to develop our method-
ology and describe commonly encountered problems in
T2* image analysis of USPIO.
Methods
This was an open-label observational multi-centre
cohort study using human volunteers recruited as part
of a larger trial, recruiting patients with cardiac inflam-
mation. The study was performed in accordance with
the declaration of Helsinki, the approval of the Scotland
A research ethics committee, and the written informed
consent of all participants.
Subjects
Participants were aged over 18 years of age. Exclusion
criteria were contraindication to MRI or ferumoxytol
infusion, any systemic inflammatory comorbidity (eg
rheumatoid arthritis), renal failure (estimated glomerular
filtration rate <30 mL/min), pregnancy, breastfeeding
and women of child-bearing age not ensuring reliable
contraception.
Magnetic resonance imaging
MRI was performed using 3 T and 1.5 T scanners (Magne-
tom Verio and Avanto respectively, Siemens Healthcare
GmbH, Erlangen, Germany), with dedicated cardiac array
coils. All images were acquired using electrocardiogram-
gated breath-hold imaging. Routine steady state free preces-
sion (TrueFISP) sequences were used to acquire long-axis
and short-axis images of the heart. Standard cardiac slice
widths (6-mm width with 4-mm gap) and 8 echo times
(2.1–17.1 ms range) with matrix size of 256 × 115 were ac-
quired in order to generate T2* maps. The in-plane reso-
lution differed as required for larger or smaller subjects;
generally, a field of view of 400 × 300 mm was used with an
in-plane resolution of 2.6 × 1.6 mm. T2* relaxation maps
were generated before and approximately 24 h after admin-
istration of USPIO.
Immediately after the baseline T2* and SSFP cine im-
aging, breath-held inversion enhancement images were
acquired following an intravenous administration of gado-
linium contrast medium (0.1 and 0.15 mmol/kg at 3 T and
1.5 T respectively; Gadovist, Bayer Plc, Germany).
Fig. 1 MRI protocol
Table 1 Participant characteristics
1.5 T 3 T
Number 9 10
Male;Female 3:6 4:6
Age (years) 52 [45.5–61.5] 50 [45.25–53]
Body-mass Index (kg/m2) 22.9 [20.1–26.9] 25.9 [22.5–29.4]
Ejection Fraction (%) 63.6 ± 4.9 61.1 ± 4.1
N (%), mean ± SD, or median [interquartile range]
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Optimal inversion time (TI) was determined on a slice-by-
slice basis using standard late-enhancement TI-scout
protocols. The inversion-recovery late-enhancement
short-axis slices were acquired using similar slice positions
to the myocardial T2* imaging. The T2* acquisitions also
included imaging of the liver, spleen and spine to allow
quantification of USPIO accumulation within organs of
the reticuloendothelial system.
USPIO
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg;
Rienso®, Takeda Italia, Italy) was performed immediately
following the baseline magnetic resonance scan over at
least 15-min using a concentration of 2–8 mg/mL, di-
luted in 0.9 % saline or 5 % dextrose. Hemodynamic
monitoring was conducted throughout.
Study protocol
Volunteers received 2 MRI scans approximately 24 h
apart (Fig. 1).
Image analysis
All T2*-weighted multi-gradient-echo images for each pa-
tient were analyzed using Circle CVI software (Circle
CVI42, Canada). Regions of interest (ROI) were drawn in
the heart using standard cardiac segmentation [24], and
panmyocardial values averaged using segments 1–16. Fur-
ther ROI were drawn in skeletal muscle, kidney, liver,
spleen, blood pool (from LV cavity) and bone marrow.
An experimentally determined threshold used in previ-
ous work [8] for the coefficient of determination (r2 >
0.85) was used to exclude data that did not have an ac-
ceptable exponential decay when signal intensity (SI) was
plotted against echo time. The inverse of the mean T2*
(R2*) for each ROI was then calculated to assess the up-
take of USPIO, where the higher the value, the greater the
USPIO accumulation.
Late gadolinium enhancement (LGE), ventricular vol-
ume and functional analyses were performed using Circle
CVI software (Circle CVI42, Calgary, Canada). T2* data
were collected immediately prior to USPIO administra-
tion. USPIO-enhanced T2* data were collected 24–25 h
following ferumoxytol administration.
Statistical analysis
All statistical analysis was performed with GraphPad
Prism, version 6 (GraphPad Software, San Diego, CA).
To assess uptake of USPIO in tissues following single
administration, R2* increase from pre to 24 h following
USPIO were compared using repeated measures one-
way ANOVA. Statistical significance was defined as two-
sided p < 0.05.
Results
Twenty volunteer patients were recruited in total (10 at
1.5 T, 10 at 3 T). Forty MRI scans and 20 infusions of
ferumoxytol were completed over the course of the
study. Data from one participant at 1.5 T has been re-
moved due to the presence of LGE, (which was included













Panmyocardial average 33.5 ± 5.4 60.5 ± 7.2 26.5 ± 7.3 46.9 ± 4.1 84.2 ± 12.4 37.2 ± 9.6
Skeletal muscle 34.7 ± 4.2 44.9 ± 4.7 10.2 ± 5.8 55.5 ± 17.1 59.8 ± 6.6 4.3 ± 16.3
Kidney 16.6 ± 2.0 81.2 ± 15.2 64.6 ± 16.1 43.5 ± 39.1 115.2 ± 28.1 71.8 ± 48.8
Liver 36.0 ± 7.2 252.3 ± 34.3 216.3 ± 32.6 65.3 ± 21.2 340.9 ± 57.8 275.6 ± 69.9
Spleen 22.0 ± 7.7 358.3 ± 59.5 336.3 ± 60.3 51.2 ± 21.1 515.1 ± 137.4 463.9 ± 136.7
Blood 11.3 ± 4.1 96.0 ± 26.6 84.7 ± 27.2 18.8 ± 5.3 91.5 ± 20.9 72.6 ± 18.3
Bone 84.4 ± 29.2 154.3 ± 62.0 69.9 ± 79.9 330 ± 168.7 747.9 ± 277.8 417.9 ± 370.3
Mean ± SD
Fig. 2 Myocardial R2* pre- and post-USPIO administration at 1.5 and
3 T. Following administration, USPIO was detected by an increase in
R2* at 24 h in the myocardium at both 1.5 and 3 T.
(**** = p < 0.0001, ** = p < 0.01)
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in the cardiac MR protocol so that we could exclude vol-
unteers with any detectable cardiac MR abnormalities
according to standard cardiac MR protocols). All other
volunteers that were included had structurally normal
hearts. One participant was prescribed antihypertensive
medication but had a normal cardiac MR study and was
normotensive so the data was retained for analysis. Ad-
ministration of ferumoxytol was well tolerated with no
adverse reactions reported during or immediately after
administration in any of the participants.
Participants were predominantly middle aged, with
greater numbers of women in both groups (Table 1).
There were no differences between 1.5 T and 3 T groups
in BMI or ejection fraction at baseline.
A summary of results is shown in Table 2. At baseline,
panmyocardial R2* values were greater at 3 T than 1.5 T
(46.9 ± 4.1 versus 33.5 ± 5.4 s-1, Fig. 2, p < 0.01) as ex-
pected. Baseline R2* values were also greater at 3 T in
bone (P < 0.0001) but no baseline differences were seen
between magnetic field strength in all other tissues (Fig. 3,
p > 0.05 for all). USPIO increased panmyocardial R2*
values at 24 h in both 1.5 T and 3 T scanners (p < 0.0001
for both). Post-USPIO panmyocardial R2* values were
again greater at 3 T than 1.5 T, as expected (84.2 ± 12.4
Fig. 3 Tissue R2* pre- and post-USPIO administration at 1.5 and 3 T. Following administration, USPIO was detected by an increase in R2*, 24 h
after administration in skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and kidney, liver, spleen, blood and bone at 3 T. (**** = p < 0.0001,
*** = p < 0.001, ** = p < 0.01, * = p < 0.05)
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versus 60.5 ± 7.2 s-1, p < 0.0001). Panmyocardial change in
R2* between baseline and 24 h post USPIO at 1.5 T was
26.5 ± 7.3 s-1 and at 3 T was 37.2 ± 9.6 s-1 (p < 0.0001 for
both). Detectable increases in R2* were also observed at
24 h post-USPIO in skeletal muscle, kidney, liver, spleen
and blood at 1.5 T, and kidney, liver, spleen, blood and
bone at 3 T. (Fig. 3, p < 0.05 for all). BMI correlated with
the panmyocardial R2* changes due to USPIO contrast
(Fig. 4; r = 0.72, p < 0.001).
Discussion
For the first time, we report a range of normal T2*
values in the healthy human heart and other tissues 24 h
after ferumoxytol administration at 1.5 and 3 T. We also
report problems, solutions and guidance in ferumoxytol-
enhanced T2* image analysis.
Following administration, USPIO is detectable by T2*
imaging in the myocardium and other tissues at both 1.5
and 3 T. Tissues with small increases in R2* (less than
the blood pool) are likely to represent detection of
USPIOs within the intravascular space and include skel-
etal muscle (at 1.5 T only), myocardium and kidney. In
contrast, R2* changes that are greater than the blood
pool must be due to accumulation of USPIO, either
through iron storage, uptake by macrophages or other
phagocytes, or sequestered within tissue interstitium. In
the absence of tissue biopsies, we cannot be certain, but
as the most pronounced R2* changes were seen in the
spleen, liver and bone marrow - organs of the reticulo-
endothelial system - it would appear likely that USPIO is
incorporated quickly into tissue-resident phagocytes and
macrophages.
Detection of USPIO enhancement in skeletal muscle at
1.5 T but not 3 T is due to generally noisier data seen
across all tissues at 3 T. Due to wider data confidence inter-
vals, a larger sample size would be required to detected the
same mean change in R2*. The variation in data at 3 T is
partly artifact in the images, but also because of the lower
values at 3 T (USPIO has a faster T2* decay time at 3 T).
With the same sampling echo times, there are fewer data
points to construct the decay curve at 3 T than 1.5 T so
our error in estimation also increases.
We chose 24 h post USPIO to re-image participants as
myocardial signal attenuation at 24 h has shown to be
optimal in the myocardium compared to later time
points [8, 9]. In view of this, scanning appointments
were generally separated by 25 h, and in practice, this re-
gime worked well for both participants and MRI plan-
ning. According to previous work [8], we chose a
weight-adjusted USPIO dose of 4 mg Fe/kg body weight.
However acknowledging that the distribution of USPIO
following administration is predominantly in the organs
of the reticuloendothelial system and blood pool, this
may not be the optimum administration strategy as
blood volume does not increase linearly with weight. We
found a correlation between BMI and myocardial R2*
change, probably due to increased blood pool USPIO
concentration in those with higher BMI. We therefore
suggest that a fixed dose approach may also be appropri-
ate depending on the application.
Artifacts were commonly encountered with USPIO-
enhanced T2* imaging and made data analysis challenging.
Post contrast artifacts at the blood-pool to myocardial
interface were commonly seen and needed careful exclu-
sion when selecting myocardial ROI. (Fig. 5A) This limited
the assessment of USPIO accumulation at the endocar-
dium. Similarly, blooming artifacts from nearby organs with
high iron or blood pool USPIO content, such as lung and
liver, commonly created signal deficits within the myocar-
dium. In this situation, examination of T2* decay curves
and excluding echo times influenced by artifact aided T2*
decay curve fitting (Fig. 5).
The advantage of MRI mapping techniques is that visual
assessment and objective quantification can be made using
the same image, and these are now entering clinical prac-
tice. It seems likely that if UPSIO-enhanced MRI is adopted
into clinical practice to detect tissue inflammation, T2*
mapping would be used for image interpretation. However
based on our experiences, we would recommend caution in
interpreting maps alone. Signal attenuation seen on the T2*
map may be interpreted as tissue USPIO accumulation, but
may be due to blooming artifact from nearby susceptibility
effects, and close examination of the T2* decay curve, and
individual echoes if possible is suggested in order to distin-
guish accurately between tissue USPIO accumulation and
artifact. In theory, setting an r2 threshold as we did helps to
exclude areas grossly affected by artifact. In practice how-
ever, regions with a seemingly acceptable R2 may still be in-
fluenced by artifact (Fig. 5). Manual exclusion of later
echoes (influenced by artifact) from the curve may result in
an improvement in R2 (a measure of how well the data
Fig. 4 Body-mass Index vs Panmyocardial R2* change at 1.5 and
3 T. Body-mass index correlates with panmyocardial R2* change
pre- and post-USPIO
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points fit the curve), however there is the danger that redu-
cing the number of fitting points will in fact reduce the
overall sampling accuracy. Clearly, automated software
capable of detecting and excluding artifact would be
advantageous. This could be achieved by excluding, or ap-
plying less weight, to later echo times especially data points
at a large distance from the initial decay curve trajectory
[25, 26]. It should be noted that like all other MRI se-
quences, poor data quality heavily influenced by breathing
or movement artifact is generally non-interpretable and
post processing using automated T2* decay curve fitting
software is not likely to provide a remedy.
Echo times in this study were specific for cardiac im-
aging and were selected appropriately. Therefore they
were not optimal for imaging tissues with T2* values
substantially higher or lower than myocardium. Native
blood pool and post USPIO bone marrow (Fig. 6) pro-
vide examples of low and high T2* values respectively
that we had difficulty accurately fitting a T2* decay
curve. With high T2* values, only a short part of the
decay curve is plotted over the echo sampling time
period, and often the signal has not decayed sufficiently
for an accurate decay curve to be plotted. In contrast,
regions with particularly short T2* decay times have
decayed to a level expected from background noise be-
fore sufficient data sampling has been made. Therefore
fitting a decay curve from a small number (2–4) of echo
times is clearly difficult, and often too much emphasis is
(See figure on previous page.)
Fig. 5 Inferior Blooming artifact. Example illustrating the challenge in assessing whether the inferior myocardial signal attenuation seen arrowed
on the T2* colourmap (a, scale 0-60 ms) is true or caused by artifact. Drawing a region of interest (b) and examining the decay curve (c) along
with visualising individual echos (d1-8) helps determine that this is a ‘blooming artifact’ from outside the heart is seen to influence echos 4-8.
These can be manually removed, forming a new decay curve (e) with improvement in curve fitting (R2 value), although with fewer fitting points
Fig. 6 Example of high and low T2* values. Regions of Interest with excessively low or high T2* value (pre-contrast blood pool, a, and post
USPIO bone marrow, b, respectively) can often be difficult to generate an accurate T2* decay curve. Imaging with tissue-spcific echo times will
help generate more accurate T2* decay curves
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placed upon data decayed to the baseline level of back-
ground noise in order to generate a decay curve. Allow-
ances can be made for background noise but are of
limited value in this instance. We strongly advise apply-
ing tissue-specific echo times tailored to the expected
T2* value in order to achieve the most accurate decay
curves possible.
Limitations
There are some limitations that should be taken into ac-
count when interpreting these data. First, this study has
small numbers and a larger cohort of participants should
be studied to further validate these normal values. Fur-
thermore, due to geographical reasons, it was not feas-
ible to scan the same participants at both centres so
comparison cohorts at 1.5 T and 3 T were different. Des-
pite this, both were healthy volunteers groups and dis-
played no differences at baseline so we do not feel this
has impacted on the results. Finally, due to problems in
interpreting high and low T2* values as mentioned
above, we recommend caution in interpreting some high
non-cardiac R2* values; especially in the organs of the
reticuloendothelial system at 3 T. In these organs, the
spread of R2* data above the median value appears wide.
This is possibly caused by artifact and most evident at
3 T, and may additionally explain why these regions have
disproportionally high R2* values.
Conclusion
We have shown that ferumoxytol-enhanced MRI is feasible
at both 1.5 T and 3 T, and suggest a range of expected nor-
mal values post-ferumoxytol in a range of tissues. Refine-
ments of dose administration, optimization of acquired
echo-times, careful image analysis, and development of
post-processing and analysis software capable of excluding
common artifacts, are essential to ensure reliable and ro-
bust quantification of tissue enhancement.
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ABSTRACT
Objectives Macrophages play a central role in the 
cellular inflammatory response to myocardial infarction 
(MI) and predict subsequent clinical outcomes. We aimed 
to assess temporal changes in cellular inflammation 
and tissue oedema in patients with acute MI using 
ultrasmallsuperparamagnetic particles of iron oxide 
(USPIO)-enhanced MRI.
Methods Thirty-one patients were recruited following 
acute MI and followed up for 3 months with repeated 
T2 and USPIO-enhanced T2*-mapping MRI. Regions of 
interest were categorised into infarct, peri-infarct and 
remote myocardial zones, and compared with control 
tissues.
Results Following a single dose, USPIO enhancement 
was detected in the myocardium until 24 hours 
(p<0.0001). Histology confirmed colocalisation of iron 
and macrophages within the infarcted, but not the non-
infarcted, myocardium. Following repeated doses, USPIO 
uptake in the infarct zone peaked at days 2–3, and 
greater USPIO uptake was detected in the infarct zone 
compared with remote myocardium until days 10–16 
(p<0.05). In contrast, T2-defined myocardial oedema 
peaked at days 3–9 and remained increased in the 
infarct zone throughout the 3-month follow-up period 
(p<0.01).
Conclusion Myocardial macrophage activity can be 
detected using USPIO-enhanced MRI in the first 2 weeks 
following acute MI. This observed pattern of cellular 
inflammation is distinct, and provides complementary 
information to the more prolonged myocardial oedema 
detectable using T2 mapping. This imaging technique 
holds promise as a non-invasive method of assessing 
and monitoring myocardial cellular inflammation with 
potential application to diagnosis, risk stratification 
and assessment of novel anti-inflammatory therapeutic 
interventions.
Trial registration number Trial registration number: 
14663. Registered on UK Clinical Research Network 
(http:// public. ukcrn. org. uk) and also  ClinicalTrials. gov 
(https:// clinicaltrials. gov/ ct2/ show/ NCT02319278? term= 
DECIFER& rank=2).
INTRODUCTION
More than one person every minute suffers a 
myocardial infarction (MI) in the USA.1 Despite 
improved interventional and medical treatments, 
mortality rates following MI remain high and many 
develop heart failure.1 Postinfarct inflammation 
plays a key role in the recovery of cardiac func-
tion,2 3 and it is a target for therapeutic manipula-
tion to improve clinical outcomes.
After early neutrophil infiltration, monocyte- 
derived macrophages dominate the cellular 
infiltrate in the first 2 weeks following MI and 
sequentially coordinate digestion of damaged tissue 
and promotion of infarct healing.2 3 Optimal post-MI 
recovery is determined by the balance between 
proinflammatory and reparative macrophages, with 
uncontrolled early inflammation leading to adverse 
functional recovery.2–5
Ultrasmall superparamagnetic particles of 
iron oxide (USPIO) consist of an iron oxide core 
surrounded by a carbohydrate or polymer coating 
and are small enough to extravasate through 
diseased microvessels, where they are engulfed 
and concentrated by tissue-resident macrophages.6 
Accumulation of USPIOs reduces T2* decay time 
and creates signal deficits that can be quantified 
and visualised using T2* MRI.7 8 Thus, USPIO- 
enhanced MRI can detect tissue-resident macro-
phage activity and identify cellular inflammation 
within tissues.
In current practice, T2-weighted MRI is used to 
evaluate myocardial oedema after MI.9 10 However, 
these imaging techniques assess myocardial free 
water content and not active cellular inflammation. 
Development of a reliable non-invasive imaging 
technique capable of directly detecting myocardial 
cellular inflammation would be a major advance 
and could potentially facilitate risk stratification 
and therapeutic targeting of macrophages immedi-
ately after MI. Furthermore, this technique could 
provide diagnostic information, serial disease moni-
toring and a measure of treatment response in other 
conditions mediated by inflammatory cell infiltra-
tion of the heart.
In a recent proof-of-principle pilot study,7 we 
successfully detected inflammation following acute 
MI using USPIO-enhanced MRI. USPIO uptake, 
defined as the increase in R2* (1/T2*) 24 hours 
following administration, was seen in the infarct 
zone within the heart. In this study, we hypothe-
sised that we could track the time course of cellular 
inflammation in the 3-month period following acute 
MI using USPIO-enhanced MRI. Our primary aims 
were, first, to determine the duration and distribu-
tion of USPIO enhancement in tissues following a 
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single infusion and, second, to assess the duration of macrophage 
infiltration of the heart by tracking myocardial USPIO enhance-
ment using repeated USPIO administration, and compare this to 
measures of myocardial oedema using T2 mapping.
METHODS
This was an open-label observational cohort study. Patients were 
recruited within 7 days of acute MI. The study was performed 
in accordance with the Declaration of Helsinki, the approval of 
the local research ethics committee and the written informed 
consent of all participants.
Subjects
Participants were aged 18–80 years and had sustained a recent MI 
according to the third universal definition of MI,11 with 12-hour 
plasma troponin I concentration ≥5000 ng/L. Exclusion criteria 
were known critical stenosis (>95%) of left main stem, ongoing 
symptoms of angina, heart failure (Killip class ≥2), renal failure 
(estimated glomerular filtration rate <30 mL/min/1.73 m2) and 
contraindication to MRI or ferumoxytol infusion.
Ultrasmall superparamagnetic particles of iron oxide
Intravenous infusion of USPIO (ferumoxytol, Fe core 3.25 nm, 
total particle diameter 17–31 nm, 4 mg/kg; Rienso, Takeda 
Italia, Italy) was performed immediately following the baseline 
magnetic resonance scan over at least 15 min using a concen-
tration of 2–8 mg/mL, diluted in 0.9% saline or 5% dextrose. 
Haemodynamic monitoring was conducted throughout.
Study protocol
MRI and tissue histology were performed as described in the 
online supplementary material. A variable study protocol was 
used that was purposely designed for imaging at different time 
points after acute MI. Over a 3-month period following MI, 
patients received up to seven MRI scans and up to three infu-
sions of USPIO. Two principal analyses were performed using 
data from the same participants.
First, to assess the duration of a single dose of USPIO, R2* 
values of only the participants who first received USPIO within 
7 days of MI (21/30) were included in this analysis. They were 
followed on all subsequent MRI scans prior to receiving any 
further doses of USPIO (figure 1A). On receiving further USPIO, 
data were censored from the point of the second USPIO admin-
istration, hence the reduction in numbers during the course of 
the study.
Second, to assess the duration of myocardial macrophage 
activity, USPIO uptake was compared using repeated USPIO 
infusions over the 3-month follow-up period. All patients 
were included in this analysis. USPIO uptake was calculated 
by subtracting the baseline R2* value from values obtained at 
24 hours following USPIO infusion (figure 1B). This allowed 
repeated assessment of myocardial USPIO uptake.
Following clinical guidance for the administration of feru-
moxytol, participants were allowed a maximum of two doses 
of USPIO in a 1-month period, and a total of three over the 
3-month follow-up period to prevent iatrogenic iron over-
load. Therefore, USPIO-enhanced data were collected up to 
three times for each patient, and it was not possible to perform 
repeated USPIO-enhanced imaging at every time point in the 
same patient.
Finally, to assess myocardial oedema, T2 values were 
compared on unenhanced scans (prior to and at least 7 days 
following USPIO administration). All patients were included in 
this analysis.
Image analysis
All T2*-weighted multigradient-echo images for each patient 
were analysed using Circle CVI software (Circle CVI42, 
Canada). An experimentally determined threshold used in 
previous work7 for the coefficient of determination (r2>0.85) 
was used to exclude data that did not have an acceptable expo-
nential decay when signal intensity was plotted against echo 
time. The relaxation rate, R2*, is the inverse of the mean T2*, 
and was calculated to assess the uptake of USPIO for each region 
Figure 1 (A) Duration and distribution of USPIO enhancement after single-dose administration in the first week after MI. (B) Repeated myocardial 
uptake of USPIO following MI. MI, myocardial infarction; USPIO, ultrasmall superparamagnetic particles of iron oxide.
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of interest (ROI), where the higher the value, the greater the 
USPIO accumulation.
Late gadolinium enhancement (LGE), ventricular volume 
and functional analyses were determined manually using 
QMass software (Medis Medical Imaging Systems, Leiden, The 
Netherlands).
ROI selection
LGE images at the 3-month time point were used to determine the 
distribution and anatomy of the myocardial infarct, and served 
as reference images to which each series of T2 and T2* scans 
at each separate visit could be visually coaligned. This allowed 
myocardial ROIs to be selected on the reference short-axis LGE 
images and manually applied to T2* images corresponding to 
(1) infarct zone (defined by the short axis slice showing greatest 
LGE volume), (2) peri-infarct zone (half segment width imme-
diately adjacent to LGE), and (3) remote myocardium (at least 
half segment width, opposite the infarct zone on the same short 
axis slice, and at least one full segment clear of any LGE). Other 
selected regions included (4) liver, (5) spleen, (6) bone marrow, 
(7) kidney, (8) blood pool, (9) aortic wall (inside arch) and (10) 
skeletal muscle.
T2 values were measured immediately prior to USPIO 
administration. USPIO-enhanced data were collected 24 hours 
following USPIO administration.
Statistical analysis
All statistical analyses were performed with GraphPad Prism, 
V.6 (GraphPad Software, San Diego, California, USA). To 
assess the duration of USPIO enhancement in tissues following 
single administration in the first week after MI, R2* values on 
subsequent MRI scans (prior to any further USPIO dosing) were 
compared using one-way analysis of variance (ANOVA) with 
Tukey’s post hoc test for multiple comparisons.
To assess variation and duration of myocardial inflammation, 
USPIO uptake (R2* increase from pre to 24 hours following 
USPIO) was compared using one-way ANOVA with Tukey’s post 
hoc test for multiple comparisons (repeated measures where 
appropriate). As a further method to assess USPIO accumula-
tion within the heart, post-USPIO R2* 24 hours after adminis-
tration (without baseline R2* subtraction) was compared in the 
same way.
Finally, to assess variation and duration of myocardial oedema, 
T2 values for infarct, peri-infarct and remote myocardium were 
compared again using one-way ANOVA with Tukey’s post hoc 
test for multiple comparisons (repeated measures where appro-
priate). Statistical significance was defined as two sided, p<0.05.
RESULTS
Thirty-one patients were recruited although 1 patient was 
excluded due to claustrophobia. A total of 147 MRI scans and 
54 infusions of ferumoxytol were completed during the course 
of the study. Administration of ferumoxytol was well tolerated 
with no adverse reactions reported during or immediately after 
administration.
Participants were predominantly middle-aged men with 
current or previously diagnosed hypercholesterolaemia or 
smoking habit (table 1). Around half of the participants were 
hypertensive and had a family history of premature coronary 
heart disease. Twenty-five patients had ST-segment elevation 
MI, 5 patients had non-ST-segment elevation MI, 26 underwent 
percutaneous coronary intervention, and 4 had coronary artery 
bypass grafting (CABG) surgery. The mean elevation in plasma 
troponin was 31 200 ng/L.
Enhancement after single USPIO dose
Twenty-one of the 30 participants received USPIO in the first 
week after MI and were included in this analysis.
USPIO was detected by an increase in R2* in all myocardial 
regions, blood pool, kidney and aortic wall until 24 hours, being 
cleared by 4–9 days (figure 2, online supplementary figure 1 
and online supplementary table 1). USPIO was detected in bone 
marrow until 4–9 days and in liver and spleen until 13–21 days. 
There was no change in R2* following USPIO infusion in skel-
etal muscle.
Myocardial biopsies were taken from three of four patients 
undergoing CABG and revealed an abundance of inflammatory 
cells and early granulation tissue in keeping with a region of 
healing myocardium from around the infarct zone. Histological 
staining revealed colocalisation of the presence of iron (Prussian 
blue) and macrophages (CD68). No staining for iron or macro-
phages was seen within the adjacent regions of healthy myocar-
dium (figure 2).
Time course of enhancement with repeated USPIO 
administration
There were no differences in baseline (pre-USPIO) R2* value 
between infarct and remote myocardium at all time points. Time 
course variation in USPIO uptake was seen in the infarct zone 
over the 3-month period, peaking at days 2 and 3 (figures 3a, 4 
and online supplementary table 2a). There was no time course 
variation in USPIO uptake in the peri-infarct and remote 
myocardium or extra-cardiac tissues over the 3-month follow-up 
period.








Diabetes mellitus 8 (27)
Hypercholesterolaemia 27 (90)
Family history 14 (47)











Baseline ejection fraction (%) 48.5±11.2
Infarct size (% of LV mass) 31.6±19.5
Infarct volume (mL) 43.9±27.5
Plasma troponin (ng/L) 31 229±18 563
Subsequent CABG/biopsy) 4/3
Mean±SD, N (%). 
CABG, coronary artery bypass grafting; LV, left ventricle; NSTEMI, non-ST-elevation 
myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation 
myocardial infarction.
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Compared with remote myocardium, greater USPIO uptake 
was seen in the infarct zone until days 10–16 (mean +56 s−1; 
95% CI 33 to 79; p<0.001, +47 s−1; 95% CI 31 to 62; p<0.0001, 
and +33 s−1; 95% CI 4 to 61; p<0.05 at 2–3 days, 4–7 days and 
10–16 days, respectively) but not thereafter (figure 3a). Simi-
larly, comparing R2* 24 hours following USPIO (without base-
line R2* subtraction), greater USPIO uptake was again evident 
in infarct myocardium compared with remote myocardium until 
10–16 days (mean +60 s−1; 95% CI 33 to 86; p<0.01, +49 s−1; 
95% CI 21 to 77; p<0.01, and +45 s−1; 95% CI 2 to 87; p<0.05 
at 2–3 days, 4–7 days and 10–16 days, respectively, figure 3b and 
online supplementary table 2b).
Assessment of myocardial oedema using T2 mapping
Following acute MI, time course variation in infarct and peri- 
infarct T2 values was seen (see figure 5 and online supplemen-
tary table 3). No time course variation in T2 value was seen 
Figure 2 Histology section of trucut biopsy from infarcted myocardium. (A) Haematoxylin and eosin (×5 magnification) stain displaying a thin 
region of viable healthy myocardium (strip of dark pink) surrounded by infarcted myocardium (lighter pink). (D) Infarcted myocardium shows an 
abundance of inflammatory cells and early granulation formation. (B) Prussian blue (×5) staining revealing intracellular iron (E, ×20 and G, ×50), not 
seen in the region of healthy myocardium. (C) CD68 (×5) staining revealing macrophages within the infarcted myocardium (F, ×20 and H, ×50), again 
not seen in healthy myocardium. G+H show colocalisation of iron within macrophages.
Figure 3 (A) USPIO uptake in myocardium after MI with repeated USPIO administration. (B) R2* 24 hours following USPIO (without subtraction of 
baseline values). Time course variation in USPIO uptake was seen in the infarct zone peaking at days 2 and 3. No variation of USPIO uptake was seen 
in peri-infarct and remote myocardium. Compared with remote myocardium, increased USPIO uptake was seen in the infarct zone until days 10–16 
post MI. (****p<0.0001, ***p<0.001, **p<0.01, *p<0.05). Compared with remote myocardium, greater post-USPIO R2* was seen in the infarct 
zone until days 10–16 post MI. (***p<0.001, **p<0.01, *p<0.05). A+B: n = 11 (days 2–3, 4–7 and 17–25), 10 (days 10–16) and 10 (days 78–99). 
MI, myocardial infarction; USPIO, ultrasmall superparamagnetic particles of iron oxide.
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in remote myocardium. Compared with remote myocardium, 
greater myocardial T2 value was detected in the infarct zone 
and remained present throughout the 3-month follow-up period 
(mean +12 ms, 95% CI 7 to 18, p<0.001; +14 ms, 95% CI 9 
to 18, p<0.0001; +15 ms, 95% CI 6 to 24, p<0.01; +12 ms, 
95% CI 5 to 19, p<0.01 and +6 ms, 95% CI 2 to 9, p<0.01 at 
days 1–2, 3–9, 10–16, 17–24 and 77–98, respectively).
DISCUSSION
For the first time, we have simultaneously investigated cellular 
inflammation and tissue oedema for 3 months following acute 
MI using USPIO-enhanced T2* and T2-mapping MRI. We 
have demonstrated that while tissue oedema persists for at 
least 3 months, cellular inflammation in the infarct zone is 
transient and lasts for only 2 weeks following MI. The time 
course of USPIO uptake following MI demonstrates a pattern 
of macrophage inflammation that is distinct to tissue oedema 
caused by the loss of capillary integrity. This suggests that while 
capillary integrity may take several months to resolve, cellular 
inflammation and specifically macrophage activity predominates 
in the first 2 weeks following MI.
USPIO can be used as an MRI contrast agent as it is 
immediately apparent in the blood pool following intravenous 
administration.12 Tissue enhancement with USPIO following 
inflammation has been suggested to occur as a result of either 
partitioning of USPIOs into the tissues because of the loss of 
capillary integrity alone or as a result of macrophage phago-
cytic activity clearing tissue-resident particles.8 We here provide 
confirmatory evidence that USPIO enhancement predominantly 
occurs as a result of cellular inflammation within the myocar-
dium. We used T2 mapping to describe the loss of capillary 
integrity following MI. Using this comparator, we demonstrate 
that there is a discontinuity between the prolonged (up to 3 
months) T2-defined time course of tissue oedema, and the brief 
(first 2 weeks) T2*-defined time-limited cellular inflammation. 
This observed USPIO uptake in the infarct zone for up to 2 
weeks following MI is consistent with data from previous studies 
demonstrating that tissue-resident macrophages are active and 
Figure 4 Examples of myocardial oedema and USPIO enhancement in the infarct zone after MI. Three examples of MI (1—anteroseptal, 2—lateral 
and 3—inferior) illustrating LGE, USPIO enhancement (R2* map) and oedema (T2 map) at early (up to 10 days) and late (3 months) time points. 
Early inflammation and oedema seen on R2* (dark region) and T2 maps (light region), respectively, have improved or resolved by 3 months. LGE, late 
gadolinium enhancement; MI, myocardial infarction; USPIO, ultrasmall superparamagnetic particles of iron oxide.
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predominate within the infarcted myocardium in the first 2 
weeks after MI.3 5 In addition, we obtained myocardial biopsies 
in patients undergoing CABG surgery within 2 weeks of MI and 
24 hours after USPIO administration. We demonstrated marked 
colocalisation of iron staining with tissue-resident macrophages 
in infarcted but not in non-infarcted tissue. It is not possible to 
resolve specific USPIOs on histology, and we cannot discount 
the possibility that there is some contribution from postinfarct 
haemosiderin staining. However, we would contend that the 
majority of iron staining is attributable to USPIO uptake given 
the selective, transient and marked R2* enhancement on MRI, 
and the relatively constant contribution from haemosiderin 
during the period of assessment. Moreover, we did not detect 
substantial quantities of iron that were free in the extracel-
lular space and were not associated with areas of macrophage 
infiltration.
Following a single infusion in the first week after MI, USPIO 
enhancement is seen in all regions of the myocardium, but 
greatest within the infarct zone, after 24 hours. USPIO enhance-
ment is also observed until 4–9 days in bone marrow and until 
13–21 days in the liver and spleen. Therefore, the duration 
of USPIO enhancement is longest in the mononuclear phago-
cyte-rich reticuloendothelial system. It is likely that resident 
phagocytes within these organs ingest USPIOs from circulating 
blood. Efflux of myocardial macrophages containing USPIO 
may also contribute to the reticuloendothelial system T2* signal. 
Ultimately, once within macrophages, the iron oxide core is 
broken down by lysosomes, providing a supply of iron ions for 
haemoglobin synthesis.13 14
The observed duration of enhancement following a single 
infusion of USPIO in tissues helped guide the minimum time 
interval between repeated USPIO administrations. Complete 
washout of the previous dose of USPIO, allowing baseline R2* 
to return to normal, is required to reassess uptake of USPIO 
accurately, without influence from previous USPIO administra-
tion. We have shown that USPIO is no longer detectable in the 
myocardium at 1 week following intravenous administration, 
and we suggest that 1 week is the minimum interval between 
repeated doses of USPIO.
USPIO is detectable in the peri-infarct and remote myocar-
dium, kidney and aortic wall at 24 hours following administra-
tion. However, the amplitude of R2* change is less than that of 
blood pool, suggesting this is likely to be due to a diluted effect 
of blood-pool USPIO and not macrophage uptake of USPIO 
Figure 5 T2 value in the myocardium after MI. Time course variation 
in infarct and peri-infarct T2 was seen in the 3-month period following 
MI, both peaking at days 3–9. Compared with remote myocardium, 
higher T2 was seen in the infarct zone throughout the duration of the 
study and in the peri-infarct zone until days 17–24 (****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05); n = 15 (days 1–2), 14 (days 3–9 and 
77–98), 8 (days 10–16) and 10 (days 17–24). MI, myocardial infarction.
Figure 6 USPIO enhancement after single-dose administration in the first week following MI. Following single-dose administration, USPIO 
enhancement was detected in all myocardial regions at 24 hours. USPIO was detected in bone marrow until 4–9 days, and spleen and liver until 
13–21 days (****p<0.0001, ***p<0.001, *p<0.05); n = 21 (baseline, 24 hours), 11 (days 4–9), 15 (days 13–21) and 5 (days 78–99). MI, myocardial 
infarction; USPIO, ultrasmall superparamagnetic particles of iron oxide.
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within these tissues. Although there appears a trend to suggest 
that the peri-infarct zone displays an early relative increase in 
USPIO uptake compared with remote myocardium, this failed to 
reach statistical significance.
Previous studies have suggested that the remote myocar-
dium may exhibit USPIO and macrophage accumulation.7 8 15 
We have shown here that there is no time course variation in 
USPIO uptake in remote myocardium after MI, and the small 
R2* increase following USPIO is likely to be reflective of intra-
vascular capillary-bed blood-pool USPIO rather than more wide-
spread macrophage activity throughout the myocardium. This is 
consistent with our recent report of similar R2* increases in the 
myocardium of healthy volunteers which we again attribute to 
the blood pool signal of USPIO.16
Although no patients in this study displayed imaging evidence 
of myocardial haemorrhage, we were able to account for the 
presence of microscopic iron due to haemorrhage by subtracting 
baseline R2*. Therefore, any R2* increase detected is due to 
accumulation of USPIO and not iron from myocardial haem-
orrhage. We acknowledge that intramyocardial haemorrhage 
occurring between the pre and 24 hours post USPIO scans could 
theoretically increase R2*, but the earliest we imaged patients 
was at least 24 hours after MI, by which time haemorrhage is 
likely to have taken place.
We chose T2 mapping to assess myocardial oedema as it 
provides improved sensitivity and addresses some of the problems 
with subjective image interpretation using traditional T2-weighted 
techniques.17 18 The finding of ongoing myocardial oedema in the 
infarct zone at 3 months after MI may at first appear surprising. 
However, several groups have described the long-lasting presence 
of myocardial oedema, often up to 6 months after MI.19 20 This 
suggests that it may take many months for complete resolution of 
injury and return of normal vascular homeostasis and function.
What are the clinical applications of our technique? We have 
here used the ‘model’ of acute MI and demonstrated the predicted 
time course of tissue-resident macrophage uptake using USPIOs. 
We therefore suggest that this technique has utility in defining 
the extent of myocardial cellular inflammation that has potential 
utility in risk stratification. Perhaps more importantly, USPIO-en-
hanced MRI may prove a useful tool to assess the response to novel 
anti-inflammatory interventions targeted at reducing myocardial 
cellular inflammation to improve clinical outcomes. Such a study 
was carried out at our centre and has recently been published.21 
Currently, there is no USPIO licensed as a contrast agent for 
routine clinical MRI, which limits its widespread use. However, 
the most exciting application would be to extend this technique to 
help diagnose, monitor disease progression and assess therapeutic 
intervention in myocardial diseases associated with and mediated 
by macrophage infiltration. Such diseases include myocarditis, 
cardiac transplant rejection and cardiac sarcoidosis, and a multi-
centre study is currently under way to assess this (EUDRACT 
2013-002336-24). This would be important given the lack of 
simple definitive diagnostic tests in these conditions, the challenges 
of unreliable cardiac biopsies, and the need for rapid assessments 
of disease progression and therapeutic interventions.
In conclusion, we have successfully imaged, quantified and 
validated macrophage inflammation and myocardial oedema 
over 3 months in patients following MI using USPIO-enhanced 
T2* MRI and T2 mapping. This technique can provide a 
non-invasive method for the diagnosis and monitoring of tissue 
inflammatory macrophage activity in the heart. It also provides 
a potential platform on which to assess existing and novel thera-
peutic interventions that might modify the inflammatory process 
after MI and in other inflammatory processes affecting the heart.
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ABSTRACT
Objectives Ultrasmall superparamagnetic particles of 
iron oxide (USPIO)-enhanced MRI can detect tissue-
resident macrophage activity and identify cellular 
inflammation within tissues. We hypothesised that 
USPIO-enhanced MRI would provide a non-invasive 
imaging technique that would improve the diagnosis and 
management of patients with acute myocarditis.
Methods Ten volunteers and 14 patients with 
suspected acute myocarditis underwent T2, T2* and late 
gadolinium enhancement (LGE) 3T MRI, with further T2* 
imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) 
infusion, at baseline and 3 months. Myocardial oedema 
and USPIO enhancement were determined within areas 
of LGE as well as throughout the myocardium.
Results Myocarditis was confirmed in nine of the 
14 suspected cases of myocarditis. There was greater 
myocardial oedema in regions of LGE in patients with 
myocarditis when compared with healthy volunteer 
myocardium (T2 value, 57.1±5.3 vs 46.7±1.6 ms, 
p<0.0001). There was no demonstrable difference in USPIO 
enhancement between patients and volunteers even within 
regions displaying LGE (change in R2*, 35.0±15.0 vs 
37.2±9.6 s−1, p>0.05). Imaging after 3 months in patients 
with myocarditis revealed a reduction in volume of LGE, a 
reduction in oedema measures within regions displaying 
LGE and improvement in ejection fraction (mean −19.7 mL, 
95% CI (−0.5 to −40.0)), −5.8 ms (−0.9 to −10.7) and 
+6% (0.5% to 11.5%), respectively, p<0.05 for all).
Conclusion In patients with acute myocarditis, USPIO-
enhanced MRI does not provide additional clinically 
relevant information to LGE and T2 mapping MRI. This 
suggests that tissue-resident macrophages do not 
provide a substantial contribution to the myocardial 
inflammation in this condition. Clinical trial registration 
NCT02319278; Results.
INTRODUCTION
Acute myocarditis comprises a wide clinical spec-
trum from subclinical disease to severe heart 
failure and is a major cause of sudden death in 
young adults.1 Pathologically, it is characterised 
by inflammatory cell infiltration of the myocar-
dium with evidence of myocyte necrosis that is not 
characteristic of an ischaemic aetiology.2 Causes of 
myocarditis include infections, immune-mediated 
injury and toxins (such as anthracyclines) although 
frequently no cause is identified.3
A variety of inflammatory cells infiltrate the 
myocardium during myocarditis. In viral myocar-
ditis, the infiltrate is predominantly lymphocyte 
rich, but other cells including plasma cells, neutro-
phils, eosinophils, giant cells and macrophages 
are also present.2 4–9 Monocytes differentiate into 
macrophages at sites of myocarditis, suggesting that 
they play an important role in the injury or repair 
of the myocardium.10
Endomyocardial biopsy is considered the gold 
standard investigation for diagnosis. However, this 
is prone to sampling error and is uncommon in 
routine clinical practice.3 Cardiac MRI plays a key 
role in the diagnosis and shows typical appearances 
on T2-weighted and late gadolinium enhance-
ment (LGE) imaging according to the Lake Louise 
Criteria.11 More recently, quantitative mapping 
techniques appear to improve diagnostic accuracy 
further.12
Iron oxide nanoparticles are generating 
interest as an MRI contrast agent able to detect 
macrophages, and clinical applications are now 
emerging.13–21 Ultrasmall superparamagnetic 
particles of iron oxide (USPIO) consist of an 
iron oxide core surrounded by a carbohydrate or 
polymer coating. They are small enough to extrav-
asate passively through capillaries, where they are 
engulfed by tissue-resident macrophages22 and are 
detectable by T2*-weighted MRI. Thus, USPIO-en-
hanced MRI can identify tissue-resident macro-
phage activity and identify cellular inflammation 
within tissues.
In a promising preclinical study of autoimmune 
myocarditis,23 iron nanoparticles were ingested by 
inflammatory cells and improved distinction of 
areas with severe inflammation on MRI compared 
with conventional T2-weighted and gadolinium-en-
hanced MRI. We aimed to assess and quantify 
myocardial USPIO enhancement in acute myocar-
ditis and to correlate enhancement with clinical 
measures of inflammation and oedema using 
T2 mapping and LGE MRI and compare these 
measures with healthy volunteers.24 We hypoth-
esised that USPIO-enhanced MRI would detect 
myocardial macrophage activity in myocarditis and 
provide a cellular-specific non-invasive imaging 
technique that may aid and improve patient diag-
nosis and management.
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METHODS
Patients were recruited from a single centre as part of an open-
label observational multicentre cohort study ( ClinicalTrials. gov 
(NCT02319278); Results). The study was performed in accor-
dance with the Declaration of Helsinki, the approval of the Scot-
land A Research Ethics Committee and the written informed 
consent of all participants. The Medicines and Healthcare prod-
ucts Regulatory Authority of the UK gave Clinical Trial Authori-
sation for the study (EUDraCT 2013-002336-24).
Study populations
Adult (>18 years of age) patients with suspected acute 
myocarditis were recruited into the study. The clinical diag-
nosis was made by an independent clinical cardiologist based 
on the history, ECG, serum troponin (ARCHITECT STAT 
troponin I assay, Abbott Laboratories, Illinois, USA) and other 
available imaging modalities. The diagnosis of myocarditis 
was verified from case note review by an independent cardi-
ologist and retained for analysis if the MRI scan (reported 
and agreed by two independent radiologists) showed imaging 
features of myocarditis on LGE and/or T2 mapping.11 Healthy 
volunteers had no clinically significant medical history. Exclu-
sion criteria were contraindication to MRI or ferumoxytol 
infusion, any other inflammatory comorbidity, renal failure 
(estimated glomerular filtration rate <30 mL/min/1.73 m2), 
pregnancy, breast feeding and women of childbearing poten-
tial without reliable contraception.
Study protocol
Patients with suspected myocarditis and healthy volunteers 
underwent paired MRI scans at baseline, and patients were 
invited to return for repeat imaging after 3 months.
MRI
MRI was performed using a MAGNETOM Verio 3T MRI 
scanner running software V.VB17 (Siemens Healthcare, 
Erlangen, Germany), with a dedicated cardiac array coil. All 
images were acquired using ECG-gated breath holds. Routine 
steady state free precession (TrueFISP) sequences were used to 
acquire long-axis and short-axis images of the heart. Oedema 
imaging was conducted using a Siemens T2 mapping based 
on a prototype T2-prepared TrueFISP acquisition acquiring 
identical long-axis and short-axis slice positions. Quantitative 
USPIO imaging was performed in similar slice positions using 
a prototype T2*-weighted multigradient-echo acquisition 
using a volumetric shim applied over the entire heart volume. 
Standard cardiac slice widths (6 mm width with 4 mm gap) 
and eight echo times (2.1–17.1 ms range) with matrix size of 
256×115 were acquired for T2* maps. The in-plane resolu-
tion differed as required for larger or smaller objects; gener-
ally, a field of view of 400×300 mm was used with an in-plane 
resolution of 2.6×1.6 mm. T2* relaxation times were calcu-
lated before and after administration of USPIO.
Immediately after the baseline T2, T2* and TrueFISP cine 
imaging, breath-held inversion recovery sequences in long-axis 
and short-axis planes were used to acquire late enhancement 
images following an intravenous administration of gadolinium 
contrast medium (0.1 mmol/kg; Gadovist, Bayer, Germany). 
Optimal inversion time (TI) was determined on a slice-by-slice 
basis using standard late-enhancement TI-scout protocols. The 
inversion-recovery late-enhancement short-axis slices were 
acquired using similar slice positions as the T2 and T2* imaging.
USPIO
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg; Rienso, 
Takeda Italia, Italy) was performed immediately following the 
baseline magnetic resonance scan over 15 min using a concen-
tration of 2–8 mg/mL, diluted in 0.9% saline or 5% dextrose. 
Haemodynamic monitoring was conducted throughout.
Image analysis
All T2*-weighted multigradient echo images for each patient 
were analysed using Circle CVI software (Circle CVI42, 
Canada). An experimentally determined threshold used in 
previous work14 for the coefficient of determination (r2>0.85) 
was used to exclude data that did not have an acceptable expo-
nential decay when signal intensity (SI) was plotted against echo 
time. Individual images affected by artefact were excluded. The 
inverse of the mean T2* (R2*) for each regions of interest (ROI) 
was then calculated to assess the uptake of USPIO, where the 
higher the value, the greater the USPIO accumulation.
T2 mapping, LGE, ventricular volume and functional anal-
yses were also performed using Circle CVI software. T2 and T2* 
data were collected immediately prior to USPIO administration. 
USPIO-enhanced T2* data were collected 24–25 hour following 
ferumoxytol administration.
ROI selection
ROI were drawn using the standard 16-segment cardiac model25 
and panmyocardial values averaged using all 16 segments. As 
a final method of analysis to focus on inflamed myocardium, 
regions with contiguous LGE>1 cm2 on a single short-axis slice 
were retained and visually coaligned with corresponding T2 and 
T2* images. These corresponding coaligned regions were then 
averaged to form LGE+T2 and T2* regions.
Statistical analysis
All statistical analysis was performed with GraphPad Prism V.6 
(GraphPad Software, San Diego, California, USA). Shapiro-Wilk 
normality testing was carried out prior to testing. To compare 
USPIO uptake and myocardial oedema in patients and volun-
teers, R2* and T2 values were compared using paired and 
unpaired t-tests, Mann-Whitney and Wilcoxon tests depending 
on pairing and normality of data. To compare results at 3 months 
with baseline, a paired t-test was used. Statistical significance was 
defined as two-sided p<0.05.
RESULTS
Ten volunteers and 14 patients with suspected myocarditis were 
recruited. Nine patients had confirmed myocarditis according to 
imaging criteria and independent review. Baseline imaging was 
conducted within a week of diagnosis. Four patients had alter-
native diagnoses (takotsubo cardiomyopathy (n=2), lung cancer 
(n=1), polymyositis (n=1)) and one patient had an incidental 
finding of an unknown chest wall metallic implant. These five 
patients were excluded from further analysis. All nine patients 
retained for analysis had typical features of myocarditis on LGE 
imaging. Of these nine patients, one patient did not return at 
baseline for the 24 hours post-USPIO scan. Seven of the nine 
patients returned at 3 months for repeat imaging.
The healthy volunteer group was older with greater ejection 
fraction than the myocarditis group at baseline (p<0.001 for both, 
table 1). Patients with myocarditis had greater neutrophil count, 
C-reactive protein (CRP) and serum troponin concentrations 
than volunteers (p<0.05, p<0.01 and p<0.0001, respectively). 
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There were no other significant differences between participant 
groups at baseline.
Administration of ferumoxytol was well tolerated with no 
adverse reactions reported during or immediately after adminis-
tration in any of the participants.
USPIO enhancement
At baseline, there were no differences in R2* values between 
healthy volunteers and patients with myocarditis (panmyocar-
dium and LGE+ regions; Figures 1, 2). After USPIO adminis-
tration, the R2* in all three groups increased but there was no 
difference in either the change in or post-USPIO, R2* between 
the groups (figure 2 and table 2).
Myocardial oedema
There was no difference in panmyocardial T2 between volun-
teers and patients with myocarditis. Regions displaying LGE in 
myocarditis patients had higher T2 than panmyocardial values 
for both healthy volunteers and patients with myocarditis 
(p<0.0001 and p<0.01, respectively; figure 2 and table 2).
Baseline versus 3-month imaging in patients with myocarditis
There were no changes in myocardial USPIO uptake between 
baseline and 3 months either on panmyocardial analysis 
(mean +7.6 s−1 95% CI (−4.8 to 19.9)) or in regions with LGE 
(−4.2 s−1 (−21.9 to 13.5), p>0.05 for both; figure 3). Panmyo-
cardial T2 did not change over 3 months (−1.1 (-5.8 to 3.5), 
p>0.05). Volume of LGE and T2 within regions displaying LGE 
reduced over the 3-month period (−19.7 mL (−0.5 to −40.0) 
and −5.8 ms (−0.9 to −10.7), respectively, p<0.05 for both). 
Ejection fraction increased over the 3-month period (+6% (0.5 
to 11.5), p<0.05).
DISCUSSION
For the first time, we report the combined assessment of myocar-
ditis using LGE, T2 mapping and USPIO-enhanced T2* MRI. 
USPIO-enhanced T2* MRI has previously been used in man to 
assess cardiovascular inflammation in a range of different condi-
tions,14 16 21 26 with preliminary positive results from a rodent 
model of myocarditis. This raised hope that USPIO-enhanced 
T2*MRI might add useful cell-specific clinical information in 
patients with myocarditis. However, while we found typical 
features of myocarditis using standard imaging with LGE and 







Number 10 9 7
Female 6 1 1
Age (years) 50 (45–53) 28 (24–34)*** 25 (23–35)
Body mass index (kg/m2) 26 (23–29) 25 (22–29) 25 (22–27)







  ST elevation 7
  T-wave inversion 1
  Normal 1
Coronary angiogram n/a 4/9
  Normal 4
Echo n/a 8/9
  Wall motion 
abnormality
4
  Normal 4
Blood tests
  White cell count 
(×109/L)
5.8 (4.2–7.1) 7.1 (6.1–8.9) 5.1 (4.6–5.6)
  Neutrophil count 
(×109/L)
3.2 (2.2–4.2) 4.4 (3.7–5.2)* 2.8 (2.7–3.5)
  Lymphocyte count 
(×109/L)
1.7 (1.4–2.1) 1.8 (1.3–2.2) 1.8 (1.2–1.9)
  Monocyte count 
(×109/L)
0.4 (0.3–0.7) 0.6 (0.5–0.8) 0.4 (0.3–0.5)
  C-reactive protein 
(mg/L)
1.0 (1.0–2.5) 38(14-63)** 2.0 (1.0–2.0)
  Troponin (ng/L) 2.0 {1.5–4.0) 1 21 842 (3950–
25 722)****
4.0 (2.0–6.0)
Mean±SD or median (IQR).
* p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 (compared with volunteers at 
baseline).
Figure 1 Images of patient with myocarditis. Three chamber and 
basal short-axis images of a patient with myocarditis displaying patchy 
posterolateral late gadolinium enhancement (LGE) (white regions, 
arrowed) that correspond to oedematous regions of myocardium on 
the T2 map (lighter regions, arrowed). There is no uptake of ultrasmall 
superparamagnetic particles of iron oxide (USPIO) in the post-USPIO 
R2* maps; corresponding regions may even have lower R2* in this 
patient. Myocardial oedema appears to normalise but subtle LGE 
remains at 3 months.
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T2 mapping cardiovascular magnetic resonance (CMR), we did 
not detect USPIO enhancement within the myocardium of our 
patients. This suggests that USPIO-enhanced MRI provides no 
additional diagnostic value in these patients and that tissue-res-
ident macrophages are not a major contributor to the cellular 
inflammation following acute myocarditis.
Our case study population of nine patients were excellent 
examples of myocarditis. They were young, with significantly 
elevated levels of systemic inflammatory markers, including 
neutrophil count, CRP and cardiac-specific high-sensitivity 
troponin, and all had typical features of myocarditis on CMR 
reported by two independent clinical radiologists. Most patients 
had ECG changes suggesting significant myocyte injury and 
several had normal coronary angiograms. All patients that did 
not have a coronary angiogram did not have any risk factors for 
coronary artery disease. We detected MRI features of myocar-
ditis in every patient. LGE was discontinuous in nature and 
generally epicardial and subepicardial in distribution, but could 
be found in the midwall and occasionally in the subendocar-
dium. LGE was never found in the subendocardium alone or 
confined to one coronary territory that would be more sugges-
tive of myocardial infarction. In keeping with the typical distri-
bution of myocarditis, most patients displayed LGE in the infe-
rior, posterior and lateral walls. We are therefore confident that 
the diagnosis of myocarditis was robust in all patients, and an 
independent cardiologist verified this.
Myocardial oedema was easily visualised, and indeed quan-
tified, using T2 mapping (Figure 2). We found intense myocar-
dial oedema in our myocarditis cohort with maximal T2 
values approaching 70 ms on T2 mapping. Within regions 
displaying LGE (LGE+), there was a profound increase in T2 
when compared with volunteers. This signal was so powerful 
that a trend remained evident when comparing panmyocardial 
T2 values to those of volunteers, although the difference was 
not statistically significant. Seven patients returned for repeat 
imaging assessment at 3 months, where we recorded an improve-
ment in clinical features: a reduction in the volume of LGE (by 
around 50%), a reduction in oedema within inflamed (LGE+) 
regions and an overall improvement in ejection fraction.
We were unable to detect USPIO accumulation in our cohort 
of patients with myocarditis. We know that macrophages can 
be present in myocarditis, although they are generally not the 
predominant cell type. It is possible that patients within our 
group had predominantly lymphocytic or neutrophil-rich cell 
infiltrate and the finding of greater levels of neutrophils in 
patients with myocarditis at baseline may support the latter. The 
clinical care team did not feel that endomyocardial biopsy was 
justified in any of the cases, and lack of histological data is clearly 
a limitation. In recent work, we have detected USPIO-laden 
macrophages in patients with recent myocardial infarction and 
demonstrated macrophage uptake of USPIOs in biopsies taken 
at the time of cardiac surgery.13 We therefore acknowledge that 
while some USPIO-laden macrophages may have been present in 
patients with myocarditis, there were either insufficient numbers 
of macrophages or USPIO engulfment was inhibited or deficient. 
Ultimately, USPIO-enhanced T2* CMR was unable to demon-
strate increased macrophage activity and lacked sensitivity for 
detecting myocarditis.
A further contributory reason for failure to detect USPIO 
enhancement within inflamed regions may be due to diffi-
culties encountered in USPIO-enhanced T2* imaging. These 
are discussed in greater detail elsewhere,24 but artefact due 
to breathing and in particular, ‘blooming’ artefacts from the 
vascular organs of the lungs, liver and stomach can be prob-
lematic. This can make analysis more challenging by having 
to exclude the affected later echo times from T2* decay curve 
fitting. Indeed, ‘blooming’ artefacts from nearby tissues and 
organs most commonly affect the inferior and lateral walls, 
Figure 2 Myocardial USPIO enhancement vs Oedema at Baseline. Changes in myocardial R2* due to USPIO accumulation (A, left) and myocardial 
oedema by T2 mapping (B, right) are shown in healthy volunteers (HV) and patients with myocarditis (M) using panmyocardial average, and further 
limited to regions displaying LGE in patients with myocarditis (M LGE+).There were no significant differences in ΔR2* due to USPIO accumulation 
between all groups (p>0.05 for all). There was no difference in panmyocardial T2 between volunteers with patients with myocarditis. Myocardial 
regions displaying LGE (M LGE+) had greater T2 than the panmyocardial value for healthy volunteers and myocarditis patients (****p<0.0001 and 
**p<0.01 respectively).



















T2 (ms) 46.7±1.6 48.9±3.1 57.1±5.3****
Mean±SD.
****p<0.0001 (compared with volunteers).
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which is the usual site of inflammation in myocarditis. There-
fore, the myocardial regions of greatest interest were often the 
most difficult to analyse although this can usually be overcome.24 
This may go some way to explain why there is greater spread 
of R2* data in patients with myocarditis, especially in LGE+ 
regions. Finally, patients with myocarditis often had symptoms 
of pleurisy and pericarditis, and despite adequate analgesia, 
often found the long breath holding required for T2* imaging 
difficult.
Some final limitations also deserve mention. First, the sample 
size was small, but numbers in this pilot study were sufficient 
to show that USPIO-enhanced T2* CMR fails to add clinically 
relevant information to CMR imaging parameters of LGE and 
T2 mapping for individual patients. Second, the control volun-
teer group was not age or sex matched but we have no reason 
to believe that this influenced the results. Lastly, myocardial 
geometry is affected by several factors that vary between scans 
such as the presence of tissue oedema, heart rate and blood 
volume status and accurate coregistration can be challenging.
Despite these results, USPIO-enhanced imaging still holds 
promise as a non-invasive imaging method for the diagnosis and 
monitoring of tissue inflammatory macrophages in the heart. 
We have recently found that USPIO-enhanced MRI can detect 
and serially monitor macrophages after myocardial infarction 
(MI)13 and work is under way at our centre as part of this project 
(NCT02319278) to assess the value of this technique in diag-
nosing cardiac sarcoidosis and cardiac transplant rejection. If 
successful, USPIO-enhanced MRI may provide a platform on 
which to assess existing and novel therapeutic interventions that 
might modify the inflammatory process, not only after MI but 
also in other inflammatory processes affecting the heart.
In conclusion, we have shown that in patients with acute 
myocarditis, USPIO-enhanced T2* MRI does not provide addi-
tional clinically relevant information to that of LGE and T2 
mapping MRI. This suggests that tissue-resident macrophages do 
not provide a substantial contribution to the myocardial inflam-
mation in this condition.
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Key messages
What is already known about this subject?
Ultrasmall superparamagnetic particles of iron oxide (USPIO) are 
ingested by tissue macrophages that can be visualised using MRI 
to highlight areas of inflammation within the heart.
What does this study add?
USPIO-enhanced T2* MRI does not provide additional clinically 
relevant information to that of LGE and T2 mapping MRI. This 
suggests that tissue-resident macrophages do not provide a 
substantial contribution to the myocardial inflammation in this 
condition.
How might this impact on clinical practice?
USPIO-enhanced T2* MRI may still prove to be of value in 
diagnosing and monitoring conditions with macrophage-
driven myocardial inflammation, but its role in assessing acute 
myocarditis appears limited.
Figure 3 Changes on repeat imaging at 3 months in patients with myocarditis. There was no significant (ns) difference in ultrasmall 
superparamagnetic particles of iron oxide uptake between baseline and 3 months in both panmyocardium (A) and in regions displaying late 
gadolinium enhancement (LGE) (B). There was no difference in panmyocardial T2 (C) over 3 months. T2 in regions displaying LGE (D) reduced, as did 
the volume of LGE (E) over the 3-month period. There was an increase in ejection fraction (EF) between baseline and 3 months (F); *p<0.05.
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